#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


#Text=Abnormal fronto-limbic engagement in incarcerated stimulant users during moral processing
#Text=Rationale
#Text=Stimulant use is a significant and prevalent problem, particularly in criminal populations.
1-1	0-8	Abnormal	_
1-2	9-22	fronto-limbic	_
1-3	23-33	engagement	_
1-4	34-36	in	_
1-5	37-49	incarcerated	_
1-6	50-59	stimulant	http://maven.renci.org/NeuroBridge/neurobridge#StimulantDependence[1]
1-7	60-65	users	http://maven.renci.org/NeuroBridge/neurobridge#StimulantDependence[1]
1-8	66-72	during	_
1-9	73-78	moral	_
1-10	79-89	processing	_
1-11	90-99	Rationale	_
1-12	100-109	Stimulant	http://maven.renci.org/NeuroBridge/neurobridge#StimulantDependence[2]
1-13	110-113	use	http://maven.renci.org/NeuroBridge/neurobridge#StimulantDependence[2]
1-14	114-116	is	_
1-15	117-118	a	_
1-16	119-130	significant	_
1-17	131-134	and	_
1-18	135-144	prevalent	_
1-19	145-152	problem	_
1-20	152-153	,	_
1-21	154-166	particularly	_
1-22	167-169	in	_
1-23	170-178	criminal	_
1-24	179-190	populations	_
1-25	190-191	.	_

#Text=Previous studies found that cocaine and methamphetamine use is related to impairment in identifying emotions and empathy.
2-1	192-200	Previous	_
2-2	201-208	studies	_
2-3	209-214	found	_
2-4	215-219	that	_
2-5	220-227	cocaine	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder[3]|http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[4]
2-6	228-231	and	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder[3]
2-7	232-247	methamphetamine	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder[3]|http://maven.renci.org/NeuroBridge/neurobridge#MethamphetamineDependence[5]
2-8	248-251	use	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder[3]|http://maven.renci.org/NeuroBridge/neurobridge#MethamphetamineDependence[5]
2-9	252-254	is	_
2-10	255-262	related	_
2-11	263-265	to	_
2-12	266-276	impairment	_
2-13	277-279	in	_
2-14	280-291	identifying	_
2-15	292-300	emotions	_
2-16	301-304	and	_
2-17	305-312	empathy	_
2-18	312-313	.	_

#Text=Stimulant users also have abnormal neural structure and function of the ventromedial prefrontal cortex (vmPFC), amygdala, anterior (ACC) and posterior cingulate (PCC), regions implicated in moral decision making.
3-1	314-323	Stimulant	http://maven.renci.org/NeuroBridge/neurobridge#StimulantDependence[6]
3-2	324-329	users	http://maven.renci.org/NeuroBridge/neurobridge#StimulantDependence[6]
3-3	330-334	also	_
3-4	335-339	have	_
3-5	340-348	abnormal	_
3-6	349-355	neural	_
3-7	356-365	structure	_
3-8	366-369	and	_
3-9	370-378	function	_
3-10	379-381	of	_
3-11	382-385	the	_
3-12	386-398	ventromedial	_
3-13	399-409	prefrontal	_
3-14	410-416	cortex	_
3-15	417-418	(	_
3-16	418-423	vmPFC	_
3-17	423-424	)	_
3-18	424-425	,	_
3-19	426-434	amygdala	_
3-20	434-435	,	_
3-21	436-444	anterior	_
3-22	445-446	(	_
3-23	446-449	ACC	_
3-24	449-450	)	_
3-25	451-454	and	_
3-26	455-464	posterior	_
3-27	465-474	cingulate	_
3-28	475-476	(	_
3-29	476-479	PCC	_
3-30	479-480	)	_
3-31	480-481	,	_
3-32	482-489	regions	_
3-33	490-500	implicated	_
3-34	501-503	in	_
3-35	504-509	moral	_
3-36	510-518	decision	_
3-37	519-525	making	_
3-38	525-526	.	_

#Text=However, no research has studied the neural correlates of stimulant use and explicit moral processing in an incarcerated population.
4-1	527-534	However	_
4-2	534-535	,	_
4-3	536-538	no	_
4-4	539-547	research	_
4-5	548-551	has	_
4-6	552-559	studied	_
4-7	560-563	the	_
4-8	564-570	neural	_
4-9	571-581	correlates	_
4-10	582-584	of	_
4-11	585-594	stimulant	http://maven.renci.org/NeuroBridge/neurobridge#StimulantDependence[7]
4-12	595-598	use	http://maven.renci.org/NeuroBridge/neurobridge#StimulantDependence[7]
4-13	599-602	and	_
4-14	603-611	explicit	_
4-15	612-617	moral	_
4-16	618-628	processing	_
4-17	629-631	in	_
4-18	632-634	an	_
4-19	635-647	incarcerated	_
4-20	648-658	population	_
4-21	658-659	.	_

#Text=Objectives
#Text=Here we examine how stimulant use affects sociomoral processing that might contribute to antisocial behavior.
5-1	660-670	Objectives	_
5-2	671-675	Here	_
5-3	676-678	we	_
5-4	679-686	examine	_
5-5	687-690	how	_
5-6	691-700	stimulant	http://maven.renci.org/NeuroBridge/neurobridge#StimulantDependence[8]
5-7	701-704	use	http://maven.renci.org/NeuroBridge/neurobridge#StimulantDependence[8]
5-8	705-712	affects	_
5-9	713-723	sociomoral	_
5-10	724-734	processing	_
5-11	735-739	that	_
5-12	740-745	might	_
5-13	746-756	contribute	_
5-14	757-759	to	_
5-15	760-770	antisocial	_
5-16	771-779	behavior	_
5-17	779-780	.	_

#Text=We predicted that vmPFC, amygdala, PCC, and ACC would show abnormal neural response during a moral processing task in incarcerated methamphetamine and cocaine users.
6-1	781-783	We	_
6-2	784-793	predicted	_
6-3	794-798	that	_
6-4	799-804	vmPFC	_
6-5	804-805	,	_
6-6	806-814	amygdala	_
6-7	814-815	,	_
6-8	816-819	PCC	_
6-9	819-820	,	_
6-10	821-824	and	_
6-11	825-828	ACC	_
6-12	829-834	would	_
6-13	835-839	show	_
6-14	840-848	abnormal	_
6-15	849-855	neural	_
6-16	856-864	response	_
6-17	865-871	during	_
6-18	872-873	a	_
6-19	874-879	moral	_
6-20	880-890	processing	_
6-21	891-895	task	_
6-22	896-898	in	_
6-23	899-911	incarcerated	_
6-24	912-927	methamphetamine	http://maven.renci.org/NeuroBridge/neurobridge#MethamphetamineDependence
6-25	928-931	and	_
6-26	932-939	cocaine	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[9]
6-27	940-945	users	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[9]
6-28	945-946	.	_

#Text=Methods
#Text=Incarcerated adult males (N = 211) were scanned with a Mobile MRI system while completing a moral decision making task.
7-1	947-954	Methods	_
7-2	955-967	Incarcerated	_
7-3	968-973	adult	_
7-4	974-979	males	_
7-5	980-981	(	_
7-6	981-982	N	_
7-7	983-984	=	_
7-8	985-988	211	_
7-9	988-989	)	_
7-10	990-994	were	_
7-11	995-1002	scanned	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[10]
7-12	1003-1007	with	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[10]
7-13	1008-1009	a	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[10]
7-14	1010-1016	Mobile	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[10]
7-15	1017-1020	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[10]
7-16	1021-1027	system	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[10]
7-17	1028-1033	while	_
7-18	1034-1044	completing	_
7-19	1045-1046	a	_
7-20	1047-1052	moral	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[11]
7-21	1053-1061	decision	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[11]
7-22	1062-1068	making	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[11]
7-23	1069-1073	task	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[11]
7-24	1073-1074	.	_

#Text=Lifetime drug use was assessed.
8-1	1075-1083	Lifetime	_
8-2	1084-1088	drug	http://maven.renci.org/NeuroBridge/neurobridge#DrugDependence[12]
8-3	1089-1092	use	http://maven.renci.org/NeuroBridge/neurobridge#DrugDependence[12]
8-4	1093-1096	was	_
8-5	1097-1105	assessed	_
8-6	1105-1106	.	_

#Text=Neural responses during moral processing were compared between users and non-users.
9-1	1107-1113	Neural	_
9-2	1114-1123	responses	_
9-3	1124-1130	during	_
9-4	1131-1136	moral	_
9-5	1137-1147	processing	_
9-6	1148-1152	were	_
9-7	1153-1161	compared	_
9-8	1162-1169	between	_
9-9	1170-1175	users	_
9-10	1176-1179	and	_
9-11	1180-1189	non-users	_
9-12	1189-1190	.	_

#Text=The relationship between duration of use and neural function was also examined.
10-1	1191-1194	The	_
10-2	1195-1207	relationship	_
10-3	1208-1215	between	_
10-4	1216-1224	duration	_
10-5	1225-1227	of	_
10-6	1228-1231	use	_
10-7	1232-1235	and	_
10-8	1236-1242	neural	_
10-9	1243-1251	function	_
10-10	1252-1255	was	_
10-11	1256-1260	also	_
10-12	1261-1269	examined	_
10-13	1269-1270	.	_

#Text=Results
#Text=Incarcerated stimulant users showed less amygdala engagement than non-users during moral processing.
11-1	1271-1278	Results	_
11-2	1279-1291	Incarcerated	_
11-3	1292-1301	stimulant	http://maven.renci.org/NeuroBridge/neurobridge#StimulantDependence[13]
11-4	1302-1307	users	http://maven.renci.org/NeuroBridge/neurobridge#StimulantDependence[13]
11-5	1308-1314	showed	_
11-6	1315-1319	less	_
11-7	1320-1328	amygdala	_
11-8	1329-1339	engagement	_
11-9	1340-1344	than	_
11-10	1345-1354	non-users	_
11-11	1355-1361	during	_
11-12	1362-1367	moral	_
11-13	1368-1378	processing	_
11-14	1378-1379	.	_

#Text=Duration of stimulant use was negatively associated with activity in ACC and positively associated with vmPFC response during moral processing.
12-1	1380-1388	Duration	_
12-2	1389-1391	of	_
12-3	1392-1401	stimulant	http://maven.renci.org/NeuroBridge/neurobridge#StimulantDependence[14]
12-4	1402-1405	use	http://maven.renci.org/NeuroBridge/neurobridge#StimulantDependence[14]
12-5	1406-1409	was	_
12-6	1410-1420	negatively	_
12-7	1421-1431	associated	_
12-8	1432-1436	with	_
12-9	1437-1445	activity	_
12-10	1446-1448	in	_
12-11	1449-1452	ACC	_
12-12	1453-1456	and	_
12-13	1457-1467	positively	_
12-14	1468-1478	associated	_
12-15	1479-1483	with	_
12-16	1484-1489	vmPFC	_
12-17	1490-1498	response	_
12-18	1499-1505	during	_
12-19	1506-1511	moral	_
12-20	1512-1522	processing	_
12-21	1522-1523	.	_

#Text=Conclusions
#Text=These results suggest a dynamic pattern of fronto-limbic moral processing related to stimulant use with deficits in both central motive and cognitive integration elements of biological moral processes theory.
13-1	1524-1535	Conclusions	_
13-2	1536-1541	These	_
13-3	1542-1549	results	_
13-4	1550-1557	suggest	_
13-5	1558-1559	a	_
13-6	1560-1567	dynamic	_
13-7	1568-1575	pattern	_
13-8	1576-1578	of	_
13-9	1579-1592	fronto-limbic	_
13-10	1593-1598	moral	_
13-11	1599-1609	processing	_
13-12	1610-1617	related	_
13-13	1618-1620	to	_
13-14	1621-1630	stimulant	http://maven.renci.org/NeuroBridge/neurobridge#StimulantDependence[15]
13-15	1631-1634	use	http://maven.renci.org/NeuroBridge/neurobridge#StimulantDependence[15]
13-16	1635-1639	with	_
13-17	1640-1648	deficits	_
13-18	1649-1651	in	_
13-19	1652-1656	both	_
13-20	1657-1664	central	_
13-21	1665-1671	motive	_
13-22	1672-1675	and	_
13-23	1676-1685	cognitive	_
13-24	1686-1697	integration	_
13-25	1698-1706	elements	_
13-26	1707-1709	of	_
13-27	1710-1720	biological	_
13-28	1721-1726	moral	_
13-29	1727-1736	processes	_
13-30	1737-1743	theory	_
13-31	1743-1744	.	_

#Text=This increases our understanding of how drug use relates to moral processing in the brain in an ultra-high risk population.
14-1	1745-1749	This	_
14-2	1750-1759	increases	_
14-3	1760-1763	our	_
14-4	1764-1777	understanding	_
14-5	1778-1780	of	_
14-6	1781-1784	how	_
14-7	1785-1789	drug	http://maven.renci.org/NeuroBridge/neurobridge#DrugDependence[16]
14-8	1790-1793	use	http://maven.renci.org/NeuroBridge/neurobridge#DrugDependence[16]
14-9	1794-1801	relates	_
14-10	1802-1804	to	_
14-11	1805-1810	moral	_
14-12	1811-1821	processing	_
14-13	1822-1824	in	_
14-14	1825-1828	the	_
14-15	1829-1834	brain	_
14-16	1835-1837	in	_
14-17	1838-1840	an	_
14-18	1841-1851	ultra-high	_
14-19	1852-1856	risk	_
14-20	1857-1867	population	_
14-21	1867-1868	.	_

#Text=Substance abuse is a staggering problem, costing the United States up to $11 billion dollars in annual health care costs alone.
15-1	1869-1878	Substance	_
15-2	1879-1884	abuse	_
15-3	1885-1887	is	_
15-4	1888-1889	a	_
15-5	1890-1900	staggering	_
15-6	1901-1908	problem	_
15-7	1908-1909	,	_
15-8	1910-1917	costing	_
15-9	1918-1921	the	_
15-10	1922-1928	United	_
15-11	1929-1935	States	_
15-12	1936-1938	up	_
15-13	1939-1941	to	_
15-14	1942-1945	$11	_
15-15	1946-1953	billion	_
15-16	1954-1961	dollars	_
15-17	1962-1964	in	_
15-18	1965-1971	annual	_
15-19	1972-1978	health	_
15-20	1979-1983	care	_
15-21	1984-1989	costs	_
15-22	1990-1995	alone	_
15-23	1995-1996	.	_

#Text=When considering other factors, such as crime and lost productivity, the cost is more than ten times that.
16-1	1997-2001	When	_
16-2	2002-2013	considering	_
16-3	2014-2019	other	_
16-4	2020-2027	factors	_
16-5	2027-2028	,	_
16-6	2029-2033	such	_
16-7	2034-2036	as	_
16-8	2037-2042	crime	_
16-9	2043-2046	and	_
16-10	2047-2051	lost	_
16-11	2052-2064	productivity	_
16-12	2064-2065	,	_
16-13	2066-2069	the	_
16-14	2070-2074	cost	_
16-15	2075-2077	is	_
16-16	2078-2082	more	_
16-17	2083-2087	than	_
16-18	2088-2091	ten	_
16-19	2092-2097	times	_
16-20	2098-2102	that	_
16-21	2102-2103	.	_

#Text=In addition to the societal costs, users of stimulants, such as cocaine and methamphetamine, have significant lifetime prevalence rates, with over 15% of all adults in the United States having used cocaine and upwards of 5% having used methamphetamine.
17-1	2104-2106	In	_
17-2	2107-2115	addition	_
17-3	2116-2118	to	_
17-4	2119-2122	the	_
17-5	2123-2131	societal	_
17-6	2132-2137	costs	_
17-7	2137-2138	,	_
17-8	2139-2144	users	_
17-9	2145-2147	of	_
17-10	2148-2158	stimulants	_
17-11	2158-2159	,	_
17-12	2160-2164	such	_
17-13	2165-2167	as	_
17-14	2168-2175	cocaine	_
17-15	2176-2179	and	_
17-16	2180-2195	methamphetamine	_
17-17	2195-2196	,	_
17-18	2197-2201	have	_
17-19	2202-2213	significant	_
17-20	2214-2222	lifetime	_
17-21	2223-2233	prevalence	_
17-22	2234-2239	rates	_
17-23	2239-2240	,	_
17-24	2241-2245	with	_
17-25	2246-2250	over	_
17-26	2251-2254	15%	_
17-27	2255-2257	of	_
17-28	2258-2261	all	_
17-29	2262-2268	adults	_
17-30	2269-2271	in	_
17-31	2272-2275	the	_
17-32	2276-2282	United	_
17-33	2283-2289	States	_
17-34	2290-2296	having	_
17-35	2297-2301	used	_
17-36	2302-2309	cocaine	_
17-37	2310-2313	and	_
17-38	2314-2321	upwards	_
17-39	2322-2324	of	_
17-40	2325-2327	5%	_
17-41	2328-2334	having	_
17-42	2335-2339	used	_
17-43	2340-2355	methamphetamine	_
17-44	2355-2356	.	_

#Text=Additionally, 1.5 million people in the United States are current cocaine users while nearly 600,000 are current methamphetamine users, nearly tripling the number of current users since 2011.
18-1	2357-2369	Additionally	_
18-2	2369-2370	,	_
18-3	2371-2374	1.5	_
18-4	2375-2382	million	_
18-5	2383-2389	people	_
18-6	2390-2392	in	_
18-7	2393-2396	the	_
18-8	2397-2403	United	_
18-9	2404-2410	States	_
18-10	2411-2414	are	_
18-11	2415-2422	current	_
18-12	2423-2430	cocaine	_
18-13	2431-2436	users	_
18-14	2437-2442	while	_
18-15	2443-2449	nearly	_
18-16	2450-2457	600,000	_
18-17	2458-2461	are	_
18-18	2462-2469	current	_
18-19	2470-2485	methamphetamine	_
18-20	2486-2491	users	_
18-21	2491-2492	,	_
18-22	2493-2499	nearly	_
18-23	2500-2508	tripling	_
18-24	2509-2512	the	_
18-25	2513-2519	number	_
18-26	2520-2522	of	_
18-27	2523-2530	current	_
18-28	2531-2536	users	_
18-29	2537-2542	since	_
18-30	2543-2547	2011	_
18-31	2547-2548	.	_

#Text=Meanwhile, nearly 50% of prison inmates report having used cocaine or methamphetamine in their lifetimes.
19-1	2549-2558	Meanwhile	_
19-2	2558-2559	,	_
19-3	2560-2566	nearly	_
19-4	2567-2570	50%	_
19-5	2571-2573	of	_
19-6	2574-2580	prison	_
19-7	2581-2588	inmates	_
19-8	2589-2595	report	_
19-9	2596-2602	having	_
19-10	2603-2607	used	_
19-11	2608-2615	cocaine	_
19-12	2616-2618	or	_
19-13	2619-2634	methamphetamine	_
19-14	2635-2637	in	_
19-15	2638-2643	their	_
19-16	2644-2653	lifetimes	_
19-17	2653-2654	.	_

#Text=Additionally, 12% report being high on cocaine while committing their crime while an additional 6% of inmates report using methamphetamine at the time of offense.
20-1	2655-2667	Additionally	_
20-2	2667-2668	,	_
20-3	2669-2672	12%	_
20-4	2673-2679	report	_
20-5	2680-2685	being	_
20-6	2686-2690	high	_
20-7	2691-2693	on	_
20-8	2694-2701	cocaine	_
20-9	2702-2707	while	_
20-10	2708-2718	committing	_
20-11	2719-2724	their	_
20-12	2725-2730	crime	_
20-13	2731-2736	while	_
20-14	2737-2739	an	_
20-15	2740-2750	additional	_
20-16	2751-2753	6%	_
20-17	2754-2756	of	_
20-18	2757-2764	inmates	_
20-19	2765-2771	report	_
20-20	2772-2777	using	_
20-21	2778-2793	methamphetamine	_
20-22	2794-2796	at	_
20-23	2797-2800	the	_
20-24	2801-2805	time	_
20-25	2806-2808	of	_
20-26	2809-2816	offense	_
20-27	2816-2817	.	_

#Text=As might be expected given the relation between stimulant use and crime, research has suggested that stimulant abusers show deficits in several types of socio-affective processes that are related to moral judgement and prosocial behavior.
21-1	2818-2820	As	_
21-2	2821-2826	might	_
21-3	2827-2829	be	_
21-4	2830-2838	expected	_
21-5	2839-2844	given	_
21-6	2845-2848	the	_
21-7	2849-2857	relation	_
21-8	2858-2865	between	_
21-9	2866-2875	stimulant	_
21-10	2876-2879	use	_
21-11	2880-2883	and	_
21-12	2884-2889	crime	_
21-13	2889-2890	,	_
21-14	2891-2899	research	_
21-15	2900-2903	has	_
21-16	2904-2913	suggested	_
21-17	2914-2918	that	_
21-18	2919-2928	stimulant	_
21-19	2929-2936	abusers	_
21-20	2937-2941	show	_
21-21	2942-2950	deficits	_
21-22	2951-2953	in	_
21-23	2954-2961	several	_
21-24	2962-2967	types	_
21-25	2968-2970	of	_
21-26	2971-2986	socio-affective	_
21-27	2987-2996	processes	_
21-28	2997-3001	that	_
21-29	3002-3005	are	_
21-30	3006-3013	related	_
21-31	3014-3016	to	_
21-32	3017-3022	moral	_
21-33	3023-3032	judgement	_
21-34	3033-3036	and	_
21-35	3037-3046	prosocial	_
21-36	3047-3055	behavior	_
21-37	3055-3056	.	_

#Text=Both active and abstinent stimulant users have difficulty identifying others’ emotions, particularly fear.
22-1	3057-3061	Both	_
22-2	3062-3068	active	_
22-3	3069-3072	and	_
22-4	3073-3082	abstinent	_
22-5	3083-3092	stimulant	_
22-6	3093-3098	users	_
22-7	3099-3103	have	_
22-8	3104-3114	difficulty	_
22-9	3115-3126	identifying	_
22-10	3127-3133	others	_
22-11	3133-3134	’	_
22-12	3135-3143	emotions	_
22-13	3143-3144	,	_
22-14	3145-3157	particularly	_
22-15	3158-3162	fear	_
22-16	3162-3163	.	_

#Text=Additionally, stimulant use is related to diminished empathy and perspective taking, abilities that play an important role in moral decision making.
23-1	3164-3176	Additionally	_
23-2	3176-3177	,	_
23-3	3178-3187	stimulant	_
23-4	3188-3191	use	_
23-5	3192-3194	is	_
23-6	3195-3202	related	_
23-7	3203-3205	to	_
23-8	3206-3216	diminished	_
23-9	3217-3224	empathy	_
23-10	3225-3228	and	_
23-11	3229-3240	perspective	_
23-12	3241-3247	taking	_
23-13	3247-3248	,	_
23-14	3249-3258	abilities	_
23-15	3259-3263	that	_
23-16	3264-3268	play	_
23-17	3269-3271	an	_
23-18	3272-3281	important	_
23-19	3282-3286	role	_
23-20	3287-3289	in	_
23-21	3290-3295	moral	_
23-22	3296-3304	decision	_
23-23	3305-3311	making	_
23-24	3311-3312	.	_

#Text=In addition to behavioral deficits, chronic stimulant users exhibit abnormal neural engagement in both top down and bottom up processes, such as significantly reduced activation compared to controls in the anterior cingulate (ACC), prefrontal cortex, and posterior cingulate (PCC) during response inhibition, prediction, and stress imagery.
24-1	3313-3315	In	_
24-2	3316-3324	addition	_
24-3	3325-3327	to	_
24-4	3328-3338	behavioral	_
24-5	3339-3347	deficits	_
24-6	3347-3348	,	_
24-7	3349-3356	chronic	_
24-8	3357-3366	stimulant	_
24-9	3367-3372	users	_
24-10	3373-3380	exhibit	_
24-11	3381-3389	abnormal	_
24-12	3390-3396	neural	_
24-13	3397-3407	engagement	_
24-14	3408-3410	in	_
24-15	3411-3415	both	_
24-16	3416-3419	top	_
24-17	3420-3424	down	_
24-18	3425-3428	and	_
24-19	3429-3435	bottom	_
24-20	3436-3438	up	_
24-21	3439-3448	processes	_
24-22	3448-3449	,	_
24-23	3450-3454	such	_
24-24	3455-3457	as	_
24-25	3458-3471	significantly	_
24-26	3472-3479	reduced	_
24-27	3480-3490	activation	_
24-28	3491-3499	compared	_
24-29	3500-3502	to	_
24-30	3503-3511	controls	_
24-31	3512-3514	in	_
24-32	3515-3518	the	_
24-33	3519-3527	anterior	_
24-34	3528-3537	cingulate	_
24-35	3538-3539	(	_
24-36	3539-3542	ACC	_
24-37	3542-3543	)	_
24-38	3543-3544	,	_
24-39	3545-3555	prefrontal	_
24-40	3556-3562	cortex	_
24-41	3562-3563	,	_
24-42	3564-3567	and	_
24-43	3568-3577	posterior	_
24-44	3578-3587	cingulate	_
24-45	3588-3589	(	_
24-46	3589-3592	PCC	_
24-47	3592-3593	)	_
24-48	3594-3600	during	_
24-49	3601-3609	response	_
24-50	3610-3620	inhibition	_
24-51	3620-3621	,	_
24-52	3622-3632	prediction	_
24-53	3632-3633	,	_
24-54	3634-3637	and	_
24-55	3638-3644	stress	_
24-56	3645-3652	imagery	_
24-57	3652-3653	.	_

#Text=Abusers of both illicit and non-illicit stimulants also show increased ACC activity during reward cues and less amygdala and prefrontal cortex activations during delay discounting, although another study of intertemporal choice found less activation in methamphetamine users compared to controls in the dorsal ACC.
25-1	3654-3661	Abusers	_
25-2	3662-3664	of	_
25-3	3665-3669	both	_
25-4	3670-3677	illicit	_
25-5	3678-3681	and	_
25-6	3682-3693	non-illicit	_
25-7	3694-3704	stimulants	_
25-8	3705-3709	also	_
25-9	3710-3714	show	_
25-10	3715-3724	increased	_
25-11	3725-3728	ACC	_
25-12	3729-3737	activity	_
25-13	3738-3744	during	_
25-14	3745-3751	reward	_
25-15	3752-3756	cues	_
25-16	3757-3760	and	_
25-17	3761-3765	less	_
25-18	3766-3774	amygdala	_
25-19	3775-3778	and	_
25-20	3779-3789	prefrontal	_
25-21	3790-3796	cortex	_
25-22	3797-3808	activations	_
25-23	3809-3815	during	_
25-24	3816-3821	delay	_
25-25	3822-3833	discounting	_
25-26	3833-3834	,	_
25-27	3835-3843	although	_
25-28	3844-3851	another	_
25-29	3852-3857	study	_
25-30	3858-3860	of	_
25-31	3861-3874	intertemporal	_
25-32	3875-3881	choice	_
25-33	3882-3887	found	_
25-34	3888-3892	less	_
25-35	3893-3903	activation	_
25-36	3904-3906	in	_
25-37	3907-3922	methamphetamine	_
25-38	3923-3928	users	_
25-39	3929-3937	compared	_
25-40	3938-3940	to	_
25-41	3941-3949	controls	_
25-42	3950-3952	in	_
25-43	3953-3956	the	_
25-44	3957-3963	dorsal	_
25-45	3964-3967	ACC	_
25-46	3967-3968	.	_

#Text=This pattern of both hypo- and hyper-activations in various brain regions is thought to reflect neurocognitive impairments and compensatory cognitive processes, respectively.
26-1	3969-3973	This	_
26-2	3974-3981	pattern	_
26-3	3982-3984	of	_
26-4	3985-3989	both	_
26-5	3990-3994	hypo	_
26-6	3994-3995	-	_
26-7	3996-3999	and	_
26-8	4000-4017	hyper-activations	_
26-9	4018-4020	in	_
26-10	4021-4028	various	_
26-11	4029-4034	brain	_
26-12	4035-4042	regions	_
26-13	4043-4045	is	_
26-14	4046-4053	thought	_
26-15	4054-4056	to	_
26-16	4057-4064	reflect	_
26-17	4065-4079	neurocognitive	_
26-18	4080-4091	impairments	_
26-19	4092-4095	and	_
26-20	4096-4108	compensatory	_
26-21	4109-4118	cognitive	_
26-22	4119-4128	processes	_
26-23	4128-4129	,	_
26-24	4130-4142	respectively	_
26-25	4142-4143	.	_

#Text=Anatomical imaging studies have found that chronic stimulant use is associated with reduced gray matter in the ventromedial prefrontal cortex (vmPFC), insula, and temporal cortex.
27-1	4144-4154	Anatomical	_
27-2	4155-4162	imaging	_
27-3	4163-4170	studies	_
27-4	4171-4175	have	_
27-5	4176-4181	found	_
27-6	4182-4186	that	_
27-7	4187-4194	chronic	_
27-8	4195-4204	stimulant	_
27-9	4205-4208	use	_
27-10	4209-4211	is	_
27-11	4212-4222	associated	_
27-12	4223-4227	with	_
27-13	4228-4235	reduced	_
27-14	4236-4240	gray	_
27-15	4241-4247	matter	_
27-16	4248-4250	in	_
27-17	4251-4254	the	_
27-18	4255-4267	ventromedial	_
27-19	4268-4278	prefrontal	_
27-20	4279-4285	cortex	_
27-21	4286-4287	(	_
27-22	4287-4292	vmPFC	_
27-23	4292-4293	)	_
27-24	4293-4294	,	_
27-25	4295-4301	insula	_
27-26	4301-4302	,	_
27-27	4303-4306	and	_
27-28	4307-4315	temporal	_
27-29	4316-4322	cortex	_
27-30	4322-4323	.	_

#Text=Reductions have also been detected in other frontal regions including anterior and posterior cingulate as well as the amygdala.
28-1	4324-4334	Reductions	_
28-2	4335-4339	have	_
28-3	4340-4344	also	_
28-4	4345-4349	been	_
28-5	4350-4358	detected	_
28-6	4359-4361	in	_
28-7	4362-4367	other	_
28-8	4368-4375	frontal	_
28-9	4376-4383	regions	_
28-10	4384-4393	including	_
28-11	4394-4402	anterior	_
28-12	4403-4406	and	_
28-13	4407-4416	posterior	_
28-14	4417-4426	cingulate	_
28-15	4427-4429	as	_
28-16	4430-4434	well	_
28-17	4435-4437	as	_
28-18	4438-4441	the	_
28-19	4442-4450	amygdala	_
28-20	4450-4451	.	_

#Text=These patterns of structural abnormalities combine with functional work to suggest a pattern of frontocorticol deficits in chronic methamphetamine users.
29-1	4452-4457	These	_
29-2	4458-4466	patterns	_
29-3	4467-4469	of	_
29-4	4470-4480	structural	_
29-5	4481-4494	abnormalities	_
29-6	4495-4502	combine	_
29-7	4503-4507	with	_
29-8	4508-4518	functional	_
29-9	4519-4523	work	_
29-10	4524-4526	to	_
29-11	4527-4534	suggest	_
29-12	4535-4536	a	_
29-13	4537-4544	pattern	_
29-14	4545-4547	of	_
29-15	4548-4562	frontocorticol	_
29-16	4563-4571	deficits	_
29-17	4572-4574	in	_
29-18	4575-4582	chronic	_
29-19	4583-4598	methamphetamine	_
29-20	4599-4604	users	_
29-21	4604-4605	.	_

#Text=Several of the regions implicated in functional and anatomical imaging studies of stimulant use, particularly the vmPFC, amygdala, PCC, and ACC, are consistently engaged during moral judgments in non-clinical populations.
30-1	4606-4613	Several	_
30-2	4614-4616	of	_
30-3	4617-4620	the	_
30-4	4621-4628	regions	_
30-5	4629-4639	implicated	_
30-6	4640-4642	in	_
30-7	4643-4653	functional	_
30-8	4654-4657	and	_
30-9	4658-4668	anatomical	_
30-10	4669-4676	imaging	_
30-11	4677-4684	studies	_
30-12	4685-4687	of	_
30-13	4688-4697	stimulant	_
30-14	4698-4701	use	_
30-15	4701-4702	,	_
30-16	4703-4715	particularly	_
30-17	4716-4719	the	_
30-18	4720-4725	vmPFC	_
30-19	4725-4726	,	_
30-20	4727-4735	amygdala	_
30-21	4735-4736	,	_
30-22	4737-4740	PCC	_
30-23	4740-4741	,	_
30-24	4742-4745	and	_
30-25	4746-4749	ACC	_
30-26	4749-4750	,	_
30-27	4751-4754	are	_
30-28	4755-4767	consistently	_
30-29	4768-4775	engaged	_
30-30	4776-4782	during	_
30-31	4783-4788	moral	_
30-32	4789-4798	judgments	_
30-33	4799-4801	in	_
30-34	4802-4814	non-clinical	_
30-35	4815-4826	populations	_
30-36	4826-4827	.	_

#Text=During moral processing in the brain, event sequences are stored in the prefrontal cortex and then represented in the vmPFC.
31-1	4828-4834	During	_
31-2	4835-4840	moral	_
31-3	4841-4851	processing	_
31-4	4852-4854	in	_
31-5	4855-4858	the	_
31-6	4859-4864	brain	_
31-7	4864-4865	,	_
31-8	4866-4871	event	_
31-9	4872-4881	sequences	_
31-10	4882-4885	are	_
31-11	4886-4892	stored	_
31-12	4893-4895	in	_
31-13	4896-4899	the	_
31-14	4900-4910	prefrontal	_
31-15	4911-4917	cortex	_
31-16	4918-4921	and	_
31-17	4922-4926	then	_
31-18	4927-4938	represented	_
31-19	4939-4941	in	_
31-20	4942-4945	the	_
31-21	4946-4951	vmPFC	_
31-22	4951-4952	.	_

#Text=Meanwhile, emotional experiences are represented in limbic regions such as the amygdala and PCC.
32-1	4953-4962	Meanwhile	_
32-2	4962-4963	,	_
32-3	4964-4973	emotional	_
32-4	4974-4985	experiences	_
32-5	4986-4989	are	_
32-6	4990-5001	represented	_
32-7	5002-5004	in	_
32-8	5005-5011	limbic	_
32-9	5012-5019	regions	_
32-10	5020-5024	such	_
32-11	5025-5027	as	_
32-12	5028-5031	the	_
32-13	5032-5040	amygdala	_
32-14	5041-5044	and	_
32-15	5045-5048	PCC	_
32-16	5048-5049	.	_

#Text=The connections between these regions enable moral decisions, with the ACC playing an important role coordinating reinforcement, affect, and executive action.
33-1	5050-5053	The	_
33-2	5054-5065	connections	_
33-3	5066-5073	between	_
33-4	5074-5079	these	_
33-5	5080-5087	regions	_
33-6	5088-5094	enable	_
33-7	5095-5100	moral	_
33-8	5101-5110	decisions	_
33-9	5110-5111	,	_
33-10	5112-5116	with	_
33-11	5117-5120	the	_
33-12	5121-5124	ACC	_
33-13	5125-5132	playing	_
33-14	5133-5135	an	_
33-15	5136-5145	important	_
33-16	5146-5150	role	_
33-17	5151-5163	coordinating	_
33-18	5164-5177	reinforcement	_
33-19	5177-5178	,	_
33-20	5179-5185	affect	_
33-21	5185-5186	,	_
33-22	5187-5190	and	_
33-23	5191-5200	executive	_
33-24	5201-5207	action	_
33-25	5207-5208	.	_

#Text=Additionally, the PCC is engaged during evaluative behavior such as theory of mind, self-reflection, and emotion integration during moral decision-making.
34-1	5209-5221	Additionally	_
34-2	5221-5222	,	_
34-3	5223-5226	the	_
34-4	5227-5230	PCC	_
34-5	5231-5233	is	_
34-6	5234-5241	engaged	_
34-7	5242-5248	during	_
34-8	5249-5259	evaluative	_
34-9	5260-5268	behavior	_
34-10	5269-5273	such	_
34-11	5274-5276	as	_
34-12	5277-5283	theory	_
34-13	5284-5286	of	_
34-14	5287-5291	mind	_
34-15	5291-5292	,	_
34-16	5293-5308	self-reflection	_
34-17	5308-5309	,	_
34-18	5310-5313	and	_
34-19	5314-5321	emotion	_
34-20	5322-5333	integration	_
34-21	5334-5340	during	_
34-22	5341-5346	moral	_
34-23	5347-5362	decision-making	_
34-24	5362-5363	.	_

#Text=Thus, poor decision making, including antisocial behavior, in stimulant users may be related to abnormalities in the neural network responsible for evaluating and making decisions about moral situations.
35-1	5364-5368	Thus	_
35-2	5368-5369	,	_
35-3	5370-5374	poor	_
35-4	5375-5383	decision	_
35-5	5384-5390	making	_
35-6	5390-5391	,	_
35-7	5392-5401	including	_
35-8	5402-5412	antisocial	_
35-9	5413-5421	behavior	_
35-10	5421-5422	,	_
35-11	5423-5425	in	_
35-12	5426-5435	stimulant	_
35-13	5436-5441	users	_
35-14	5442-5445	may	_
35-15	5446-5448	be	_
35-16	5449-5456	related	_
35-17	5457-5459	to	_
35-18	5460-5473	abnormalities	_
35-19	5474-5476	in	_
35-20	5477-5480	the	_
35-21	5481-5487	neural	_
35-22	5488-5495	network	_
35-23	5496-5507	responsible	_
35-24	5508-5511	for	_
35-25	5512-5522	evaluating	_
35-26	5523-5526	and	_
35-27	5527-5533	making	_
35-28	5534-5543	decisions	_
35-29	5544-5549	about	_
35-30	5550-5555	moral	_
35-31	5556-5566	situations	_
35-32	5566-5567	.	_

#Text=Work with methamphetamine users has found evidence of functional connectivity deficits between frontal and corticolimbic regions leading to risky decision making and impulsivity.
36-1	5568-5572	Work	_
36-2	5573-5577	with	_
36-3	5578-5593	methamphetamine	_
36-4	5594-5599	users	_
36-5	5600-5603	has	_
36-6	5604-5609	found	_
36-7	5610-5618	evidence	_
36-8	5619-5621	of	_
36-9	5622-5632	functional	_
36-10	5633-5645	connectivity	_
36-11	5646-5654	deficits	_
36-12	5655-5662	between	_
36-13	5663-5670	frontal	_
36-14	5671-5674	and	_
36-15	5675-5688	corticolimbic	_
36-16	5689-5696	regions	_
36-17	5697-5704	leading	_
36-18	5705-5707	to	_
36-19	5708-5713	risky	_
36-20	5714-5722	decision	_
36-21	5723-5729	making	_
36-22	5730-5733	and	_
36-23	5734-5745	impulsivity	_
36-24	5745-5746	.	_

#Text=Only two studies to date have directly examined how stimulant users’ brains process morally-salient stimuli.
37-1	5747-5751	Only	_
37-2	5752-5755	two	_
37-3	5756-5763	studies	_
37-4	5764-5766	to	_
37-5	5767-5771	date	_
37-6	5772-5776	have	_
37-7	5777-5785	directly	_
37-8	5786-5794	examined	_
37-9	5795-5798	how	_
37-10	5799-5808	stimulant	_
37-11	5809-5814	users	_
37-12	5814-5815	’	_
37-13	5816-5822	brains	_
37-14	5823-5830	process	_
37-15	5831-5846	morally-salient	_
37-16	5847-5854	stimuli	_
37-17	5854-5855	.	_

#Text=In one study, cocaine users who were participating in an inpatient treatment program, relative to non-cocaine users, showed lower task related activity in the dorsal ACC while evaluating moral dilemmas.
38-1	5856-5858	In	_
38-2	5859-5862	one	_
38-3	5863-5868	study	_
38-4	5868-5869	,	_
38-5	5870-5877	cocaine	_
38-6	5878-5883	users	_
38-7	5884-5887	who	_
38-8	5888-5892	were	_
38-9	5893-5906	participating	_
38-10	5907-5909	in	_
38-11	5910-5912	an	_
38-12	5913-5922	inpatient	_
38-13	5923-5932	treatment	_
38-14	5933-5940	program	_
38-15	5940-5941	,	_
38-16	5942-5950	relative	_
38-17	5951-5953	to	_
38-18	5954-5965	non-cocaine	_
38-19	5966-5971	users	_
38-20	5971-5972	,	_
38-21	5973-5979	showed	_
38-22	5980-5985	lower	_
38-23	5986-5990	task	_
38-24	5991-5998	related	_
38-25	5999-6007	activity	_
38-26	6008-6010	in	_
38-27	6011-6014	the	_
38-28	6015-6021	dorsal	_
38-29	6022-6025	ACC	_
38-30	6026-6031	while	_
38-31	6032-6042	evaluating	_
38-32	6043-6048	moral	_
38-33	6049-6057	dilemmas	_
38-34	6057-6058	.	_

#Text=Additionally, in previous work we found that abstinent, incarcerated cocaine-users, relative to non-using incarcerated controls, had lower activation in the ACC and vmPFC during implicit moral processing.
39-1	6059-6071	Additionally	_
39-2	6071-6072	,	_
39-3	6073-6075	in	_
39-4	6076-6084	previous	_
39-5	6085-6089	work	_
39-6	6090-6092	we	_
39-7	6093-6098	found	_
39-8	6099-6103	that	_
39-9	6104-6113	abstinent	_
39-10	6113-6114	,	_
39-11	6115-6127	incarcerated	_
39-12	6128-6141	cocaine-users	_
39-13	6141-6142	,	_
39-14	6143-6151	relative	_
39-15	6152-6154	to	_
39-16	6155-6164	non-using	_
39-17	6165-6177	incarcerated	_
39-18	6178-6186	controls	_
39-19	6186-6187	,	_
39-20	6188-6191	had	_
39-21	6192-6197	lower	_
39-22	6198-6208	activation	_
39-23	6209-6211	in	_
39-24	6212-6215	the	_
39-25	6216-6219	ACC	_
39-26	6220-6223	and	_
39-27	6224-6229	vmPFC	_
39-28	6230-6236	during	_
39-29	6237-6245	implicit	_
39-30	6246-6251	moral	_
39-31	6252-6262	processing	_
39-32	6262-6263	.	_

#Text=Implicit moral processing triggers automatic moral processes but does not have moral task demands (e.g., shows a picture of a murder scene and asks if the scene is inside or outside.)
40-1	6264-6272	Implicit	_
40-2	6273-6278	moral	_
40-3	6279-6289	processing	_
40-4	6290-6298	triggers	_
40-5	6299-6308	automatic	_
40-6	6309-6314	moral	_
40-7	6315-6324	processes	_
40-8	6325-6328	but	_
40-9	6329-6333	does	_
40-10	6334-6337	not	_
40-11	6338-6342	have	_
40-12	6343-6348	moral	_
40-13	6349-6353	task	_
40-14	6354-6361	demands	_
40-15	6362-6363	(	_
40-16	6363-6366	e.g	_
40-17	6366-6367	.	_
40-18	6367-6368	,	_
40-19	6369-6374	shows	_
40-20	6375-6376	a	_
40-21	6377-6384	picture	_
40-22	6385-6387	of	_
40-23	6388-6389	a	_
40-24	6390-6396	murder	_
40-25	6397-6402	scene	_
40-26	6403-6406	and	_
40-27	6407-6411	asks	_
40-28	6412-6414	if	_
40-29	6415-6418	the	_
40-30	6419-6424	scene	_
40-31	6425-6427	is	_
40-32	6428-6434	inside	_
40-33	6435-6437	or	_
40-34	6438-6445	outside	_
40-35	6445-6446	.	_
40-36	6446-6447	)	_

#Text=However, to our knowledge, no study to date has investigated the neural correlates of explicit (i.e., having moral task demands) moral judgment in incarcerated methamphetamine abusers, despite the fact that many addicts become incarcerated at some point in their lives and 75% of inmates have substance abuse problems, according to epidemiological studies.
41-1	6448-6455	However	_
41-2	6455-6456	,	_
41-3	6457-6459	to	_
41-4	6460-6463	our	_
41-5	6464-6473	knowledge	_
41-6	6473-6474	,	_
41-7	6475-6477	no	_
41-8	6478-6483	study	_
41-9	6484-6486	to	_
41-10	6487-6491	date	_
41-11	6492-6495	has	_
41-12	6496-6508	investigated	_
41-13	6509-6512	the	_
41-14	6513-6519	neural	_
41-15	6520-6530	correlates	_
41-16	6531-6533	of	_
41-17	6534-6542	explicit	_
41-18	6543-6544	(	_
41-19	6544-6547	i.e	_
41-20	6547-6548	.	_
41-21	6548-6549	,	_
41-22	6550-6556	having	_
41-23	6557-6562	moral	_
41-24	6563-6567	task	_
41-25	6568-6575	demands	_
41-26	6575-6576	)	_
41-27	6577-6582	moral	_
41-28	6583-6591	judgment	_
41-29	6592-6594	in	_
41-30	6595-6607	incarcerated	_
41-31	6608-6623	methamphetamine	_
41-32	6624-6631	abusers	_
41-33	6631-6632	,	_
41-34	6633-6640	despite	_
41-35	6641-6644	the	_
41-36	6645-6649	fact	_
41-37	6650-6654	that	_
41-38	6655-6659	many	_
41-39	6660-6667	addicts	_
41-40	6668-6674	become	_
41-41	6675-6687	incarcerated	_
41-42	6688-6690	at	_
41-43	6691-6695	some	_
41-44	6696-6701	point	_
41-45	6702-6704	in	_
41-46	6705-6710	their	_
41-47	6711-6716	lives	_
41-48	6717-6720	and	_
41-49	6721-6724	75%	_
41-50	6725-6727	of	_
41-51	6728-6735	inmates	_
41-52	6736-6740	have	_
41-53	6741-6750	substance	_
41-54	6751-6756	abuse	_
41-55	6757-6765	problems	_
41-56	6765-6766	,	_
41-57	6767-6776	according	_
41-58	6777-6779	to	_
41-59	6780-6795	epidemiological	_
41-60	6796-6803	studies	_
41-61	6803-6804	.	_

#Text=Here we examined moral processing in cocaine and methamphetamine chronic users in a large incarcerated sample, allowing us to assess the effects of chronic stimulant use not confounded by acute use and compared to a control group matched on incarceration and background.
42-1	6805-6809	Here	_
42-2	6810-6812	we	_
42-3	6813-6821	examined	_
42-4	6822-6827	moral	_
42-5	6828-6838	processing	_
42-6	6839-6841	in	_
42-7	6842-6849	cocaine	_
42-8	6850-6853	and	_
42-9	6854-6869	methamphetamine	_
42-10	6870-6877	chronic	_
42-11	6878-6883	users	_
42-12	6884-6886	in	_
42-13	6887-6888	a	_
42-14	6889-6894	large	_
42-15	6895-6907	incarcerated	_
42-16	6908-6914	sample	_
42-17	6914-6915	,	_
42-18	6916-6924	allowing	_
42-19	6925-6927	us	_
42-20	6928-6930	to	_
42-21	6931-6937	assess	_
42-22	6938-6941	the	_
42-23	6942-6949	effects	_
42-24	6950-6952	of	_
42-25	6953-6960	chronic	_
42-26	6961-6970	stimulant	_
42-27	6971-6974	use	_
42-28	6975-6978	not	_
42-29	6979-6989	confounded	_
42-30	6990-6992	by	_
42-31	6993-6998	acute	_
42-32	6999-7002	use	_
42-33	7003-7006	and	_
42-34	7007-7015	compared	_
42-35	7016-7018	to	_
42-36	7019-7020	a	_
42-37	7021-7028	control	_
42-38	7029-7034	group	_
42-39	7035-7042	matched	_
42-40	7043-7045	on	_
42-41	7046-7059	incarceration	_
42-42	7060-7063	and	_
42-43	7064-7074	background	_
42-44	7074-7075	.	_

#Text=We hypothesized that incarcerated individuals with a history of chronic stimulant use, compared to incarcerated individuals with no history of regular stimulant use, would show reduced activation in the ACC, PCC, amygdala, and vmPFC when making moral judgments about morally controversial issues.
43-1	7076-7078	We	_
43-2	7079-7091	hypothesized	_
43-3	7092-7096	that	_
43-4	7097-7109	incarcerated	_
43-5	7110-7121	individuals	_
43-6	7122-7126	with	_
43-7	7127-7128	a	_
43-8	7129-7136	history	_
43-9	7137-7139	of	_
43-10	7140-7147	chronic	_
43-11	7148-7157	stimulant	_
43-12	7158-7161	use	_
43-13	7161-7162	,	_
43-14	7163-7171	compared	_
43-15	7172-7174	to	_
43-16	7175-7187	incarcerated	_
43-17	7188-7199	individuals	_
43-18	7200-7204	with	_
43-19	7205-7207	no	_
43-20	7208-7215	history	_
43-21	7216-7218	of	_
43-22	7219-7226	regular	_
43-23	7227-7236	stimulant	_
43-24	7237-7240	use	_
43-25	7240-7241	,	_
43-26	7242-7247	would	_
43-27	7248-7252	show	_
43-28	7253-7260	reduced	_
43-29	7261-7271	activation	_
43-30	7272-7274	in	_
43-31	7275-7278	the	_
43-32	7279-7282	ACC	_
43-33	7282-7283	,	_
43-34	7284-7287	PCC	_
43-35	7287-7288	,	_
43-36	7289-7297	amygdala	_
43-37	7297-7298	,	_
43-38	7299-7302	and	_
43-39	7303-7308	vmPFC	_
43-40	7309-7313	when	_
43-41	7314-7320	making	_
43-42	7321-7326	moral	_
43-43	7327-7336	judgments	_
43-44	7337-7342	about	_
43-45	7343-7350	morally	_
43-46	7351-7364	controversial	_
43-47	7365-7371	issues	_
43-48	7371-7372	.	_

#Text=These regions have been found to be significantly engaged in non-incarcerated, non-substance abusing individuals during moral processing and are related to abnormal grey matter volume and function in chronic substance users (see discussion above)..
44-1	7373-7378	These	_
44-2	7379-7386	regions	_
44-3	7387-7391	have	_
44-4	7392-7396	been	_
44-5	7397-7402	found	_
44-6	7403-7405	to	_
44-7	7406-7408	be	_
44-8	7409-7422	significantly	_
44-9	7423-7430	engaged	_
44-10	7431-7433	in	_
44-11	7434-7450	non-incarcerated	_
44-12	7450-7451	,	_
44-13	7452-7465	non-substance	_
44-14	7466-7473	abusing	_
44-15	7474-7485	individuals	_
44-16	7486-7492	during	_
44-17	7493-7498	moral	_
44-18	7499-7509	processing	_
44-19	7510-7513	and	_
44-20	7514-7517	are	_
44-21	7518-7525	related	_
44-22	7526-7528	to	_
44-23	7529-7537	abnormal	_
44-24	7538-7542	grey	_
44-25	7543-7549	matter	_
44-26	7550-7556	volume	_
44-27	7557-7560	and	_
44-28	7561-7569	function	_
44-29	7570-7572	in	_
44-30	7573-7580	chronic	_
44-31	7581-7590	substance	_
44-32	7591-7596	users	_
44-33	7597-7598	(	_
44-34	7598-7601	see	_
44-35	7602-7612	discussion	_
44-36	7613-7618	above	_
44-37	7618-7619	)	_
44-38	7619-7620	.	_
44-39	7620-7621	.	_

#Text=We also predicted that duration of stimulant use, quantified by years of regular cocaine and methamphetamine use, would be related to more pronounced abnormalities in these regions.
45-1	7622-7624	We	_
45-2	7625-7629	also	_
45-3	7630-7639	predicted	_
45-4	7640-7644	that	_
45-5	7645-7653	duration	_
45-6	7654-7656	of	_
45-7	7657-7666	stimulant	_
45-8	7667-7670	use	_
45-9	7670-7671	,	_
45-10	7672-7682	quantified	_
45-11	7683-7685	by	_
45-12	7686-7691	years	_
45-13	7692-7694	of	_
45-14	7695-7702	regular	_
45-15	7703-7710	cocaine	_
45-16	7711-7714	and	_
45-17	7715-7730	methamphetamine	_
45-18	7731-7734	use	_
45-19	7734-7735	,	_
45-20	7736-7741	would	_
45-21	7742-7744	be	_
45-22	7745-7752	related	_
45-23	7753-7755	to	_
45-24	7756-7760	more	_
45-25	7761-7771	pronounced	_
45-26	7772-7785	abnormalities	_
45-27	7786-7788	in	_
45-28	7789-7794	these	_
45-29	7795-7802	regions	_
45-30	7802-7803	.	_

#Text=Methods
#Text=Participants
#Text=Participants were adult males incarcerated in New Mexico and Wisconsin prisons (N= 211).
46-1	7804-7811	Methods	http://www.case.edu/ProvCaRe/provcare#StudyMethod
46-2	7812-7824	Participants	_
46-3	7825-7837	Participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]
46-4	7838-7842	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]
46-5	7843-7848	adult	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]
46-6	7849-7854	males	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]
46-7	7855-7867	incarcerated	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]
46-8	7868-7870	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]
46-9	7871-7874	New	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]
46-10	7875-7881	Mexico	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]
46-11	7882-7885	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]
46-12	7886-7895	Wisconsin	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]
46-13	7896-7903	prisons	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]
46-14	7904-7905	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]
46-15	7905-7906	N	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]
46-16	7906-7907	=	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]
46-17	7908-7911	211	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]
46-18	7911-7912	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]
46-19	7912-7913	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]

#Text=Inclusion criteria were: age between 18 and 65, IQ of 80 or above, at least 4th grade English reading level, and no history of neurological disorder or history of psychosis in self or first-degree relative.
47-1	7914-7923	Inclusion	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
47-2	7924-7932	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
47-3	7933-7937	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
47-4	7937-7938	:	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
47-5	7939-7942	age	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
47-6	7943-7950	between	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
47-7	7951-7953	18	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
47-8	7954-7957	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
47-9	7958-7960	65	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
47-10	7960-7961	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
47-11	7962-7964	IQ	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
47-12	7965-7967	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
47-13	7968-7970	80	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
47-14	7971-7973	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
47-15	7974-7979	above	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
47-16	7979-7980	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
47-17	7981-7983	at	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
47-18	7984-7989	least	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
47-19	7990-7993	4th	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
47-20	7994-7999	grade	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
47-21	8000-8007	English	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
47-22	8008-8015	reading	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
47-23	8016-8021	level	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
47-24	8021-8022	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
47-25	8023-8026	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
47-26	8027-8029	no	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
47-27	8030-8037	history	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
47-28	8038-8040	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
47-29	8041-8053	neurological	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
47-30	8054-8062	disorder	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
47-31	8063-8065	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
47-32	8066-8073	history	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
47-33	8074-8076	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
47-34	8077-8086	psychosis	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
47-35	8087-8089	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
47-36	8090-8094	self	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
47-37	8095-8097	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
47-38	8098-8110	first-degree	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
47-39	8111-8119	relative	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
47-40	8119-8120	.	_

#Text=Participants with a history of regular stimulant use (n = 131) were compared to participants with no history of regular stimulant use (n = 80).
48-1	8121-8133	Participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
48-2	8134-8138	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
48-3	8139-8140	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
48-4	8141-8148	history	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
48-5	8149-8151	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
48-6	8152-8159	regular	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]|http://maven.renci.org/NeuroBridge/neurobridge#StimulantDependence[20]
48-7	8160-8169	stimulant	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]|http://maven.renci.org/NeuroBridge/neurobridge#StimulantDependence[20]
48-8	8170-8173	use	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]|http://maven.renci.org/NeuroBridge/neurobridge#StimulantDependence[20]
48-9	8174-8175	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
48-10	8175-8176	n	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
48-11	8177-8178	=	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
48-12	8179-8182	131	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
48-13	8182-8183	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
48-14	8184-8188	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
48-15	8189-8197	compared	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
48-16	8198-8200	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
48-17	8201-8213	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[21]
48-18	8214-8218	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[21]
48-19	8219-8221	no	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[21]
48-20	8222-8229	history	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[21]
48-21	8230-8232	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[21]
48-22	8233-8240	regular	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[21]
48-23	8241-8250	stimulant	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[21]
48-24	8251-8254	use	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[21]
48-25	8255-8256	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
48-26	8256-8257	n	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
48-27	8258-8259	=	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
48-28	8260-8262	80	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
48-29	8262-8263	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
48-30	8263-8264	.	_

#Text=Characteristics of each group are provided in Table 1.
49-1	8265-8280	Characteristics	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]
49-2	8281-8283	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]
49-3	8284-8288	each	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]
49-4	8289-8294	group	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]
49-5	8295-8298	are	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]
49-6	8299-8307	provided	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]
49-7	8308-8310	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]
49-8	8311-8316	Table	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]
49-9	8317-8318	1	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]
49-10	8318-8319	.	_

#Text=All participants provided written, informed consent prior to their inclusion in the study and were compensated at an hourly rate comparable to pay rates for work within the facilities.
50-1	8320-8323	All	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
50-2	8324-8336	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
50-3	8337-8345	provided	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
50-4	8346-8353	written	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
50-5	8353-8354	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
50-6	8355-8363	informed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
50-7	8364-8371	consent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
50-8	8372-8377	prior	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
50-9	8378-8380	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
50-10	8381-8386	their	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
50-11	8387-8396	inclusion	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
50-12	8397-8399	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
50-13	8400-8403	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
50-14	8404-8409	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
50-15	8410-8413	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
50-16	8414-8418	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
50-17	8419-8430	compensated	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
50-18	8431-8433	at	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
50-19	8434-8436	an	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
50-20	8437-8443	hourly	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
50-21	8444-8448	rate	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
50-22	8449-8459	comparable	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
50-23	8460-8462	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
50-24	8463-8466	pay	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
50-25	8467-8472	rates	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
50-26	8473-8476	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
50-27	8477-8481	work	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
50-28	8482-8488	within	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
50-29	8489-8492	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
50-30	8493-8503	facilities	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
50-31	8503-8504	.	_

#Text=All procedures and materials were approved by the University of New Mexico Institutional Review Board (IRB) and thus have been performed in accordance with the ethical standards of the Declaration of Helsinki.
51-1	8505-8508	All	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]
51-2	8509-8519	procedures	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]
51-3	8520-8523	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]
51-4	8524-8533	materials	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]
51-5	8534-8538	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]
51-6	8539-8547	approved	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]
51-7	8548-8550	by	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]
51-8	8551-8554	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]
51-9	8555-8565	University	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]
51-10	8566-8568	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]
51-11	8569-8572	New	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]
51-12	8573-8579	Mexico	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]
51-13	8580-8593	Institutional	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]
51-14	8594-8600	Review	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]
51-15	8601-8606	Board	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]
51-16	8607-8608	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]
51-17	8608-8611	IRB	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]
51-18	8611-8612	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]
51-19	8613-8616	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]
51-20	8617-8621	thus	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]
51-21	8622-8626	have	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]
51-22	8627-8631	been	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]
51-23	8632-8641	performed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]
51-24	8642-8644	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]
51-25	8645-8655	accordance	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]
51-26	8656-8660	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]
51-27	8661-8664	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]
51-28	8665-8672	ethical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]
51-29	8673-8682	standards	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]
51-30	8683-8685	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]
51-31	8686-8689	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]
51-32	8690-8701	Declaration	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]
51-33	8702-8704	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]
51-34	8705-8713	Helsinki	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]
51-35	8713-8714	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]

#Text=Assessments
#Text=Substance use was assessed using a modified version of the Addiction Severity Index (ASI-X), in which participants were asked about characteristics of use for a variety of substance classes, including age of first use and years of regular use (defined as three or more times a week).
52-1	8715-8726	Assessments	_
52-2	8727-8736	Substance	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder[25]
52-3	8737-8740	use	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder[25]
52-4	8741-8744	was	_
52-5	8745-8753	assessed	_
52-6	8754-8759	using	_
52-7	8760-8761	a	_
52-8	8762-8770	modified	_
52-9	8771-8778	version	_
52-10	8779-8781	of	_
52-11	8782-8785	the	_
52-12	8786-8795	Addiction	http://maven.renci.org/NeuroBridge/neurobridge#AddictionSeverityIndex[26]
52-13	8796-8804	Severity	http://maven.renci.org/NeuroBridge/neurobridge#AddictionSeverityIndex[26]
52-14	8805-8810	Index	http://maven.renci.org/NeuroBridge/neurobridge#AddictionSeverityIndex[26]
52-15	8811-8812	(	http://maven.renci.org/NeuroBridge/neurobridge#AddictionSeverityIndex[26]
52-16	8812-8817	ASI-X	http://maven.renci.org/NeuroBridge/neurobridge#AddictionSeverityIndex[26]
52-17	8817-8818	)	http://maven.renci.org/NeuroBridge/neurobridge#AddictionSeverityIndex[26]
52-18	8818-8819	,	_
52-19	8820-8822	in	_
52-20	8823-8828	which	_
52-21	8829-8841	participants	_
52-22	8842-8846	were	_
52-23	8847-8852	asked	_
52-24	8853-8858	about	_
52-25	8859-8874	characteristics	_
52-26	8875-8877	of	_
52-27	8878-8881	use	_
52-28	8882-8885	for	_
52-29	8886-8887	a	_
52-30	8888-8895	variety	_
52-31	8896-8898	of	_
52-32	8899-8908	substance	_
52-33	8909-8916	classes	_
52-34	8916-8917	,	_
52-35	8918-8927	including	_
52-36	8928-8931	age	_
52-37	8932-8934	of	_
52-38	8935-8940	first	_
52-39	8941-8944	use	_
52-40	8945-8948	and	_
52-41	8949-8954	years	_
52-42	8955-8957	of	_
52-43	8958-8965	regular	_
52-44	8966-8969	use	_
52-45	8970-8971	(	_
52-46	8971-8978	defined	_
52-47	8979-8981	as	_
52-48	8982-8987	three	_
52-49	8988-8990	or	_
52-50	8991-8995	more	_
52-51	8996-9001	times	_
52-52	9002-9003	a	_
52-53	9004-9008	week	_
52-54	9008-9009	)	_
52-55	9009-9010	.	_

#Text=If a participant had any regular use of cocaine or methamphetamine in his lifetime, he was classified as a lifetime stimulant user.
53-1	9011-9013	If	_
53-2	9014-9015	a	_
53-3	9016-9027	participant	_
53-4	9028-9031	had	_
53-5	9032-9035	any	_
53-6	9036-9043	regular	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder[27]|http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[28]
53-7	9044-9047	use	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder[27]|http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[28]
53-8	9048-9050	of	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder[27]|http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[28]
53-9	9051-9058	cocaine	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder[27]|http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[28]
53-10	9059-9061	or	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder[27]
53-11	9062-9077	methamphetamine	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder[27]|http://maven.renci.org/NeuroBridge/neurobridge#MethamphetamineDependence[29]
53-12	9078-9080	in	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder[27]
53-13	9081-9084	his	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder[27]
53-14	9085-9093	lifetime	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder[27]
53-15	9093-9094	,	_
53-16	9095-9097	he	_
53-17	9098-9101	was	_
53-18	9102-9112	classified	_
53-19	9113-9115	as	_
53-20	9116-9117	a	_
53-21	9118-9126	lifetime	http://maven.renci.org/NeuroBridge/neurobridge#StimulantDependence[30]
53-22	9127-9136	stimulant	http://maven.renci.org/NeuroBridge/neurobridge#StimulantDependence[30]
53-23	9137-9141	user	http://maven.renci.org/NeuroBridge/neurobridge#StimulantDependence[30]
53-24	9141-9142	.	_

#Text=This was also used to quantify lifetime years of regular non-stimulant drug and alcohol use.
54-1	9143-9147	This	_
54-2	9148-9151	was	_
54-3	9152-9156	also	_
54-4	9157-9161	used	_
54-5	9162-9164	to	_
54-6	9165-9173	quantify	_
54-7	9174-9182	lifetime	_
54-8	9183-9188	years	_
54-9	9189-9191	of	_
54-10	9192-9199	regular	_
54-11	9200-9213	non-stimulant	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder[31]
54-12	9214-9218	drug	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder[31]
54-13	9219-9222	and	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder[31]
54-14	9223-9230	alcohol	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder[31]|http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[32]
54-15	9231-9234	use	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder[31]|http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[32]
54-16	9234-9235	.	_

#Text=Although methamphetamine and cocaine are distinct substances, both are stimulant class and there is precedent for examining their use together [i.e., ], as well as evidence that the substances have similar trajectories, effects on the brain and outcomes.
55-1	9236-9244	Although	_
55-2	9245-9260	methamphetamine	http://maven.renci.org/NeuroBridge/neurobridge#MethamphetamineDependence
55-3	9261-9264	and	_
55-4	9265-9272	cocaine	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse
55-5	9273-9276	are	_
55-6	9277-9285	distinct	_
55-7	9286-9296	substances	_
55-8	9296-9297	,	_
55-9	9298-9302	both	_
55-10	9303-9306	are	_
55-11	9307-9316	stimulant	_
55-12	9317-9322	class	_
55-13	9323-9326	and	_
55-14	9327-9332	there	_
55-15	9333-9335	is	_
55-16	9336-9345	precedent	_
55-17	9346-9349	for	_
55-18	9350-9359	examining	_
55-19	9360-9365	their	_
55-20	9366-9369	use	_
55-21	9370-9378	together	_
55-22	9379-9380	[	_
55-23	9380-9383	i.e	_
55-24	9383-9384	.	_
55-25	9384-9385	,	_
55-26	9386-9387	]	_
55-27	9387-9388	,	_
55-28	9389-9391	as	_
55-29	9392-9396	well	_
55-30	9397-9399	as	_
55-31	9400-9408	evidence	_
55-32	9409-9413	that	_
55-33	9414-9417	the	_
55-34	9418-9428	substances	_
55-35	9429-9433	have	_
55-36	9434-9441	similar	_
55-37	9442-9454	trajectories	_
55-38	9454-9455	,	_
55-39	9456-9463	effects	_
55-40	9464-9466	on	_
55-41	9467-9470	the	_
55-42	9471-9476	brain	_
55-43	9477-9480	and	_
55-44	9481-9489	outcomes	_
55-45	9489-9490	.	_

#Text=In addition to the ASI-X, we collected additional measures to quantify possible confounding factors as well as to evaluate for the exclusion criteria discussed above.
56-1	9491-9493	In	_
56-2	9494-9502	addition	_
56-3	9503-9505	to	_
56-4	9506-9509	the	_
56-5	9510-9515	ASI-X	http://maven.renci.org/NeuroBridge/neurobridge#AddictionSeverityIndex
56-6	9515-9516	,	_
56-7	9517-9519	we	_
56-8	9520-9529	collected	_
56-9	9530-9540	additional	_
56-10	9541-9549	measures	_
56-11	9550-9552	to	_
56-12	9553-9561	quantify	_
56-13	9562-9570	possible	_
56-14	9571-9582	confounding	_
56-15	9583-9590	factors	_
56-16	9591-9593	as	_
56-17	9594-9598	well	_
56-18	9599-9601	as	_
56-19	9602-9604	to	_
56-20	9605-9613	evaluate	_
56-21	9614-9617	for	_
56-22	9618-9621	the	_
56-23	9622-9631	exclusion	_
56-24	9632-9640	criteria	_
56-25	9641-9650	discussed	_
56-26	9651-9656	above	_
56-27	9656-9657	.	_

#Text=Smoking was assessed using the Fagerstrom Test for Nicotine Dependence.
57-1	9658-9665	Smoking	_
57-2	9666-9669	was	_
57-3	9670-9678	assessed	_
57-4	9679-9684	using	_
57-5	9685-9688	the	_
57-6	9689-9699	Fagerstrom	http://maven.renci.org/NeuroBridge/neurobridge#FagerstromTestforNicotineDependence[33]
57-7	9700-9704	Test	http://maven.renci.org/NeuroBridge/neurobridge#FagerstromTestforNicotineDependence[33]
57-8	9705-9708	for	http://maven.renci.org/NeuroBridge/neurobridge#FagerstromTestforNicotineDependence[33]
57-9	9709-9717	Nicotine	http://maven.renci.org/NeuroBridge/neurobridge#FagerstromTestforNicotineDependence[33]
57-10	9718-9728	Dependence	http://maven.renci.org/NeuroBridge/neurobridge#FagerstromTestforNicotineDependence[33]
57-11	9728-9729	.	http://maven.renci.org/NeuroBridge/neurobridge#FagerstromTestforNicotineDependence[33]

#Text=IQ was estimated using the Vocabulary and Matrix Reasoning subtests of the Adult Intelligence Scale (WAIS).
58-1	9730-9732	IQ	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest
58-2	9733-9736	was	_
58-3	9737-9746	estimated	_
58-4	9747-9752	using	_
58-5	9753-9756	the	_
58-6	9757-9767	Vocabulary	_
58-7	9768-9771	and	_
58-8	9772-9778	Matrix	_
58-9	9779-9788	Reasoning	_
58-10	9789-9797	subtests	_
58-11	9798-9800	of	_
58-12	9801-9804	the	_
58-13	9805-9810	Adult	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[34]
58-14	9811-9823	Intelligence	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[34]
58-15	9824-9829	Scale	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[34]
58-16	9830-9831	(	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[34]
58-17	9831-9835	WAIS	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[34]
58-18	9835-9836	)	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[34]
58-19	9836-9837	.	_

#Text=Because stimulant use is likely to be comorbid with psychopathy, psychopathy and stimulant abuse show overlapping brain regions of decreased structure/function, and psychopathy is higher among incarcerated versus non-incarcerated individuals, psychopathy was assessed in all study participants using the Hare Psychopathy Checklist- Revised (PCL-R).
59-1	9838-9845	Because	_
59-2	9846-9855	stimulant	http://maven.renci.org/NeuroBridge/neurobridge#StimulantDependence[35]
59-3	9856-9859	use	http://maven.renci.org/NeuroBridge/neurobridge#StimulantDependence[35]
59-4	9860-9862	is	_
59-5	9863-9869	likely	_
59-6	9870-9872	to	_
59-7	9873-9875	be	_
59-8	9876-9884	comorbid	_
59-9	9885-9889	with	_
59-10	9890-9901	psychopathy	_
59-11	9901-9902	,	_
59-12	9903-9914	psychopathy	_
59-13	9915-9918	and	_
59-14	9919-9928	stimulant	http://maven.renci.org/NeuroBridge/neurobridge#StimulantDependence[36]
59-15	9929-9934	abuse	http://maven.renci.org/NeuroBridge/neurobridge#StimulantDependence[36]
59-16	9935-9939	show	_
59-17	9940-9951	overlapping	_
59-18	9952-9957	brain	_
59-19	9958-9965	regions	_
59-20	9966-9968	of	_
59-21	9969-9978	decreased	_
59-22	9979-9988	structure	_
59-23	9988-9989	/	_
59-24	9989-9997	function	_
59-25	9997-9998	,	_
59-26	9999-10002	and	_
59-27	10003-10014	psychopathy	_
59-28	10015-10017	is	_
59-29	10018-10024	higher	_
59-30	10025-10030	among	_
59-31	10031-10043	incarcerated	_
59-32	10044-10050	versus	_
59-33	10051-10067	non-incarcerated	_
59-34	10068-10079	individuals	_
59-35	10079-10080	,	_
59-36	10081-10092	psychopathy	_
59-37	10093-10096	was	_
59-38	10097-10105	assessed	_
59-39	10106-10108	in	_
59-40	10109-10112	all	_
59-41	10113-10118	study	_
59-42	10119-10131	participants	_
59-43	10132-10137	using	_
59-44	10138-10141	the	_
59-45	10142-10146	Hare	http://www.case.edu/ProvCaRe/provcare#Questionnaire[37]
59-46	10147-10158	Psychopathy	http://www.case.edu/ProvCaRe/provcare#Questionnaire[37]
59-47	10159-10168	Checklist	http://www.case.edu/ProvCaRe/provcare#Questionnaire[37]
59-48	10168-10169	-	http://www.case.edu/ProvCaRe/provcare#Questionnaire[37]
59-49	10170-10177	Revised	http://www.case.edu/ProvCaRe/provcare#Questionnaire[37]
59-50	10178-10179	(	http://www.case.edu/ProvCaRe/provcare#Questionnaire[37]
59-51	10179-10184	PCL-R	http://www.case.edu/ProvCaRe/provcare#Questionnaire[37]
59-52	10184-10185	)	http://www.case.edu/ProvCaRe/provcare#Questionnaire[37]
59-53	10185-10186	.	_

#Text=The PCL-R is the most widely used assessment of psychopathy in forensic populations, consisting of a semi-structured interview on topics such as interpersonal style and criminal history.
60-1	10187-10190	The	_
60-2	10191-10196	PCL-R	_
60-3	10197-10199	is	_
60-4	10200-10203	the	_
60-5	10204-10208	most	_
60-6	10209-10215	widely	_
60-7	10216-10220	used	_
60-8	10221-10231	assessment	_
60-9	10232-10234	of	_
60-10	10235-10246	psychopathy	_
60-11	10247-10249	in	_
60-12	10250-10258	forensic	_
60-13	10259-10270	populations	_
60-14	10270-10271	,	_
60-15	10272-10282	consisting	_
60-16	10283-10285	of	_
60-17	10286-10287	a	_
60-18	10288-10303	semi-structured	_
60-19	10304-10313	interview	_
60-20	10314-10316	on	_
60-21	10317-10323	topics	_
60-22	10324-10328	such	_
60-23	10329-10331	as	_
60-24	10332-10345	interpersonal	_
60-25	10346-10351	style	_
60-26	10352-10355	and	_
60-27	10356-10364	criminal	_
60-28	10365-10372	history	_
60-29	10372-10373	.	_

#Text=Participants are scored on a scale of 0–40, where higher scores indicate stronger psychopathic traits.
61-1	10374-10386	Participants	_
61-2	10387-10390	are	_
61-3	10391-10397	scored	_
61-4	10398-10400	on	_
61-5	10401-10402	a	_
61-6	10403-10408	scale	_
61-7	10409-10411	of	_
61-8	10412-10413	0	_
61-9	10413-10414	–	_
61-10	10414-10416	40	_
61-11	10416-10417	,	_
61-12	10418-10423	where	_
61-13	10424-10430	higher	_
61-14	10431-10437	scores	_
61-15	10438-10446	indicate	_
61-16	10447-10455	stronger	_
61-17	10456-10468	psychopathic	_
61-18	10469-10475	traits	_
61-19	10475-10476	.	_

#Text=Psychiatric histories were assessed with the Structured Clinical Interview for DSM-IV disorders (SCID) both to evaluate psychotic disorders for exclusion purposes and to evaluate other Axis I disorders.
62-1	10477-10488	Psychiatric	_
62-2	10489-10498	histories	_
62-3	10499-10503	were	_
62-4	10504-10512	assessed	_
62-5	10513-10517	with	_
62-6	10518-10521	the	_
62-7	10522-10532	Structured	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[38]
62-8	10533-10541	Clinical	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[38]
62-9	10542-10551	Interview	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[38]
62-10	10552-10555	for	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[38]
62-11	10556-10562	DSM-IV	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[38]
62-12	10563-10572	disorders	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[38]
62-13	10573-10574	(	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[38]
62-14	10574-10578	SCID	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[38]
62-15	10578-10579	)	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[38]
62-16	10580-10584	both	_
62-17	10585-10587	to	_
62-18	10588-10596	evaluate	_
62-19	10597-10606	psychotic	_
62-20	10607-10616	disorders	_
62-21	10617-10620	for	_
62-22	10621-10630	exclusion	_
62-23	10631-10639	purposes	_
62-24	10640-10643	and	_
62-25	10644-10646	to	_
62-26	10647-10655	evaluate	_
62-27	10656-10661	other	_
62-28	10662-10666	Axis	_
62-29	10667-10668	I	_
62-30	10669-10678	disorders	_
62-31	10678-10679	.	_

#Text=All interviews were conducted by trained research staff.
63-1	10680-10683	All	_
63-2	10684-10694	interviews	_
63-3	10695-10699	were	_
63-4	10700-10709	conducted	_
63-5	10710-10712	by	_
63-6	10713-10720	trained	_
63-7	10721-10729	research	_
63-8	10730-10735	staff	_
63-9	10735-10736	.	_

#Text=Moral task
#Text=Participants were shown words and phrases describing moral acts or concepts adapted from a task previously developed and validated by.
64-1	10737-10742	Moral	_
64-2	10743-10747	task	_
64-3	10748-10760	Participants	_
64-4	10761-10765	were	_
64-5	10766-10771	shown	_
64-6	10772-10777	words	_
64-7	10778-10781	and	_
64-8	10782-10789	phrases	_
64-9	10790-10800	describing	_
64-10	10801-10806	moral	_
64-11	10807-10811	acts	_
64-12	10812-10814	or	_
64-13	10815-10823	concepts	_
64-14	10824-10831	adapted	_
64-15	10832-10836	from	_
64-16	10837-10838	a	_
64-17	10839-10843	task	_
64-18	10844-10854	previously	_
64-19	10855-10864	developed	_
64-20	10865-10868	and	_
64-21	10869-10878	validated	_
64-22	10879-10881	by	_
64-23	10881-10882	.	_

#Text=Fifty stimuli were classified as noncontroversial negative (e.g., murder, slavery), fifty were classified as noncontroversial positive (e.g., charity, kindness), and fifty were classified as controversial (e.g., animal testing, gun control).
65-1	10883-10888	Fifty	_
65-2	10889-10896	stimuli	_
65-3	10897-10901	were	_
65-4	10902-10912	classified	_
65-5	10913-10915	as	_
65-6	10916-10932	noncontroversial	_
65-7	10933-10941	negative	_
65-8	10942-10943	(	_
65-9	10943-10946	e.g	_
65-10	10946-10947	.	_
65-11	10947-10948	,	_
65-12	10949-10955	murder	_
65-13	10955-10956	,	_
65-14	10957-10964	slavery	_
65-15	10964-10965	)	_
65-16	10965-10966	,	_
65-17	10967-10972	fifty	_
65-18	10973-10977	were	_
65-19	10978-10988	classified	_
65-20	10989-10991	as	_
65-21	10992-11008	noncontroversial	_
65-22	11009-11017	positive	_
65-23	11018-11019	(	_
65-24	11019-11022	e.g	_
65-25	11022-11023	.	_
65-26	11023-11024	,	_
65-27	11025-11032	charity	_
65-28	11032-11033	,	_
65-29	11034-11042	kindness	_
65-30	11042-11043	)	_
65-31	11043-11044	,	_
65-32	11045-11048	and	_
65-33	11049-11054	fifty	_
65-34	11055-11059	were	_
65-35	11060-11070	classified	_
65-36	11071-11073	as	_
65-37	11074-11087	controversial	_
65-38	11088-11089	(	_
65-39	11089-11092	e.g	_
65-40	11092-11093	.	_
65-41	11093-11094	,	_
65-42	11095-11101	animal	_
65-43	11102-11109	testing	_
65-44	11109-11110	,	_
65-45	11111-11114	gun	_
65-46	11115-11122	control	_
65-47	11122-11123	)	_
65-48	11123-11124	.	_

#Text=Controversial stimuli required more processing than noncontroversial stimuli; this was confirmed in our study by an increased response time to the stimuli.
66-1	11125-11138	Controversial	_
66-2	11139-11146	stimuli	_
66-3	11147-11155	required	_
66-4	11156-11160	more	_
66-5	11161-11171	processing	_
66-6	11172-11176	than	_
66-7	11177-11193	noncontroversial	_
66-8	11194-11201	stimuli	_
66-9	11201-11202	;	_
66-10	11203-11207	this	_
66-11	11208-11211	was	_
66-12	11212-11221	confirmed	_
66-13	11222-11224	in	_
66-14	11225-11228	our	_
66-15	11229-11234	study	_
66-16	11235-11237	by	_
66-17	11238-11240	an	_
66-18	11241-11250	increased	_
66-19	11251-11259	response	_
66-20	11260-11264	time	_
66-21	11265-11267	to	_
66-22	11268-11271	the	_
66-23	11272-11279	stimuli	_
66-24	11279-11280	.	_

#Text=Participants were presented with a given stimulus and asked to press one button to indicate they thought the word or phrase was morally wrong and a different button to indicate that they thought the stimuli was morally not wrong.
67-1	11281-11293	Participants	_
67-2	11294-11298	were	_
67-3	11299-11308	presented	_
67-4	11309-11313	with	_
67-5	11314-11315	a	_
67-6	11316-11321	given	_
67-7	11322-11330	stimulus	_
67-8	11331-11334	and	_
67-9	11335-11340	asked	_
67-10	11341-11343	to	_
67-11	11344-11349	press	_
67-12	11350-11353	one	_
67-13	11354-11360	button	_
67-14	11361-11363	to	_
67-15	11364-11372	indicate	_
67-16	11373-11377	they	_
67-17	11378-11385	thought	_
67-18	11386-11389	the	_
67-19	11390-11394	word	_
67-20	11395-11397	or	_
67-21	11398-11404	phrase	_
67-22	11405-11408	was	_
67-23	11409-11416	morally	_
67-24	11417-11422	wrong	_
67-25	11423-11426	and	_
67-26	11427-11428	a	_
67-27	11429-11438	different	_
67-28	11439-11445	button	_
67-29	11446-11448	to	_
67-30	11449-11457	indicate	_
67-31	11458-11462	that	_
67-32	11463-11467	they	_
67-33	11468-11475	thought	_
67-34	11476-11479	the	_
67-35	11480-11487	stimuli	_
67-36	11488-11491	was	_
67-37	11492-11499	morally	_
67-38	11500-11503	not	_
67-39	11504-11509	wrong	_
67-40	11509-11510	.	_

#Text=After the button was pressed, a black screen was shown jittered for 1 to 6 seconds.
68-1	11511-11516	After	_
68-2	11517-11520	the	_
68-3	11521-11527	button	_
68-4	11528-11531	was	_
68-5	11532-11539	pressed	_
68-6	11539-11540	,	_
68-7	11541-11542	a	_
68-8	11543-11548	black	_
68-9	11549-11555	screen	_
68-10	11556-11559	was	_
68-11	11560-11565	shown	_
68-12	11566-11574	jittered	_
68-13	11575-11578	for	_
68-14	11579-11580	1	_
68-15	11581-11583	to	_
68-16	11584-11585	6	_
68-17	11586-11593	seconds	_
68-18	11593-11594	.	_

#Text=Three runs of the task were administered, each including 50 stimuli evenly divided amongst stimulus types.
69-1	11595-11600	Three	_
69-2	11601-11605	runs	_
69-3	11606-11608	of	_
69-4	11609-11612	the	_
69-5	11613-11617	task	_
69-6	11618-11622	were	_
69-7	11623-11635	administered	_
69-8	11635-11636	,	_
69-9	11637-11641	each	_
69-10	11642-11651	including	_
69-11	11652-11654	50	_
69-12	11655-11662	stimuli	_
69-13	11663-11669	evenly	_
69-14	11670-11677	divided	_
69-15	11678-11685	amongst	_
69-16	11686-11694	stimulus	_
69-17	11695-11700	types	_
69-18	11700-11701	.	_

#Text=MRI data acquisition
#Text=Participants were scanned using the Mind Research Network’s 1.5T Siemens Avanto mobile MRI scanner stationed at correctional facilities.
70-1	11702-11705	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[39]
70-2	11706-11710	data	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[39]
70-3	11711-11722	acquisition	_
70-4	11723-11735	Participants	_
70-5	11736-11740	were	_
70-6	11741-11748	scanned	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[40]
70-7	11749-11754	using	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[40]
70-8	11755-11758	the	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[40]
70-9	11759-11763	Mind	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[40]
70-10	11764-11772	Research	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[40]
70-11	11773-11780	Network	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[40]
70-12	11780-11781	’	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[40]
70-13	11781-11782	s	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[40]
70-14	11783-11787	1.5T	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[40]
70-15	11788-11795	Siemens	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[40]
70-16	11796-11802	Avanto	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[40]
70-17	11803-11809	mobile	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[40]
70-18	11810-11813	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[40]
70-19	11814-11821	scanner	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[40]
70-20	11822-11831	stationed	_
70-21	11832-11834	at	_
70-22	11835-11847	correctional	_
70-23	11848-11858	facilities	_
70-24	11858-11859	.	_

#Text=The scans were acquired using an EPI gradient-echo pulse sequence (parameters: repetition time (TR) 2000, echo time (TE) 39 ms, flip angle 75°, FOV 24 x 24 cm, 64 x 64 matrix, 4 mm slice thickness with a 1mm gap, 27 slices).
71-1	11860-11863	The	_
71-2	11864-11869	scans	_
71-3	11870-11874	were	_
71-4	11875-11883	acquired	_
71-5	11884-11889	using	_
71-6	11890-11892	an	_
71-7	11893-11896	EPI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[41]
71-8	11897-11910	gradient-echo	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[41]
71-9	11911-11916	pulse	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[41]
71-10	11917-11925	sequence	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[41]
71-11	11926-11927	(	_
71-12	11927-11937	parameters	_
71-13	11937-11938	:	_
71-14	11939-11949	repetition	_
71-15	11950-11954	time	_
71-16	11955-11956	(	_
71-17	11956-11958	TR	_
71-18	11958-11959	)	_
71-19	11960-11964	2000	_
71-20	11964-11965	,	_
71-21	11966-11970	echo	_
71-22	11971-11975	time	_
71-23	11976-11977	(	_
71-24	11977-11979	TE	_
71-25	11979-11980	)	_
71-26	11981-11983	39	_
71-27	11984-11986	ms	_
71-28	11986-11987	,	_
71-29	11988-11992	flip	_
71-30	11993-11998	angle	_
71-31	11999-12001	75	_
71-32	12001-12002	°	_
71-33	12002-12003	,	_
71-34	12004-12007	FOV	_
71-35	12008-12010	24	_
71-36	12011-12012	x	_
71-37	12013-12015	24	_
71-38	12016-12018	cm	_
71-39	12018-12019	,	_
71-40	12020-12022	64	_
71-41	12023-12024	x	_
71-42	12025-12027	64	_
71-43	12028-12034	matrix	_
71-44	12034-12035	,	_
71-45	12036-12037	4	_
71-46	12038-12040	mm	_
71-47	12041-12046	slice	_
71-48	12047-12056	thickness	_
71-49	12057-12061	with	_
71-50	12062-12063	a	_
71-51	12064-12067	1mm	_
71-52	12068-12071	gap	_
71-53	12071-12072	,	_
71-54	12073-12075	27	_
71-55	12076-12082	slices	_
71-56	12082-12083	)	_
71-57	12083-12084	.	_

#Text=The task was presented using E-Prime software.
72-1	12085-12088	The	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[42]
72-2	12089-12093	task	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[42]
72-3	12094-12097	was	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[42]
72-4	12098-12107	presented	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[42]
72-5	12108-12113	using	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[42]
72-6	12114-12121	E-Prime	_
72-7	12122-12130	software	_
72-8	12130-12131	.	_

#Text=A T1-weighted scan was collected (parameters: TR 2530, TE 1.64 ms, 3.50ms, 5.36ms, 7.22ms, inversion time = 1100 ms, flip angle 7°, slice thickness = 1.3mm, 256 x 256 matrix), but it was not used in any of the functional MRI post-processing.
73-1	12132-12133	A	_
73-2	12134-12136	T1	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[43]
73-3	12136-12137	-	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[43]
73-4	12137-12145	weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[43]
73-5	12146-12150	scan	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[43]
73-6	12151-12154	was	_
73-7	12155-12164	collected	_
73-8	12165-12166	(	_
73-9	12166-12176	parameters	_
73-10	12176-12177	:	_
73-11	12178-12180	TR	_
73-12	12181-12185	2530	_
73-13	12185-12186	,	_
73-14	12187-12189	TE	_
73-15	12190-12194	1.64	_
73-16	12195-12197	ms	_
73-17	12197-12198	,	_
73-18	12199-12205	3.50ms	_
73-19	12205-12206	,	_
73-20	12207-12213	5.36ms	_
73-21	12213-12214	,	_
73-22	12215-12221	7.22ms	_
73-23	12221-12222	,	_
73-24	12223-12232	inversion	_
73-25	12233-12237	time	_
73-26	12238-12239	=	_
73-27	12240-12244	1100	_
73-28	12245-12247	ms	_
73-29	12247-12248	,	_
73-30	12249-12253	flip	_
73-31	12254-12259	angle	_
73-32	12260-12261	7	_
73-33	12261-12262	°	_
73-34	12262-12263	,	_
73-35	12264-12269	slice	_
73-36	12270-12279	thickness	_
73-37	12280-12281	=	_
73-38	12282-12287	1.3mm	_
73-39	12287-12288	,	_
73-40	12289-12292	256	_
73-41	12293-12294	x	_
73-42	12295-12298	256	_
73-43	12299-12305	matrix	_
73-44	12305-12306	)	_
73-45	12306-12307	,	_
73-46	12308-12311	but	_
73-47	12312-12314	it	_
73-48	12315-12318	was	_
73-49	12319-12322	not	_
73-50	12323-12327	used	_
73-51	12328-12330	in	_
73-52	12331-12334	any	_
73-53	12335-12337	of	_
73-54	12338-12341	the	_
73-55	12342-12352	functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[44]
73-56	12353-12356	MRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[44]
73-57	12357-12372	post-processing	_
73-58	12372-12373	.	_

#Text=Image preprocessing and analyses
#Text=Imaging data were preprocessed with Statistical Parametric Mapping software (SPM).
74-1	12374-12379	Image	_
74-2	12380-12393	preprocessing	_
74-3	12394-12397	and	_
74-4	12398-12406	analyses	_
74-5	12407-12414	Imaging	_
74-6	12415-12419	data	_
74-7	12420-12424	were	_
74-8	12425-12437	preprocessed	_
74-9	12438-12442	with	_
74-10	12443-12454	Statistical	_
74-11	12455-12465	Parametric	_
74-12	12466-12473	Mapping	_
74-13	12474-12482	software	_
74-14	12483-12484	(	_
74-15	12484-12487	SPM	_
74-16	12487-12488	)	_
74-17	12488-12489	.	_

#Text=Head motion was corrected using the ArtRepair Toolbox in SPM to identify and remove severe artifacts, defined as time points with signal change greater than 4% of the global mean signal, then INRIAlign to estimate head motion using an algorithm that is insensitive to eye movements and blood oxygenation level dependent (BOLD) activity.
75-1	12490-12494	Head	_
75-2	12495-12501	motion	_
75-3	12502-12505	was	_
75-4	12506-12515	corrected	_
75-5	12516-12521	using	_
75-6	12522-12525	the	_
75-7	12526-12535	ArtRepair	_
75-8	12536-12543	Toolbox	_
75-9	12544-12546	in	_
75-10	12547-12550	SPM	_
75-11	12551-12553	to	_
75-12	12554-12562	identify	_
75-13	12563-12566	and	_
75-14	12567-12573	remove	_
75-15	12574-12580	severe	_
75-16	12581-12590	artifacts	_
75-17	12590-12591	,	_
75-18	12592-12599	defined	_
75-19	12600-12602	as	_
75-20	12603-12607	time	_
75-21	12608-12614	points	_
75-22	12615-12619	with	_
75-23	12620-12626	signal	_
75-24	12627-12633	change	_
75-25	12634-12641	greater	_
75-26	12642-12646	than	_
75-27	12647-12649	4%	_
75-28	12650-12652	of	_
75-29	12653-12656	the	_
75-30	12657-12663	global	_
75-31	12664-12668	mean	_
75-32	12669-12675	signal	_
75-33	12675-12676	,	_
75-34	12677-12681	then	_
75-35	12682-12691	INRIAlign	_
75-36	12692-12694	to	_
75-37	12695-12703	estimate	_
75-38	12704-12708	head	_
75-39	12709-12715	motion	_
75-40	12716-12721	using	_
75-41	12722-12724	an	_
75-42	12725-12734	algorithm	_
75-43	12735-12739	that	_
75-44	12740-12742	is	_
75-45	12743-12754	insensitive	_
75-46	12755-12757	to	_
75-47	12758-12761	eye	_
75-48	12762-12771	movements	_
75-49	12772-12775	and	_
75-50	12776-12781	blood	_
75-51	12782-12793	oxygenation	_
75-52	12794-12799	level	_
75-53	12800-12809	dependent	_
75-54	12810-12811	(	_
75-55	12811-12815	BOLD	_
75-56	12815-12816	)	_
75-57	12817-12825	activity	_
75-58	12825-12826	.	_

#Text=We then spatially normalized images to the Montreal Neurological Institute (MNI) template and smoothed with an 8 mm full-width at half-maximum Gaussian smoothing kernel.
76-1	12827-12829	We	_
76-2	12830-12834	then	_
76-3	12835-12844	spatially	_
76-4	12845-12855	normalized	_
76-5	12856-12862	images	_
76-6	12863-12865	to	_
76-7	12866-12869	the	_
76-8	12870-12878	Montreal	_
76-9	12879-12891	Neurological	_
76-10	12892-12901	Institute	_
76-11	12902-12903	(	_
76-12	12903-12906	MNI	_
76-13	12906-12907	)	_
76-14	12908-12916	template	_
76-15	12917-12920	and	_
76-16	12921-12929	smoothed	_
76-17	12930-12934	with	_
76-18	12935-12937	an	_
76-19	12938-12939	8	_
76-20	12940-12942	mm	_
76-21	12943-12953	full-width	_
76-22	12954-12956	at	_
76-23	12957-12969	half-maximum	_
76-24	12970-12978	Gaussian	_
76-25	12979-12988	smoothing	_
76-26	12989-12995	kernel	_
76-27	12995-12996	.	_

#Text=A high-pass filter removed low-frequency drift below 1/128 Hertz.
77-1	12997-12998	A	_
77-2	12999-13008	high-pass	_
77-3	13009-13015	filter	_
77-4	13016-13023	removed	_
77-5	13024-13037	low-frequency	_
77-6	13038-13043	drift	_
77-7	13044-13049	below	_
77-8	13050-13051	1	_
77-9	13051-13052	/	_
77-10	13052-13055	128	_
77-11	13056-13061	Hertz	_
77-12	13061-13062	.	_

#Text=We modeled two conditions of interest at the single-subject level using the general linear model (GLM).
78-1	13063-13065	We	_
78-2	13066-13073	modeled	_
78-3	13074-13077	two	_
78-4	13078-13088	conditions	_
78-5	13089-13091	of	_
78-6	13092-13100	interest	_
78-7	13101-13103	at	_
78-8	13104-13107	the	_
78-9	13108-13122	single-subject	_
78-10	13123-13128	level	_
78-11	13129-13134	using	_
78-12	13135-13138	the	_
78-13	13139-13146	general	_
78-14	13147-13153	linear	_
78-15	13154-13159	model	_
78-16	13160-13161	(	_
78-17	13161-13164	GLM	_
78-18	13164-13165	)	_
78-19	13165-13166	.	_

#Text=These conditions were controversial and noncontroversial (including both positive and negative stimuli).
79-1	13167-13172	These	_
79-2	13173-13183	conditions	_
79-3	13184-13188	were	_
79-4	13189-13202	controversial	_
79-5	13203-13206	and	_
79-6	13207-13223	noncontroversial	_
79-7	13224-13225	(	_
79-8	13225-13234	including	_
79-9	13235-13239	both	_
79-10	13240-13248	positive	_
79-11	13249-13252	and	_
79-12	13253-13261	negative	_
79-13	13262-13269	stimuli	_
79-14	13269-13270	)	_
79-15	13270-13271	.	_

#Text=We examined the conditions time-locked to participant response.
80-1	13272-13274	We	_
80-2	13275-13283	examined	_
80-3	13284-13287	the	_
80-4	13288-13298	conditions	_
80-5	13299-13310	time-locked	_
80-6	13311-13313	to	_
80-7	13314-13325	participant	_
80-8	13326-13334	response	_
80-9	13334-13335	.	_

#Text=At the group-level, the conditions of interest were compared using a one-sample t-test (controversial > noncontroversial).
81-1	13336-13338	At	_
81-2	13339-13342	the	_
81-3	13343-13354	group-level	_
81-4	13354-13355	,	_
81-5	13356-13359	the	_
81-6	13360-13370	conditions	_
81-7	13371-13373	of	_
81-8	13374-13382	interest	_
81-9	13383-13387	were	_
81-10	13388-13396	compared	_
81-11	13397-13402	using	_
81-12	13403-13404	a	_
81-13	13405-13415	one-sample	_
81-14	13416-13422	t-test	_
81-15	13423-13424	(	_
81-16	13424-13437	controversial	_
81-17	13438-13439	>	_
81-18	13440-13456	noncontroversial	_
81-19	13456-13457	)	_
81-20	13457-13458	.	_

#Text=The main effects of this analysis replicated previous use of this task in healthy controls.
82-1	13459-13462	The	_
82-2	13463-13467	main	_
82-3	13468-13475	effects	_
82-4	13476-13478	of	_
82-5	13479-13483	this	_
82-6	13484-13492	analysis	_
82-7	13493-13503	replicated	_
82-8	13504-13512	previous	_
82-9	13513-13516	use	_
82-10	13517-13519	of	_
82-11	13520-13524	this	_
82-12	13525-13529	task	_
82-13	13530-13532	in	_
82-14	13533-13540	healthy	_
82-15	13541-13549	controls	_
82-16	13549-13550	.	_

#Text=We then used a two sample t-test to compare BOLD responses for this contrast between the lifetime stimulant use group and non-stimulant use group.
83-1	13551-13553	We	_
83-2	13554-13558	then	_
83-3	13559-13563	used	_
83-4	13564-13565	a	_
83-5	13566-13569	two	_
83-6	13570-13576	sample	_
83-7	13577-13583	t-test	_
83-8	13584-13586	to	_
83-9	13587-13594	compare	_
83-10	13595-13599	BOLD	_
83-11	13600-13609	responses	_
83-12	13610-13613	for	_
83-13	13614-13618	this	_
83-14	13619-13627	contrast	_
83-15	13628-13635	between	_
83-16	13636-13639	the	_
83-17	13640-13648	lifetime	_
83-18	13649-13658	stimulant	_
83-19	13659-13662	use	_
83-20	13663-13668	group	_
83-21	13669-13672	and	_
83-22	13673-13686	non-stimulant	_
83-23	13687-13690	use	_
83-24	13691-13696	group	_
83-25	13696-13697	.	_

#Text=Additionally, we examined the impact of stimulant use duration on moral processing by regressing total years of regular stimulant use in a separate statistical analysis using only participants in the lifetime stimulant use group.
84-1	13698-13710	Additionally	_
84-2	13710-13711	,	_
84-3	13712-13714	we	_
84-4	13715-13723	examined	_
84-5	13724-13727	the	_
84-6	13728-13734	impact	_
84-7	13735-13737	of	_
84-8	13738-13747	stimulant	_
84-9	13748-13751	use	_
84-10	13752-13760	duration	_
84-11	13761-13763	on	_
84-12	13764-13769	moral	_
84-13	13770-13780	processing	_
84-14	13781-13783	by	_
84-15	13784-13794	regressing	_
84-16	13795-13800	total	_
84-17	13801-13806	years	_
84-18	13807-13809	of	_
84-19	13810-13817	regular	_
84-20	13818-13827	stimulant	_
84-21	13828-13831	use	_
84-22	13832-13834	in	_
84-23	13835-13836	a	_
84-24	13837-13845	separate	_
84-25	13846-13857	statistical	_
84-26	13858-13866	analysis	_
84-27	13867-13872	using	_
84-28	13873-13877	only	_
84-29	13878-13890	participants	_
84-30	13891-13893	in	_
84-31	13894-13897	the	_
84-32	13898-13906	lifetime	_
84-33	13907-13916	stimulant	_
84-34	13917-13920	use	_
84-35	13921-13926	group	_
84-36	13926-13927	.	_

#Text=This stimulant use duration measure may in part quantify stimulant use severity.
85-1	13928-13932	This	_
85-2	13933-13942	stimulant	_
85-3	13943-13946	use	_
85-4	13947-13955	duration	_
85-5	13956-13963	measure	_
85-6	13964-13967	may	_
85-7	13968-13970	in	_
85-8	13971-13975	part	_
85-9	13976-13984	quantify	_
85-10	13985-13994	stimulant	_
85-11	13995-13998	use	_
85-12	13999-14007	severity	_
85-13	14007-14008	.	_

#Text=We did not use years of non-stimulant substance and alcohol use as a covariate in our primary group comparisons because it was significantly different between groups; this means that including it as a covariate would remove variance from the group difference, not the error variance.
86-1	14009-14011	We	_
86-2	14012-14015	did	_
86-3	14016-14019	not	_
86-4	14020-14023	use	_
86-5	14024-14029	years	_
86-6	14030-14032	of	_
86-7	14033-14046	non-stimulant	_
86-8	14047-14056	substance	_
86-9	14057-14060	and	_
86-10	14061-14068	alcohol	_
86-11	14069-14072	use	_
86-12	14073-14075	as	_
86-13	14076-14077	a	_
86-14	14078-14087	covariate	_
86-15	14088-14090	in	_
86-16	14091-14094	our	_
86-17	14095-14102	primary	_
86-18	14103-14108	group	_
86-19	14109-14120	comparisons	_
86-20	14121-14128	because	_
86-21	14129-14131	it	_
86-22	14132-14135	was	_
86-23	14136-14149	significantly	_
86-24	14150-14159	different	_
86-25	14160-14167	between	_
86-26	14168-14174	groups	_
86-27	14174-14175	;	_
86-28	14176-14180	this	_
86-29	14181-14186	means	_
86-30	14187-14191	that	_
86-31	14192-14201	including	_
86-32	14202-14204	it	_
86-33	14205-14207	as	_
86-34	14208-14209	a	_
86-35	14210-14219	covariate	_
86-36	14220-14225	would	_
86-37	14226-14232	remove	_
86-38	14233-14241	variance	_
86-39	14242-14246	from	_
86-40	14247-14250	the	_
86-41	14251-14256	group	_
86-42	14257-14267	difference	_
86-43	14267-14268	,	_
86-44	14269-14272	not	_
86-45	14273-14276	the	_
86-46	14277-14282	error	_
86-47	14283-14291	variance	_
86-48	14291-14292	.	_

#Text=In order to control for confounding variables in the regression model only, we used years of non-stimulant substance and alcohol use as a covariate in the regression of hemodynamic response by stimulant use duration; we also added age ( significantly related to duration of stimulant use: r = .272, p = .002, two-tailed Pearson, and PCL-R Total score to the model, but did not see substantive differences in the results.
87-1	14293-14295	In	_
87-2	14296-14301	order	_
87-3	14302-14304	to	_
87-4	14305-14312	control	_
87-5	14313-14316	for	_
87-6	14317-14328	confounding	_
87-7	14329-14338	variables	_
87-8	14339-14341	in	_
87-9	14342-14345	the	_
87-10	14346-14356	regression	_
87-11	14357-14362	model	_
87-12	14363-14367	only	_
87-13	14367-14368	,	_
87-14	14369-14371	we	_
87-15	14372-14376	used	_
87-16	14377-14382	years	_
87-17	14383-14385	of	_
87-18	14386-14399	non-stimulant	_
87-19	14400-14409	substance	_
87-20	14410-14413	and	_
87-21	14414-14421	alcohol	_
87-22	14422-14425	use	_
87-23	14426-14428	as	_
87-24	14429-14430	a	_
87-25	14431-14440	covariate	_
87-26	14441-14443	in	_
87-27	14444-14447	the	_
87-28	14448-14458	regression	_
87-29	14459-14461	of	_
87-30	14462-14473	hemodynamic	_
87-31	14474-14482	response	_
87-32	14483-14485	by	_
87-33	14486-14495	stimulant	_
87-34	14496-14499	use	_
87-35	14500-14508	duration	_
87-36	14508-14509	;	_
87-37	14510-14512	we	_
87-38	14513-14517	also	_
87-39	14518-14523	added	_
87-40	14524-14527	age	_
87-41	14528-14529	(	_
87-42	14530-14543	significantly	_
87-43	14544-14551	related	_
87-44	14552-14554	to	_
87-45	14555-14563	duration	_
87-46	14564-14566	of	_
87-47	14567-14576	stimulant	_
87-48	14577-14580	use	_
87-49	14580-14581	:	_
87-50	14582-14583	r	_
87-51	14584-14585	=	_
87-52	14586-14590	.272	_
87-53	14590-14591	,	_
87-54	14592-14593	p	_
87-55	14594-14595	=	_
87-56	14596-14600	.002	_
87-57	14600-14601	,	_
87-58	14602-14612	two-tailed	_
87-59	14613-14620	Pearson	_
87-60	14620-14621	,	_
87-61	14622-14625	and	_
87-62	14626-14631	PCL-R	_
87-63	14632-14637	Total	_
87-64	14638-14643	score	_
87-65	14644-14646	to	_
87-66	14647-14650	the	_
87-67	14651-14656	model	_
87-68	14656-14657	,	_
87-69	14658-14661	but	_
87-70	14662-14665	did	_
87-71	14666-14669	not	_
87-72	14670-14673	see	_
87-73	14674-14685	substantive	_
87-74	14686-14697	differences	_
87-75	14698-14700	in	_
87-76	14701-14704	the	_
87-77	14705-14712	results	_
87-78	14712-14713	.	_

#Text=To test our hypotheses, a priori brain regions of interest (ROIs) were examined including the ACC, PCC, amygdala, and vmPFC.
88-1	14714-14716	To	_
88-2	14717-14721	test	_
88-3	14722-14725	our	_
88-4	14726-14736	hypotheses	_
88-5	14736-14737	,	_
88-6	14738-14739	a	_
88-7	14740-14746	priori	_
88-8	14747-14752	brain	_
88-9	14753-14760	regions	_
88-10	14761-14763	of	_
88-11	14764-14772	interest	_
88-12	14773-14774	(	_
88-13	14774-14778	ROIs	_
88-14	14778-14779	)	_
88-15	14780-14784	were	_
88-16	14785-14793	examined	_
88-17	14794-14803	including	_
88-18	14804-14807	the	_
88-19	14808-14811	ACC	_
88-20	14811-14812	,	_
88-21	14813-14816	PCC	_
88-22	14816-14817	,	_
88-23	14818-14826	amygdala	_
88-24	14826-14827	,	_
88-25	14828-14831	and	_
88-26	14832-14837	vmPFC	_
88-27	14837-14838	.	_

#Text=Anatomical masks of these regions were generated from Wake Forest University Pick Atlas in SPM.
89-1	14839-14849	Anatomical	_
89-2	14850-14855	masks	_
89-3	14856-14858	of	_
89-4	14859-14864	these	_
89-5	14865-14872	regions	_
89-6	14873-14877	were	_
89-7	14878-14887	generated	_
89-8	14888-14892	from	_
89-9	14893-14897	Wake	_
89-10	14898-14904	Forest	_
89-11	14905-14915	University	_
89-12	14916-14920	Pick	_
89-13	14921-14926	Atlas	_
89-14	14927-14929	in	_
89-15	14930-14933	SPM	_
89-16	14933-14934	.	_

#Text=A small-volume correction (SVC) was applied to determine the corrected p-values based on the size of each ROI using family wise error (FWE) rate correction for multiple comparisons.
90-1	14935-14936	A	_
90-2	14937-14949	small-volume	_
90-3	14950-14960	correction	_
90-4	14961-14962	(	_
90-5	14962-14965	SVC	_
90-6	14965-14966	)	_
90-7	14967-14970	was	_
90-8	14971-14978	applied	_
90-9	14979-14981	to	_
90-10	14982-14991	determine	_
90-11	14992-14995	the	_
90-12	14996-15005	corrected	_
90-13	15006-15014	p-values	_
90-14	15015-15020	based	_
90-15	15021-15023	on	_
90-16	15024-15027	the	_
90-17	15028-15032	size	_
90-18	15033-15035	of	_
90-19	15036-15040	each	_
90-20	15041-15044	ROI	_
90-21	15045-15050	using	_
90-22	15051-15057	family	_
90-23	15058-15062	wise	_
90-24	15063-15068	error	_
90-25	15069-15070	(	_
90-26	15070-15073	FWE	_
90-27	15073-15074	)	_
90-28	15075-15079	rate	_
90-29	15080-15090	correction	_
90-30	15091-15094	for	_
90-31	15095-15103	multiple	_
90-32	15104-15115	comparisons	_
90-33	15115-15116	.	_

#Text=ROIs are represented in Figure 1.
91-1	15117-15121	ROIs	_
91-2	15122-15125	are	_
91-3	15126-15137	represented	_
91-4	15138-15140	in	_
91-5	15141-15147	Figure	_
91-6	15148-15149	1	_
91-7	15149-15150	.	_

#Text=Additionally, a whole brain analysis corrected using FWE at p < .05 was conducted to examine areas outside our a priori regions of interest.
92-1	15151-15163	Additionally	_
92-2	15163-15164	,	_
92-3	15165-15166	a	_
92-4	15167-15172	whole	_
92-5	15173-15178	brain	_
92-6	15179-15187	analysis	_
92-7	15188-15197	corrected	_
92-8	15198-15203	using	_
92-9	15204-15207	FWE	_
92-10	15208-15210	at	_
92-11	15211-15212	p	_
92-12	15213-15214	<	_
92-13	15215-15218	.05	_
92-14	15219-15222	was	_
92-15	15223-15232	conducted	_
92-16	15233-15235	to	_
92-17	15236-15243	examine	_
92-18	15244-15249	areas	_
92-19	15250-15257	outside	_
92-20	15258-15261	our	_
92-21	15262-15263	a	_
92-22	15264-15270	priori	_
92-23	15271-15278	regions	_
92-24	15279-15281	of	_
92-25	15282-15290	interest	_
92-26	15290-15291	.	_

#Text=In order to understand the contribution of cocaine and methamphetamine use to the overall stimulant use effects, we ran additional analyses with the same contrast, covariates, and ROIs.
93-1	15292-15294	In	_
93-2	15295-15300	order	_
93-3	15301-15303	to	_
93-4	15304-15314	understand	_
93-5	15315-15318	the	_
93-6	15319-15331	contribution	_
93-7	15332-15334	of	_
93-8	15335-15342	cocaine	_
93-9	15343-15346	and	_
93-10	15347-15362	methamphetamine	_
93-11	15363-15366	use	_
93-12	15367-15369	to	_
93-13	15370-15373	the	_
93-14	15374-15381	overall	_
93-15	15382-15391	stimulant	_
93-16	15392-15395	use	_
93-17	15396-15403	effects	_
93-18	15403-15404	,	_
93-19	15405-15407	we	_
93-20	15408-15411	ran	_
93-21	15412-15422	additional	_
93-22	15423-15431	analyses	_
93-23	15432-15436	with	_
93-24	15437-15440	the	_
93-25	15441-15445	same	_
93-26	15446-15454	contrast	_
93-27	15454-15455	,	_
93-28	15456-15466	covariates	_
93-29	15466-15467	,	_
93-30	15468-15471	and	_
93-31	15472-15476	ROIs	_
93-32	15476-15477	.	_

#Text=The analyses were as follows: 1) lifetime cocaine users (n = 118) versus non-cocaine users (n = 93); 2) lifetime methamphetamine users (n = 72) versus non-methamphetamine users (n = 139); 3) duration of lifetime cocaine use (n = 118); and 4) duration of lifetime methamphetamine use (n = 72).
94-1	15478-15481	The	_
94-2	15482-15490	analyses	_
94-3	15491-15495	were	_
94-4	15496-15498	as	_
94-5	15499-15506	follows	_
94-6	15506-15507	:	_
94-7	15508-15509	1	_
94-8	15509-15510	)	_
94-9	15511-15519	lifetime	_
94-10	15520-15527	cocaine	_
94-11	15528-15533	users	_
94-12	15534-15535	(	_
94-13	15535-15536	n	_
94-14	15537-15538	=	_
94-15	15539-15542	118	_
94-16	15542-15543	)	_
94-17	15544-15550	versus	_
94-18	15551-15562	non-cocaine	_
94-19	15563-15568	users	_
94-20	15569-15570	(	_
94-21	15570-15571	n	_
94-22	15572-15573	=	_
94-23	15574-15576	93	_
94-24	15576-15577	)	_
94-25	15577-15578	;	_
94-26	15579-15580	2	_
94-27	15580-15581	)	_
94-28	15582-15590	lifetime	_
94-29	15591-15606	methamphetamine	_
94-30	15607-15612	users	_
94-31	15613-15614	(	_
94-32	15614-15615	n	_
94-33	15616-15617	=	_
94-34	15618-15620	72	_
94-35	15620-15621	)	_
94-36	15622-15628	versus	_
94-37	15629-15648	non-methamphetamine	_
94-38	15649-15654	users	_
94-39	15655-15656	(	_
94-40	15656-15657	n	_
94-41	15658-15659	=	_
94-42	15660-15663	139	_
94-43	15663-15664	)	_
94-44	15664-15665	;	_
94-45	15666-15667	3	_
94-46	15667-15668	)	_
94-47	15669-15677	duration	_
94-48	15678-15680	of	_
94-49	15681-15689	lifetime	_
94-50	15690-15697	cocaine	_
94-51	15698-15701	use	_
94-52	15702-15703	(	_
94-53	15703-15704	n	_
94-54	15705-15706	=	_
94-55	15707-15710	118	_
94-56	15710-15711	)	_
94-57	15711-15712	;	_
94-58	15713-15716	and	_
94-59	15717-15718	4	_
94-60	15718-15719	)	_
94-61	15720-15728	duration	_
94-62	15729-15731	of	_
94-63	15732-15740	lifetime	_
94-64	15741-15756	methamphetamine	_
94-65	15757-15760	use	_
94-66	15761-15762	(	_
94-67	15762-15763	n	_
94-68	15764-15765	=	_
94-69	15766-15768	72	_
94-70	15768-15769	)	_
94-71	15769-15770	.	_

#Text=Results
#Text=Lifetime Stimulant Users versus Non-Stimulant Users
#Text=Stimulant users did not significantly differ from non-stimulant users on behavioral task performance, including response times and number of “wrong” vs.
95-1	15771-15778	Results	_
95-2	15779-15787	Lifetime	_
95-3	15788-15797	Stimulant	_
95-4	15798-15803	Users	_
95-5	15804-15810	versus	_
95-6	15811-15824	Non-Stimulant	_
95-7	15825-15830	Users	_
95-8	15831-15840	Stimulant	_
95-9	15841-15846	users	_
95-10	15847-15850	did	_
95-11	15851-15854	not	_
95-12	15855-15868	significantly	_
95-13	15869-15875	differ	_
95-14	15876-15880	from	_
95-15	15881-15894	non-stimulant	_
95-16	15895-15900	users	_
95-17	15901-15903	on	_
95-18	15904-15914	behavioral	_
95-19	15915-15919	task	_
95-20	15920-15931	performance	_
95-21	15931-15932	,	_
95-22	15933-15942	including	_
95-23	15943-15951	response	_
95-24	15952-15957	times	_
95-25	15958-15961	and	_
95-26	15962-15968	number	_
95-27	15969-15971	of	_
95-28	15972-15973	“	_
95-29	15973-15978	wrong	_
95-30	15978-15979	”	_
95-31	15980-15982	vs	_
95-32	15982-15983	.	_

#Text=“not wrong” responses for any of the conditions of interest (i.e. controversial & non-controversial stimuli; Table 2).
96-1	15984-15985	“	_
96-2	15985-15988	not	_
96-3	15989-15994	wrong	_
96-4	15994-15995	”	_
96-5	15996-16005	responses	_
96-6	16006-16009	for	_
96-7	16010-16013	any	_
96-8	16014-16016	of	_
96-9	16017-16020	the	_
96-10	16021-16031	conditions	_
96-11	16032-16034	of	_
96-12	16035-16043	interest	_
96-13	16044-16045	(	_
96-14	16045-16048	i.e	_
96-15	16048-16049	.	_
96-16	16050-16063	controversial	_
96-17	16064-16065	&	_
96-18	16066-16083	non-controversial	_
96-19	16084-16091	stimuli	_
96-20	16091-16092	;	_
96-21	16093-16098	Table	_
96-22	16099-16100	2	_
96-23	16100-16101	)	_
96-24	16101-16102	.	_

#Text=These results did not change when years of non-stimulant and alcohol use was included as a covariate.
97-1	16103-16108	These	_
97-2	16109-16116	results	_
97-3	16117-16120	did	_
97-4	16121-16124	not	_
97-5	16125-16131	change	_
97-6	16132-16136	when	_
97-7	16137-16142	years	_
97-8	16143-16145	of	_
97-9	16146-16159	non-stimulant	_
97-10	16160-16163	and	_
97-11	16164-16171	alcohol	_
97-12	16172-16175	use	_
97-13	16176-16179	was	_
97-14	16180-16188	included	_
97-15	16189-16191	as	_
97-16	16192-16193	a	_
97-17	16194-16203	covariate	_
97-18	16203-16204	.	_

#Text=When making decisions about controversial moral phrases, lifetime stimulant users showed less hemodynamic activity in the right amygdala relative to non-stimulant users (x = 30, y = −3, z = −27, t = −3.13, k = 51, p = .026 FWE corrected).
98-1	16205-16209	When	_
98-2	16210-16216	making	_
98-3	16217-16226	decisions	_
98-4	16227-16232	about	_
98-5	16233-16246	controversial	_
98-6	16247-16252	moral	_
98-7	16253-16260	phrases	_
98-8	16260-16261	,	_
98-9	16262-16270	lifetime	_
98-10	16271-16280	stimulant	_
98-11	16281-16286	users	_
98-12	16287-16293	showed	_
98-13	16294-16298	less	_
98-14	16299-16310	hemodynamic	_
98-15	16311-16319	activity	_
98-16	16320-16322	in	_
98-17	16323-16326	the	_
98-18	16327-16332	right	_
98-19	16333-16341	amygdala	_
98-20	16342-16350	relative	_
98-21	16351-16353	to	_
98-22	16354-16367	non-stimulant	_
98-23	16368-16373	users	_
98-24	16374-16375	(	_
98-25	16375-16376	x	_
98-26	16377-16378	=	_
98-27	16379-16381	30	_
98-28	16381-16382	,	_
98-29	16383-16384	y	_
98-30	16385-16386	=	_
98-31	16387-16388	−	_
98-32	16388-16389	3	_
98-33	16389-16390	,	_
98-34	16391-16392	z	_
98-35	16393-16394	=	_
98-36	16395-16396	−	_
98-37	16396-16398	27	_
98-38	16398-16399	,	_
98-39	16400-16401	t	_
98-40	16402-16403	=	_
98-41	16404-16405	−	_
98-42	16405-16409	3.13	_
98-43	16409-16410	,	_
98-44	16411-16412	k	_
98-45	16413-16414	=	_
98-46	16415-16417	51	_
98-47	16417-16418	,	_
98-48	16419-16420	p	_
98-49	16421-16422	=	_
98-50	16423-16427	.026	_
98-51	16428-16431	FWE	_
98-52	16432-16441	corrected	_
98-53	16441-16442	)	_
98-54	16442-16443	.	_

#Text=This same cluster was significant at a trend level in lifetime cocaine users compared to non-users (k = 49, t = −2.80, p = .055 FWE corrected).
99-1	16444-16448	This	_
99-2	16449-16453	same	_
99-3	16454-16461	cluster	_
99-4	16462-16465	was	_
99-5	16466-16477	significant	_
99-6	16478-16480	at	_
99-7	16481-16482	a	_
99-8	16483-16488	trend	_
99-9	16489-16494	level	_
99-10	16495-16497	in	_
99-11	16498-16506	lifetime	_
99-12	16507-16514	cocaine	_
99-13	16515-16520	users	_
99-14	16521-16529	compared	_
99-15	16530-16532	to	_
99-16	16533-16542	non-users	_
99-17	16543-16544	(	_
99-18	16544-16545	k	_
99-19	16546-16547	=	_
99-20	16548-16550	49	_
99-21	16550-16551	,	_
99-22	16552-16553	t	_
99-23	16554-16555	=	_
99-24	16556-16557	−	_
99-25	16557-16561	2.80	_
99-26	16561-16562	,	_
99-27	16563-16564	p	_
99-28	16565-16566	=	_
99-29	16567-16571	.055	_
99-30	16572-16575	FWE	_
99-31	16576-16585	corrected	_
99-32	16585-16586	)	_
99-33	16586-16587	.	_

#Text=No results in the whole brain analysis survived correction for multiple comparisons.
100-1	16588-16590	No	_
100-2	16591-16598	results	_
100-3	16599-16601	in	_
100-4	16602-16605	the	_
100-5	16606-16611	whole	_
100-6	16612-16617	brain	_
100-7	16618-16626	analysis	_
100-8	16627-16635	survived	_
100-9	16636-16646	correction	_
100-10	16647-16650	for	_
100-11	16651-16659	multiple	_
100-12	16660-16671	comparisons	_
100-13	16671-16672	.	_

#Text=Duration of Lifetime Stimulant Use
#Text=Duration of lifetime stimulant use was not significantly associated with response times or number of “wrong” vs.
101-1	16673-16681	Duration	_
101-2	16682-16684	of	_
101-3	16685-16693	Lifetime	_
101-4	16694-16703	Stimulant	_
101-5	16704-16707	Use	_
101-6	16708-16716	Duration	_
101-7	16717-16719	of	_
101-8	16720-16728	lifetime	_
101-9	16729-16738	stimulant	_
101-10	16739-16742	use	_
101-11	16743-16746	was	_
101-12	16747-16750	not	_
101-13	16751-16764	significantly	_
101-14	16765-16775	associated	_
101-15	16776-16780	with	_
101-16	16781-16789	response	_
101-17	16790-16795	times	_
101-18	16796-16798	or	_
101-19	16799-16805	number	_
101-20	16806-16808	of	_
101-21	16809-16810	“	_
101-22	16810-16815	wrong	_
101-23	16815-16816	”	_
101-24	16817-16819	vs	_
101-25	16819-16820	.	_

#Text=“not wrong” responses in any of the conditions of interest (i.e., controversial & non-controversial stimuli; Table 2).
102-1	16821-16822	“	_
102-2	16822-16825	not	_
102-3	16826-16831	wrong	_
102-4	16831-16832	”	_
102-5	16833-16842	responses	_
102-6	16843-16845	in	_
102-7	16846-16849	any	_
102-8	16850-16852	of	_
102-9	16853-16856	the	_
102-10	16857-16867	conditions	_
102-11	16868-16870	of	_
102-12	16871-16879	interest	_
102-13	16880-16881	(	_
102-14	16881-16884	i.e	_
102-15	16884-16885	.	_
102-16	16885-16886	,	_
102-17	16887-16900	controversial	_
102-18	16901-16902	&	_
102-19	16903-16920	non-controversial	_
102-20	16921-16928	stimuli	_
102-21	16928-16929	;	_
102-22	16930-16935	Table	_
102-23	16936-16937	2	_
102-24	16937-16938	)	_
102-25	16938-16939	.	_

#Text=These results did not change when years of non-stimulant use was not included as a covariate.
103-1	16940-16945	These	_
103-2	16946-16953	results	_
103-3	16954-16957	did	_
103-4	16958-16961	not	_
103-5	16962-16968	change	_
103-6	16969-16973	when	_
103-7	16974-16979	years	_
103-8	16980-16982	of	_
103-9	16983-16996	non-stimulant	_
103-10	16997-17000	use	_
103-11	17001-17004	was	_
103-12	17005-17008	not	_
103-13	17009-17017	included	_
103-14	17018-17020	as	_
103-15	17021-17022	a	_
103-16	17023-17032	covariate	_
103-17	17032-17033	.	_

#Text=In the regression, years of stimulant use was inversely related to hemodynamic response in the ACC (x = −15, y = 21, z = 27, k = 29, t = −3.68, p = .042 FWE corrected; Table 4).
104-1	17034-17036	In	_
104-2	17037-17040	the	_
104-3	17041-17051	regression	_
104-4	17051-17052	,	_
104-5	17053-17058	years	_
104-6	17059-17061	of	_
104-7	17062-17071	stimulant	_
104-8	17072-17075	use	_
104-9	17076-17079	was	_
104-10	17080-17089	inversely	_
104-11	17090-17097	related	_
104-12	17098-17100	to	_
104-13	17101-17112	hemodynamic	_
104-14	17113-17121	response	_
104-15	17122-17124	in	_
104-16	17125-17128	the	_
104-17	17129-17132	ACC	_
104-18	17133-17134	(	_
104-19	17134-17135	x	_
104-20	17136-17137	=	_
104-21	17138-17139	−	_
104-22	17139-17141	15	_
104-23	17141-17142	,	_
104-24	17143-17144	y	_
104-25	17145-17146	=	_
104-26	17147-17149	21	_
104-27	17149-17150	,	_
104-28	17151-17152	z	_
104-29	17153-17154	=	_
104-30	17155-17157	27	_
104-31	17157-17158	,	_
104-32	17159-17160	k	_
104-33	17161-17162	=	_
104-34	17163-17165	29	_
104-35	17165-17166	,	_
104-36	17167-17168	t	_
104-37	17169-17170	=	_
104-38	17171-17172	−	_
104-39	17172-17176	3.68	_
104-40	17176-17177	,	_
104-41	17178-17179	p	_
104-42	17180-17181	=	_
104-43	17182-17186	.042	_
104-44	17187-17190	FWE	_
104-45	17191-17200	corrected	_
104-46	17200-17201	;	_
104-47	17202-17207	Table	_
104-48	17208-17209	4	_
104-49	17209-17210	)	_
104-50	17210-17211	.	_

#Text=Years of cocaine use was also inversely related to engagement in that region, although at a trend level (x = −15, y = 18, z = 27, k = 24, t = −3.53, p = .061 FWE corrected).
105-1	17212-17217	Years	_
105-2	17218-17220	of	_
105-3	17221-17228	cocaine	_
105-4	17229-17232	use	_
105-5	17233-17236	was	_
105-6	17237-17241	also	_
105-7	17242-17251	inversely	_
105-8	17252-17259	related	_
105-9	17260-17262	to	_
105-10	17263-17273	engagement	_
105-11	17274-17276	in	_
105-12	17277-17281	that	_
105-13	17282-17288	region	_
105-14	17288-17289	,	_
105-15	17290-17298	although	_
105-16	17299-17301	at	_
105-17	17302-17303	a	_
105-18	17304-17309	trend	_
105-19	17310-17315	level	_
105-20	17316-17317	(	_
105-21	17317-17318	x	_
105-22	17319-17320	=	_
105-23	17321-17322	−	_
105-24	17322-17324	15	_
105-25	17324-17325	,	_
105-26	17326-17327	y	_
105-27	17328-17329	=	_
105-28	17330-17332	18	_
105-29	17332-17333	,	_
105-30	17334-17335	z	_
105-31	17336-17337	=	_
105-32	17338-17340	27	_
105-33	17340-17341	,	_
105-34	17342-17343	k	_
105-35	17344-17345	=	_
105-36	17346-17348	24	_
105-37	17348-17349	,	_
105-38	17350-17351	t	_
105-39	17352-17353	=	_
105-40	17354-17355	−	_
105-41	17355-17359	3.53	_
105-42	17359-17360	,	_
105-43	17361-17362	p	_
105-44	17363-17364	=	_
105-45	17365-17369	.061	_
105-46	17370-17373	FWE	_
105-47	17374-17383	corrected	_
105-48	17383-17384	)	_
105-49	17384-17385	.	_

#Text=Years of methamphetamine use were positively associated with hemodynamic response in the vmPFC (x = 6, y = 63, z = 15, k = 72, t = 3.69, p = .049 FWE corrected).
106-1	17386-17391	Years	_
106-2	17392-17394	of	_
106-3	17395-17410	methamphetamine	_
106-4	17411-17414	use	_
106-5	17415-17419	were	_
106-6	17420-17430	positively	_
106-7	17431-17441	associated	_
106-8	17442-17446	with	_
106-9	17447-17458	hemodynamic	_
106-10	17459-17467	response	_
106-11	17468-17470	in	_
106-12	17471-17474	the	_
106-13	17475-17480	vmPFC	_
106-14	17481-17482	(	_
106-15	17482-17483	x	_
106-16	17484-17485	=	_
106-17	17486-17487	6	_
106-18	17487-17488	,	_
106-19	17489-17490	y	_
106-20	17491-17492	=	_
106-21	17493-17495	63	_
106-22	17495-17496	,	_
106-23	17497-17498	z	_
106-24	17499-17500	=	_
106-25	17501-17503	15	_
106-26	17503-17504	,	_
106-27	17505-17506	k	_
106-28	17507-17508	=	_
106-29	17509-17511	72	_
106-30	17511-17512	,	_
106-31	17513-17514	t	_
106-32	17515-17516	=	_
106-33	17517-17521	3.69	_
106-34	17521-17522	,	_
106-35	17523-17524	p	_
106-36	17525-17526	=	_
106-37	17527-17531	.049	_
106-38	17532-17535	FWE	_
106-39	17536-17545	corrected	_
106-40	17545-17546	)	_
106-41	17546-17547	.	_

#Text=No results in the whole brain analysis survived correction for multiple comparisons.
107-1	17548-17550	No	_
107-2	17551-17558	results	_
107-3	17559-17561	in	_
107-4	17562-17565	the	_
107-5	17566-17571	whole	_
107-6	17572-17577	brain	_
107-7	17578-17586	analysis	_
107-8	17587-17595	survived	_
107-9	17596-17606	correction	_
107-10	17607-17610	for	_
107-11	17611-17619	multiple	_
107-12	17620-17631	comparisons	_
107-13	17631-17632	.	_

#Text=These results did not change when years of non-stimulant use was included as a covariate.
108-1	17633-17638	These	_
108-2	17639-17646	results	_
108-3	17647-17650	did	_
108-4	17651-17654	not	_
108-5	17655-17661	change	_
108-6	17662-17666	when	_
108-7	17667-17672	years	_
108-8	17673-17675	of	_
108-9	17676-17689	non-stimulant	_
108-10	17690-17693	use	_
108-11	17694-17697	was	_
108-12	17698-17706	included	_
108-13	17707-17709	as	_
108-14	17710-17711	a	_
108-15	17712-17721	covariate	_
108-16	17721-17722	.	_

#Text=None of the results are presented as Figures?
109-1	17723-17727	None	_
109-2	17728-17730	of	_
109-3	17731-17734	the	_
109-4	17735-17742	results	_
109-5	17743-17746	are	_
109-6	17747-17756	presented	_
109-7	17757-17759	as	_
109-8	17760-17767	Figures	_
109-9	17767-17768	?	_

#Text=Was this always the case?
110-1	17769-17772	Was	_
110-2	17773-17777	this	_
110-3	17778-17784	always	_
110-4	17785-17788	the	_
110-5	17789-17793	case	_
110-6	17793-17794	?	_

#Text=Discussion
#Text=Here we investigated how stimulant use affects hemodynamic activity related to moral processing in an ultra-high risk population.
111-1	17795-17805	Discussion	_
111-2	17806-17810	Here	_
111-3	17811-17813	we	_
111-4	17814-17826	investigated	_
111-5	17827-17830	how	_
111-6	17831-17840	stimulant	_
111-7	17841-17844	use	_
111-8	17845-17852	affects	_
111-9	17853-17864	hemodynamic	_
111-10	17865-17873	activity	_
111-11	17874-17881	related	_
111-12	17882-17884	to	_
111-13	17885-17890	moral	_
111-14	17891-17901	processing	_
111-15	17902-17904	in	_
111-16	17905-17907	an	_
111-17	17908-17918	ultra-high	_
111-18	17919-17923	risk	_
111-19	17924-17934	population	_
111-20	17934-17935	.	_

#Text=We found that duration of stimulant use was inversely related to caudal ACC activity, driven by cocaine use duration, while methamphetamine use duration was positively associated with vmPFC engagement.
112-1	17936-17938	We	_
112-2	17939-17944	found	_
112-3	17945-17949	that	_
112-4	17950-17958	duration	_
112-5	17959-17961	of	_
112-6	17962-17971	stimulant	_
112-7	17972-17975	use	_
112-8	17976-17979	was	_
112-9	17980-17989	inversely	_
112-10	17990-17997	related	_
112-11	17998-18000	to	_
112-12	18001-18007	caudal	_
112-13	18008-18011	ACC	_
112-14	18012-18020	activity	_
112-15	18020-18021	,	_
112-16	18022-18028	driven	_
112-17	18029-18031	by	_
112-18	18032-18039	cocaine	_
112-19	18040-18043	use	_
112-20	18044-18052	duration	_
112-21	18052-18053	,	_
112-22	18054-18059	while	_
112-23	18060-18075	methamphetamine	_
112-24	18076-18079	use	_
112-25	18080-18088	duration	_
112-26	18089-18092	was	_
112-27	18093-18103	positively	_
112-28	18104-18114	associated	_
112-29	18115-18119	with	_
112-30	18120-18125	vmPFC	_
112-31	18126-18136	engagement	_
112-32	18136-18137	.	_

#Text=Additionally, regular stimulant users, relative to non-regular users, had hypoactivity in the right amygdala, driven by cocaine use in particular.
113-1	18138-18150	Additionally	_
113-2	18150-18151	,	_
113-3	18152-18159	regular	_
113-4	18160-18169	stimulant	_
113-5	18170-18175	users	_
113-6	18175-18176	,	_
113-7	18177-18185	relative	_
113-8	18186-18188	to	_
113-9	18189-18200	non-regular	_
113-10	18201-18206	users	_
113-11	18206-18207	,	_
113-12	18208-18211	had	_
113-13	18212-18224	hypoactivity	_
113-14	18225-18227	in	_
113-15	18228-18231	the	_
113-16	18232-18237	right	_
113-17	18238-18246	amygdala	_
113-18	18246-18247	,	_
113-19	18248-18254	driven	_
113-20	18255-18257	by	_
113-21	18258-18265	cocaine	_
113-22	18266-18269	use	_
113-23	18270-18272	in	_
113-24	18273-18283	particular	_
113-25	18283-18284	.	_

#Text=These regions have essential roles in moral processing and emotional regulation.
114-1	18285-18290	These	_
114-2	18291-18298	regions	_
114-3	18299-18303	have	_
114-4	18304-18313	essential	_
114-5	18314-18319	roles	_
114-6	18320-18322	in	_
114-7	18323-18328	moral	_
114-8	18329-18339	processing	_
114-9	18340-18343	and	_
114-10	18344-18353	emotional	_
114-11	18354-18364	regulation	_
114-12	18364-18365	.	_

#Text=The amygdala functions as a center for affective information during moral processing, interacting with goal oriented knowledge structures in the mPFC.
115-1	18366-18369	The	_
115-2	18370-18378	amygdala	_
115-3	18379-18388	functions	_
115-4	18389-18391	as	_
115-5	18392-18393	a	_
115-6	18394-18400	center	_
115-7	18401-18404	for	_
115-8	18405-18414	affective	_
115-9	18415-18426	information	_
115-10	18427-18433	during	_
115-11	18434-18439	moral	_
115-12	18440-18450	processing	_
115-13	18450-18451	,	_
115-14	18452-18463	interacting	_
115-15	18464-18468	with	_
115-16	18469-18473	goal	_
115-17	18474-18482	oriented	_
115-18	18483-18492	knowledge	_
115-19	18493-18503	structures	_
115-20	18504-18506	in	_
115-21	18507-18510	the	_
115-22	18511-18515	mPFC	_
115-23	18515-18516	.	_

#Text=Here we found abnormal responses within this system.
116-1	18517-18521	Here	_
116-2	18522-18524	we	_
116-3	18525-18530	found	_
116-4	18531-18539	abnormal	_
116-5	18540-18549	responses	_
116-6	18550-18556	within	_
116-7	18557-18561	this	_
116-8	18562-18568	system	_
116-9	18568-18569	.	_

#Text=An increase in vmPFC activity and decrease in amygdala activity is a typical pattern of hemodynamic response during emotional down regulation.
117-1	18570-18572	An	_
117-2	18573-18581	increase	_
117-3	18582-18584	in	_
117-4	18585-18590	vmPFC	_
117-5	18591-18599	activity	_
117-6	18600-18603	and	_
117-7	18604-18612	decrease	_
117-8	18613-18615	in	_
117-9	18616-18624	amygdala	_
117-10	18625-18633	activity	_
117-11	18634-18636	is	_
117-12	18637-18638	a	_
117-13	18639-18646	typical	_
117-14	18647-18654	pattern	_
117-15	18655-18657	of	_
117-16	18658-18669	hemodynamic	_
117-17	18670-18678	response	_
117-18	18679-18685	during	_
117-19	18686-18695	emotional	_
117-20	18696-18700	down	_
117-21	18701-18711	regulation	_
117-22	18711-18712	.	_

#Text=This may reflect a specific deficit in the emotion regulation element of sociomoral processing; whereas non-stimulant users use a balance of emotional and cognitive resources to make moral decisions, stimulant users may be overly reliant on cognitive systems and downregulate emotional processes when arriving at a judgment.
118-1	18713-18717	This	_
118-2	18718-18721	may	_
118-3	18722-18729	reflect	_
118-4	18730-18731	a	_
118-5	18732-18740	specific	_
118-6	18741-18748	deficit	_
118-7	18749-18751	in	_
118-8	18752-18755	the	_
118-9	18756-18763	emotion	_
118-10	18764-18774	regulation	_
118-11	18775-18782	element	_
118-12	18783-18785	of	_
118-13	18786-18796	sociomoral	_
118-14	18797-18807	processing	_
118-15	18807-18808	;	_
118-16	18809-18816	whereas	_
118-17	18817-18830	non-stimulant	_
118-18	18831-18836	users	_
118-19	18837-18840	use	_
118-20	18841-18842	a	_
118-21	18843-18850	balance	_
118-22	18851-18853	of	_
118-23	18854-18863	emotional	_
118-24	18864-18867	and	_
118-25	18868-18877	cognitive	_
118-26	18878-18887	resources	_
118-27	18888-18890	to	_
118-28	18891-18895	make	_
118-29	18896-18901	moral	_
118-30	18902-18911	decisions	_
118-31	18911-18912	,	_
118-32	18913-18922	stimulant	_
118-33	18923-18928	users	_
118-34	18929-18932	may	_
118-35	18933-18935	be	_
118-36	18936-18942	overly	_
118-37	18943-18950	reliant	_
118-38	18951-18953	on	_
118-39	18954-18963	cognitive	_
118-40	18964-18971	systems	_
118-41	18972-18975	and	_
118-42	18976-18988	downregulate	_
118-43	18989-18998	emotional	_
118-44	18999-19008	processes	_
118-45	19009-19013	when	_
118-46	19014-19022	arriving	_
118-47	19023-19025	at	_
118-48	19026-19027	a	_
118-49	19028-19036	judgment	_
118-50	19036-19037	.	_

#Text=An alternative explanation is that either the amygdala or the ACC alone has less engagement in stimulant users, but reciprocal connections between those regions account for the reduction in hemodynamic response in the other.
119-1	19038-19040	An	_
119-2	19041-19052	alternative	_
119-3	19053-19064	explanation	_
119-4	19065-19067	is	_
119-5	19068-19072	that	_
119-6	19073-19079	either	_
119-7	19080-19083	the	_
119-8	19084-19092	amygdala	_
119-9	19093-19095	or	_
119-10	19096-19099	the	_
119-11	19100-19103	ACC	_
119-12	19104-19109	alone	_
119-13	19110-19113	has	_
119-14	19114-19118	less	_
119-15	19119-19129	engagement	_
119-16	19130-19132	in	_
119-17	19133-19142	stimulant	_
119-18	19143-19148	users	_
119-19	19148-19149	,	_
119-20	19150-19153	but	_
119-21	19154-19164	reciprocal	_
119-22	19165-19176	connections	_
119-23	19177-19184	between	_
119-24	19185-19190	those	_
119-25	19191-19198	regions	_
119-26	19199-19206	account	_
119-27	19207-19210	for	_
119-28	19211-19214	the	_
119-29	19215-19224	reduction	_
119-30	19225-19227	in	_
119-31	19228-19239	hemodynamic	_
119-32	19240-19248	response	_
119-33	19249-19251	in	_
119-34	19252-19255	the	_
119-35	19256-19261	other	_
119-36	19261-19262	.	_

#Text=Rather than a deficit in cognitive control, stimulant users may also find morally controversial issues less salient or may have poor emotional insight, eliciting a weaker amygdala response that requires less cognitive override.
120-1	19263-19269	Rather	_
120-2	19270-19274	than	_
120-3	19275-19276	a	_
120-4	19277-19284	deficit	_
120-5	19285-19287	in	_
120-6	19288-19297	cognitive	_
120-7	19298-19305	control	_
120-8	19305-19306	,	_
120-9	19307-19316	stimulant	_
120-10	19317-19322	users	_
120-11	19323-19326	may	_
120-12	19327-19331	also	_
120-13	19332-19336	find	_
120-14	19337-19344	morally	_
120-15	19345-19358	controversial	_
120-16	19359-19365	issues	_
120-17	19366-19370	less	_
120-18	19371-19378	salient	_
120-19	19379-19381	or	_
120-20	19382-19385	may	_
120-21	19386-19390	have	_
120-22	19391-19395	poor	_
120-23	19396-19405	emotional	_
120-24	19406-19413	insight	_
120-25	19413-19414	,	_
120-26	19415-19424	eliciting	_
120-27	19425-19426	a	_
120-28	19427-19433	weaker	_
120-29	19434-19442	amygdala	_
120-30	19443-19451	response	_
120-31	19452-19456	that	_
120-32	19457-19465	requires	_
120-33	19466-19470	less	_
120-34	19471-19480	cognitive	_
120-35	19481-19489	override	_
120-36	19489-19490	.	_

#Text=Connectivity studies have found that the amygdala and ACC are functionally connected during emotion regulation, fear, and during resting state as well as structurally connected by projections from the amygdala
#Text=Another possible explanation is increased reliance on the cognitive override process in the vmPFC, as posited by the cognitive control theory of moral processing.
121-1	19491-19503	Connectivity	_
121-2	19504-19511	studies	_
121-3	19512-19516	have	_
121-4	19517-19522	found	_
121-5	19523-19527	that	_
121-6	19528-19531	the	_
121-7	19532-19540	amygdala	_
121-8	19541-19544	and	_
121-9	19545-19548	ACC	_
121-10	19549-19552	are	_
121-11	19553-19565	functionally	_
121-12	19566-19575	connected	_
121-13	19576-19582	during	_
121-14	19583-19590	emotion	_
121-15	19591-19601	regulation	_
121-16	19601-19602	,	_
121-17	19603-19607	fear	_
121-18	19607-19608	,	_
121-19	19609-19612	and	_
121-20	19613-19619	during	_
121-21	19620-19627	resting	_
121-22	19628-19633	state	_
121-23	19634-19636	as	_
121-24	19637-19641	well	_
121-25	19642-19644	as	_
121-26	19645-19657	structurally	_
121-27	19658-19667	connected	_
121-28	19668-19670	by	_
121-29	19671-19682	projections	_
121-30	19683-19687	from	_
121-31	19688-19691	the	_
121-32	19692-19700	amygdala	_
121-33	19702-19709	Another	_
121-34	19710-19718	possible	_
121-35	19719-19730	explanation	_
121-36	19731-19733	is	_
121-37	19734-19743	increased	_
121-38	19744-19752	reliance	_
121-39	19753-19755	on	_
121-40	19756-19759	the	_
121-41	19760-19769	cognitive	_
121-42	19770-19778	override	_
121-43	19779-19786	process	_
121-44	19787-19789	in	_
121-45	19790-19793	the	_
121-46	19794-19799	vmPFC	_
121-47	19799-19800	,	_
121-48	19801-19803	as	_
121-49	19804-19811	posited	_
121-50	19812-19814	by	_
121-51	19815-19818	the	_
121-52	19819-19828	cognitive	_
121-53	19829-19836	control	_
121-54	19837-19843	theory	_
121-55	19844-19846	of	_
121-56	19847-19852	moral	_
121-57	19853-19863	processing	_
121-58	19863-19864	.	_

#Text=However, this is not consistent with our ACC findings.
122-1	19865-19872	However	_
122-2	19872-19873	,	_
122-3	19874-19878	this	_
122-4	19879-19881	is	_
122-5	19882-19885	not	_
122-6	19886-19896	consistent	_
122-7	19897-19901	with	_
122-8	19902-19905	our	_
122-9	19906-19909	ACC	_
122-10	19910-19918	findings	_
122-11	19918-19919	.	_

#Text=In this model, cognitive control processes sub served by the ACC override emotional responses to promote rational (e.g., utilitarian) moral judgments.
123-1	19920-19922	In	_
123-2	19923-19927	this	_
123-3	19928-19933	model	_
123-4	19933-19934	,	_
123-5	19935-19944	cognitive	_
123-6	19945-19952	control	_
123-7	19953-19962	processes	_
123-8	19963-19966	sub	_
123-9	19967-19973	served	_
123-10	19974-19976	by	_
123-11	19977-19980	the	_
123-12	19981-19984	ACC	_
123-13	19985-19993	override	_
123-14	19994-20003	emotional	_
123-15	20004-20013	responses	_
123-16	20014-20016	to	_
123-17	20017-20024	promote	_
123-18	20025-20033	rational	_
123-19	20034-20035	(	_
123-20	20035-20038	e.g	_
123-21	20038-20039	.	_
123-22	20039-20040	,	_
123-23	20041-20052	utilitarian	_
123-24	20052-20053	)	_
123-25	20054-20059	moral	_
123-26	20060-20069	judgments	_
123-27	20069-20070	.	_

#Text=The increased engagement in the vmPFC may still be related to cognitive control abnormality.
124-1	20071-20074	The	_
124-2	20075-20084	increased	_
124-3	20085-20095	engagement	_
124-4	20096-20098	in	_
124-5	20099-20102	the	_
124-6	20103-20108	vmPFC	_
124-7	20109-20112	may	_
124-8	20113-20118	still	_
124-9	20119-20121	be	_
124-10	20122-20129	related	_
124-11	20130-20132	to	_
124-12	20133-20142	cognitive	_
124-13	20143-20150	control	_
124-14	20151-20162	abnormality	_
124-15	20162-20163	.	_

#Text=The vmPFC, specifically of prefrontal regions, plays a key role in integrating emotions into decision making during moral judgment.
125-1	20164-20167	The	_
125-2	20168-20173	vmPFC	_
125-3	20173-20174	,	_
125-4	20175-20187	specifically	_
125-5	20188-20190	of	_
125-6	20191-20201	prefrontal	_
125-7	20202-20209	regions	_
125-8	20209-20210	,	_
125-9	20211-20216	plays	_
125-10	20217-20218	a	_
125-11	20219-20222	key	_
125-12	20223-20227	role	_
125-13	20228-20230	in	_
125-14	20231-20242	integrating	_
125-15	20243-20251	emotions	_
125-16	20252-20256	into	_
125-17	20257-20265	decision	_
125-18	20266-20272	making	_
125-19	20273-20279	during	_
125-20	20280-20285	moral	_
125-21	20286-20294	judgment	_
125-22	20294-20295	.	_

#Text=Rather than requiring more cognitive override of emotions in moral decision making, the increase in activity in this region may indicate that stimulant users have increased difficulty in integrating emotions into those moral judgments and thus have increased activity in the vmPFC based on task demands.
126-1	20296-20302	Rather	_
126-2	20303-20307	than	_
126-3	20308-20317	requiring	_
126-4	20318-20322	more	_
126-5	20323-20332	cognitive	_
126-6	20333-20341	override	_
126-7	20342-20344	of	_
126-8	20345-20353	emotions	_
126-9	20354-20356	in	_
126-10	20357-20362	moral	_
126-11	20363-20371	decision	_
126-12	20372-20378	making	_
126-13	20378-20379	,	_
126-14	20380-20383	the	_
126-15	20384-20392	increase	_
126-16	20393-20395	in	_
126-17	20396-20404	activity	_
126-18	20405-20407	in	_
126-19	20408-20412	this	_
126-20	20413-20419	region	_
126-21	20420-20423	may	_
126-22	20424-20432	indicate	_
126-23	20433-20437	that	_
126-24	20438-20447	stimulant	_
126-25	20448-20453	users	_
126-26	20454-20458	have	_
126-27	20459-20468	increased	_
126-28	20469-20479	difficulty	_
126-29	20480-20482	in	_
126-30	20483-20494	integrating	_
126-31	20495-20503	emotions	_
126-32	20504-20508	into	_
126-33	20509-20514	those	_
126-34	20515-20520	moral	_
126-35	20521-20530	judgments	_
126-36	20531-20534	and	_
126-37	20535-20539	thus	_
126-38	20540-20544	have	_
126-39	20545-20554	increased	_
126-40	20555-20563	activity	_
126-41	20564-20566	in	_
126-42	20567-20570	the	_
126-43	20571-20576	vmPFC	_
126-44	20577-20582	based	_
126-45	20583-20585	on	_
126-46	20586-20590	task	_
126-47	20591-20598	demands	_
126-48	20598-20599	.	_

#Text=Our findings, as previously discussed, suggest less overall processing in both emotional response and cognitive override processes rather than an increase in cognitive processes.
127-1	20600-20603	Our	_
127-2	20604-20612	findings	_
127-3	20612-20613	,	_
127-4	20614-20616	as	_
127-5	20617-20627	previously	_
127-6	20628-20637	discussed	_
127-7	20637-20638	,	_
127-8	20639-20646	suggest	_
127-9	20647-20651	less	_
127-10	20652-20659	overall	_
127-11	20660-20670	processing	_
127-12	20671-20673	in	_
127-13	20674-20678	both	_
127-14	20679-20688	emotional	_
127-15	20689-20697	response	_
127-16	20698-20701	and	_
127-17	20702-20711	cognitive	_
127-18	20712-20720	override	_
127-19	20721-20730	processes	_
127-20	20731-20737	rather	_
127-21	20738-20742	than	_
127-22	20743-20745	an	_
127-23	20746-20754	increase	_
127-24	20755-20757	in	_
127-25	20758-20767	cognitive	_
127-26	20768-20777	processes	_
127-27	20777-20778	.	_

#Text=The caudal ACC has been isolated as a region predictive of recidivism in criminal offenders, above and beyond general substance use.
128-1	20779-20782	The	_
128-2	20783-20789	caudal	_
128-3	20790-20793	ACC	_
128-4	20794-20797	has	_
128-5	20798-20802	been	_
128-6	20803-20811	isolated	_
128-7	20812-20814	as	_
128-8	20815-20816	a	_
128-9	20817-20823	region	_
128-10	20824-20834	predictive	_
128-11	20835-20837	of	_
128-12	20838-20848	recidivism	_
128-13	20849-20851	in	_
128-14	20852-20860	criminal	_
128-15	20861-20870	offenders	_
128-16	20870-20871	,	_
128-17	20872-20877	above	_
128-18	20878-20881	and	_
128-19	20882-20888	beyond	_
128-20	20889-20896	general	_
128-21	20897-20906	substance	_
128-22	20907-20910	use	_
128-23	20910-20911	.	_

#Text=Specifically, individuals with lower activity in this region during response inhibition were twice as likely to reoffend.
129-1	20912-20924	Specifically	_
129-2	20924-20925	,	_
129-3	20926-20937	individuals	_
129-4	20938-20942	with	_
129-5	20943-20948	lower	_
129-6	20949-20957	activity	_
129-7	20958-20960	in	_
129-8	20961-20965	this	_
129-9	20966-20972	region	_
129-10	20973-20979	during	_
129-11	20980-20988	response	_
129-12	20989-20999	inhibition	_
129-13	21000-21004	were	_
129-14	21005-21010	twice	_
129-15	21011-21013	as	_
129-16	21014-21020	likely	_
129-17	21021-21023	to	_
129-18	21024-21032	reoffend	_
129-19	21032-21033	.	_

#Text=The current results may offer a potential mechanism for this pattern; if cognitive control during moral processing is deficient, it may incline an individual to commit moral violations often ending in rearrest.
130-1	21034-21037	The	_
130-2	21038-21045	current	_
130-3	21046-21053	results	_
130-4	21054-21057	may	_
130-5	21058-21063	offer	_
130-6	21064-21065	a	_
130-7	21066-21075	potential	_
130-8	21076-21085	mechanism	_
130-9	21086-21089	for	_
130-10	21090-21094	this	_
130-11	21095-21102	pattern	_
130-12	21102-21103	;	_
130-13	21104-21106	if	_
130-14	21107-21116	cognitive	_
130-15	21117-21124	control	_
130-16	21125-21131	during	_
130-17	21132-21137	moral	_
130-18	21138-21148	processing	_
130-19	21149-21151	is	_
130-20	21152-21161	deficient	_
130-21	21161-21162	,	_
130-22	21163-21165	it	_
130-23	21166-21169	may	_
130-24	21170-21177	incline	_
130-25	21178-21180	an	_
130-26	21181-21191	individual	_
130-27	21192-21194	to	_
130-28	21195-21201	commit	_
130-29	21202-21207	moral	_
130-30	21208-21218	violations	_
130-31	21219-21224	often	_
130-32	21225-21231	ending	_
130-33	21232-21234	in	_
130-34	21235-21243	rearrest	_
130-35	21243-21244	.	_

#Text=The vmPFC and amygdala abnormalities have implications for the continued development of moral standards and behaviors in individuals with stimulant use disorders.
131-1	21245-21248	The	_
131-2	21249-21254	vmPFC	_
131-3	21255-21258	and	_
131-4	21259-21267	amygdala	_
131-5	21268-21281	abnormalities	_
131-6	21282-21286	have	_
131-7	21287-21299	implications	_
131-8	21300-21303	for	_
131-9	21304-21307	the	_
131-10	21308-21317	continued	_
131-11	21318-21329	development	_
131-12	21330-21332	of	_
131-13	21333-21338	moral	_
131-14	21339-21348	standards	_
131-15	21349-21352	and	_
131-16	21353-21362	behaviors	_
131-17	21363-21365	in	_
131-18	21366-21377	individuals	_
131-19	21378-21382	with	_
131-20	21383-21392	stimulant	_
131-21	21393-21396	use	_
131-22	21397-21406	disorders	_
131-23	21406-21407	.	_

#Text=The amygdala and vmPFC work together through stimulus reinforcement learning to associate distress with moral transgressions.
132-1	21408-21411	The	_
132-2	21412-21420	amygdala	_
132-3	21421-21424	and	_
132-4	21425-21430	vmPFC	_
132-5	21431-21435	work	_
132-6	21436-21444	together	_
132-7	21445-21452	through	_
132-8	21453-21461	stimulus	_
132-9	21462-21475	reinforcement	_
132-10	21476-21484	learning	_
132-11	21485-21487	to	_
132-12	21488-21497	associate	_
132-13	21498-21506	distress	_
132-14	21507-21511	with	_
132-15	21512-21517	moral	_
132-16	21518-21532	transgressions	_
132-17	21532-21533	.	_

#Text=The vmPFC, a region involved in goal-oriented decision-making, has afferent connections to the amygdala, a region commonly implicated in fear conditioning.
133-1	21534-21537	The	_
133-2	21538-21543	vmPFC	_
133-3	21543-21544	,	_
133-4	21545-21546	a	_
133-5	21547-21553	region	_
133-6	21554-21562	involved	_
133-7	21563-21565	in	_
133-8	21566-21579	goal-oriented	_
133-9	21580-21595	decision-making	_
133-10	21595-21596	,	_
133-11	21597-21600	has	_
133-12	21601-21609	afferent	_
133-13	21610-21621	connections	_
133-14	21622-21624	to	_
133-15	21625-21628	the	_
133-16	21629-21637	amygdala	_
133-17	21637-21638	,	_
133-18	21639-21640	a	_
133-19	21641-21647	region	_
133-20	21648-21656	commonly	_
133-21	21657-21667	implicated	_
133-22	21668-21670	in	_
133-23	21671-21675	fear	_
133-24	21676-21688	conditioning	_
133-25	21688-21689	.	_

#Text=When communications between the vmPFC and amygdala are abnormal during socioemotional processing, as has been found here and in a previous study, affected individuals are not socialized to avoid committing moral transgressions.
134-1	21690-21694	When	_
134-2	21695-21709	communications	_
134-3	21710-21717	between	_
134-4	21718-21721	the	_
134-5	21722-21727	vmPFC	_
134-6	21728-21731	and	_
134-7	21732-21740	amygdala	_
134-8	21741-21744	are	_
134-9	21745-21753	abnormal	_
134-10	21754-21760	during	_
134-11	21761-21775	socioemotional	_
134-12	21776-21786	processing	_
134-13	21786-21787	,	_
134-14	21788-21790	as	_
134-15	21791-21794	has	_
134-16	21795-21799	been	_
134-17	21800-21805	found	_
134-18	21806-21810	here	_
134-19	21811-21814	and	_
134-20	21815-21817	in	_
134-21	21818-21819	a	_
134-22	21820-21828	previous	_
134-23	21829-21834	study	_
134-24	21834-21835	,	_
134-25	21836-21844	affected	_
134-26	21845-21856	individuals	_
134-27	21857-21860	are	_
134-28	21861-21864	not	_
134-29	21865-21875	socialized	_
134-30	21876-21878	to	_
134-31	21879-21884	avoid	_
134-32	21885-21895	committing	_
134-33	21896-21901	moral	_
134-34	21902-21916	transgressions	_
134-35	21916-21917	.	_

#Text=Amygdala dysfunction is also particularly relevant for drug use as the amygdala is thought to play a role in drug addiction in terms of abnormal neurotransmitter production.
135-1	21918-21926	Amygdala	_
135-2	21927-21938	dysfunction	_
135-3	21939-21941	is	_
135-4	21942-21946	also	_
135-5	21947-21959	particularly	_
135-6	21960-21968	relevant	_
135-7	21969-21972	for	_
135-8	21973-21977	drug	_
135-9	21978-21981	use	_
135-10	21982-21984	as	_
135-11	21985-21988	the	_
135-12	21989-21997	amygdala	_
135-13	21998-22000	is	_
135-14	22001-22008	thought	_
135-15	22009-22011	to	_
135-16	22012-22016	play	_
135-17	22017-22018	a	_
135-18	22019-22023	role	_
135-19	22024-22026	in	_
135-20	22027-22031	drug	_
135-21	22032-22041	addiction	_
135-22	22042-22044	in	_
135-23	22045-22050	terms	_
135-24	22051-22053	of	_
135-25	22054-22062	abnormal	_
135-26	22063-22079	neurotransmitter	_
135-27	22080-22090	production	_
135-28	22090-22091	.	_

#Text=Stimulant users often demonstrate deficiencies in cognitive control and corresponding neural hypoactivations; the vmPFC results do not necessarily provide evidence against this.
136-1	22092-22101	Stimulant	_
136-2	22102-22107	users	_
136-3	22108-22113	often	_
136-4	22114-22125	demonstrate	_
136-5	22126-22138	deficiencies	_
136-6	22139-22141	in	_
136-7	22142-22151	cognitive	_
136-8	22152-22159	control	_
136-9	22160-22163	and	_
136-10	22164-22177	corresponding	_
136-11	22178-22184	neural	_
136-12	22185-22200	hypoactivations	_
136-13	22200-22201	;	_
136-14	22202-22205	the	_
136-15	22206-22211	vmPFC	_
136-16	22212-22219	results	_
136-17	22220-22222	do	_
136-18	22223-22226	not	_
136-19	22227-22238	necessarily	_
136-20	22239-22246	provide	_
136-21	22247-22255	evidence	_
136-22	22256-22263	against	_
136-23	22264-22268	this	_
136-24	22268-22269	.	_

#Text=Given that our chronic stimulant use participants display normal moral judgment in the task, task demands may have required that these individuals up-regulate their processes for integrating emotion into decision-making.
137-1	22270-22275	Given	_
137-2	22276-22280	that	_
137-3	22281-22284	our	_
137-4	22285-22292	chronic	_
137-5	22293-22302	stimulant	_
137-6	22303-22306	use	_
137-7	22307-22319	participants	_
137-8	22320-22327	display	_
137-9	22328-22334	normal	_
137-10	22335-22340	moral	_
137-11	22341-22349	judgment	_
137-12	22350-22352	in	_
137-13	22353-22356	the	_
137-14	22357-22361	task	_
137-15	22361-22362	,	_
137-16	22363-22367	task	_
137-17	22368-22375	demands	_
137-18	22376-22379	may	_
137-19	22380-22384	have	_
137-20	22385-22393	required	_
137-21	22394-22398	that	_
137-22	22399-22404	these	_
137-23	22405-22416	individuals	_
137-24	22417-22428	up-regulate	_
137-25	22429-22434	their	_
137-26	22435-22444	processes	_
137-27	22445-22448	for	_
137-28	22449-22460	integrating	_
137-29	22461-22468	emotion	_
137-30	22469-22473	into	_
137-31	22474-22489	decision-making	_
137-32	22489-22490	.	_

#Text=Individuals with lesions to the vmPFC often have abnormal moral judgment and psychopathic behavior, since they cannot upregulate, as well as amygdala hyper reactivity to negative stimuli, possibly as a compensatory process on the other side of the amygdala-vmPFC system.
138-1	22491-22502	Individuals	_
138-2	22503-22507	with	_
138-3	22508-22515	lesions	_
138-4	22516-22518	to	_
138-5	22519-22522	the	_
138-6	22523-22528	vmPFC	_
138-7	22529-22534	often	_
138-8	22535-22539	have	_
138-9	22540-22548	abnormal	_
138-10	22549-22554	moral	_
138-11	22555-22563	judgment	_
138-12	22564-22567	and	_
138-13	22568-22580	psychopathic	_
138-14	22581-22589	behavior	_
138-15	22589-22590	,	_
138-16	22591-22596	since	_
138-17	22597-22601	they	_
138-18	22602-22608	cannot	_
138-19	22609-22619	upregulate	_
138-20	22619-22620	,	_
138-21	22621-22623	as	_
138-22	22624-22628	well	_
138-23	22629-22631	as	_
138-24	22632-22640	amygdala	_
138-25	22641-22646	hyper	_
138-26	22647-22657	reactivity	_
138-27	22658-22660	to	_
138-28	22661-22669	negative	_
138-29	22670-22677	stimuli	_
138-30	22677-22678	,	_
138-31	22679-22687	possibly	_
138-32	22688-22690	as	_
138-33	22691-22692	a	_
138-34	22693-22705	compensatory	_
138-35	22706-22713	process	_
138-36	22714-22716	on	_
138-37	22717-22720	the	_
138-38	22721-22726	other	_
138-39	22727-22731	side	_
138-40	22732-22734	of	_
138-41	22735-22738	the	_
138-42	22739-22753	amygdala-vmPFC	_
138-43	22754-22760	system	_
138-44	22760-22761	.	_

#Text=It is important to note, however, that methamphetamine and cocaine appear to be contributing separately to abnormalities in these two connecting regions; although lesions to either region have been sufficient to impair moral processing, this distinction may reflect compounding effects of poly-stimulant use.
139-1	22762-22764	It	_
139-2	22765-22767	is	_
139-3	22768-22777	important	_
139-4	22778-22780	to	_
139-5	22781-22785	note	_
139-6	22785-22786	,	_
139-7	22787-22794	however	_
139-8	22794-22795	,	_
139-9	22796-22800	that	_
139-10	22801-22816	methamphetamine	_
139-11	22817-22820	and	_
139-12	22821-22828	cocaine	_
139-13	22829-22835	appear	_
139-14	22836-22838	to	_
139-15	22839-22841	be	_
139-16	22842-22854	contributing	_
139-17	22855-22865	separately	_
139-18	22866-22868	to	_
139-19	22869-22882	abnormalities	_
139-20	22883-22885	in	_
139-21	22886-22891	these	_
139-22	22892-22895	two	_
139-23	22896-22906	connecting	_
139-24	22907-22914	regions	_
139-25	22914-22915	;	_
139-26	22916-22924	although	_
139-27	22925-22932	lesions	_
139-28	22933-22935	to	_
139-29	22936-22942	either	_
139-30	22943-22949	region	_
139-31	22950-22954	have	_
139-32	22955-22959	been	_
139-33	22960-22970	sufficient	_
139-34	22971-22973	to	_
139-35	22974-22980	impair	_
139-36	22981-22986	moral	_
139-37	22987-22997	processing	_
139-38	22997-22998	,	_
139-39	22999-23003	this	_
139-40	23004-23015	distinction	_
139-41	23016-23019	may	_
139-42	23020-23027	reflect	_
139-43	23028-23039	compounding	_
139-44	23040-23047	effects	_
139-45	23048-23050	of	_
139-46	23051-23065	poly-stimulant	_
139-47	23066-23069	use	_
139-48	23069-23070	.	_

#Text=These results are consistent with previous research in stimulant users.
140-1	23071-23076	These	_
140-2	23077-23084	results	_
140-3	23085-23088	are	_
140-4	23089-23099	consistent	_
140-5	23100-23104	with	_
140-6	23105-23113	previous	_
140-7	23114-23122	research	_
140-8	23123-23125	in	_
140-9	23126-23135	stimulant	_
140-10	23136-23141	users	_
140-11	23141-23142	.	_

#Text=Structural imaging studies of stimulant users have reported decreased volumes in the ACC, vmPFC and amygdala.
141-1	23143-23153	Structural	_
141-2	23154-23161	imaging	_
141-3	23162-23169	studies	_
141-4	23170-23172	of	_
141-5	23173-23182	stimulant	_
141-6	23183-23188	users	_
141-7	23189-23193	have	_
141-8	23194-23202	reported	_
141-9	23203-23212	decreased	_
141-10	23213-23220	volumes	_
141-11	23221-23223	in	_
141-12	23224-23227	the	_
141-13	23228-23231	ACC	_
141-14	23231-23232	,	_
141-15	23233-23238	vmPFC	_
141-16	23239-23242	and	_
141-17	23243-23251	amygdala	_
141-18	23251-23252	.	_

#Text=Additionally, stimulant use is related to reward based decision-making abnormalities similar to patients with vmPFC lesions.
142-1	23253-23265	Additionally	_
142-2	23265-23266	,	_
142-3	23267-23276	stimulant	_
142-4	23277-23280	use	_
142-5	23281-23283	is	_
142-6	23284-23291	related	_
142-7	23292-23294	to	_
142-8	23295-23301	reward	_
142-9	23302-23307	based	_
142-10	23308-23323	decision-making	_
142-11	23324-23337	abnormalities	_
142-12	23338-23345	similar	_
142-13	23346-23348	to	_
142-14	23349-23357	patients	_
142-15	23358-23362	with	_
142-16	23363-23368	vmPFC	_
142-17	23369-23376	lesions	_
142-18	23376-23377	.	_

#Text=No amygdala abnormalities were observed in a study of in-treatment cocaine users in moral compared to neutral dilemma judgments.
143-1	23378-23380	No	_
143-2	23381-23389	amygdala	_
143-3	23390-23403	abnormalities	_
143-4	23404-23408	were	_
143-5	23409-23417	observed	_
143-6	23418-23420	in	_
143-7	23421-23422	a	_
143-8	23423-23428	study	_
143-9	23429-23431	of	_
143-10	23432-23444	in-treatment	_
143-11	23445-23452	cocaine	_
143-12	23453-23458	users	_
143-13	23459-23461	in	_
143-14	23462-23467	moral	_
143-15	23468-23476	compared	_
143-16	23477-23479	to	_
143-17	23480-23487	neutral	_
143-18	23488-23495	dilemma	_
143-19	23496-23505	judgments	_
143-20	23505-23506	.	_

#Text=This latter study included 10 cocaine users who were compared to a community control sample, and thus may have been underpowered to reveal group differences in brain responses; criminal cocaine users may also differ from community users (e.g., in severity, comorbidities, or length of use), which could explain discrepant results.
144-1	23507-23511	This	_
144-2	23512-23518	latter	_
144-3	23519-23524	study	_
144-4	23525-23533	included	_
144-5	23534-23536	10	_
144-6	23537-23544	cocaine	_
144-7	23545-23550	users	_
144-8	23551-23554	who	_
144-9	23555-23559	were	_
144-10	23560-23568	compared	_
144-11	23569-23571	to	_
144-12	23572-23573	a	_
144-13	23574-23583	community	_
144-14	23584-23591	control	_
144-15	23592-23598	sample	_
144-16	23598-23599	,	_
144-17	23600-23603	and	_
144-18	23604-23608	thus	_
144-19	23609-23612	may	_
144-20	23613-23617	have	_
144-21	23618-23622	been	_
144-22	23623-23635	underpowered	_
144-23	23636-23638	to	_
144-24	23639-23645	reveal	_
144-25	23646-23651	group	_
144-26	23652-23663	differences	_
144-27	23664-23666	in	_
144-28	23667-23672	brain	_
144-29	23673-23682	responses	_
144-30	23682-23683	;	_
144-31	23684-23692	criminal	_
144-32	23693-23700	cocaine	_
144-33	23701-23706	users	_
144-34	23707-23710	may	_
144-35	23711-23715	also	_
144-36	23716-23722	differ	_
144-37	23723-23727	from	_
144-38	23728-23737	community	_
144-39	23738-23743	users	_
144-40	23744-23745	(	_
144-41	23745-23748	e.g	_
144-42	23748-23749	.	_
144-43	23749-23750	,	_
144-44	23751-23753	in	_
144-45	23754-23762	severity	_
144-46	23762-23763	,	_
144-47	23764-23777	comorbidities	_
144-48	23777-23778	,	_
144-49	23779-23781	or	_
144-50	23782-23788	length	_
144-51	23789-23791	of	_
144-52	23792-23795	use	_
144-53	23795-23796	)	_
144-54	23796-23797	,	_
144-55	23798-23803	which	_
144-56	23804-23809	could	_
144-57	23810-23817	explain	_
144-58	23818-23828	discrepant	_
144-59	23829-23836	results	_
144-60	23836-23837	.	_

#Text=Our participants were chronic stimulant users in a semi-controlled environment.
145-1	23838-23841	Our	_
145-2	23842-23854	participants	_
145-3	23855-23859	were	_
145-4	23860-23867	chronic	_
145-5	23868-23877	stimulant	_
145-6	23878-23883	users	_
145-7	23884-23886	in	_
145-8	23887-23888	a	_
145-9	23889-23904	semi-controlled	_
145-10	23905-23916	environment	_
145-11	23916-23917	.	_

#Text=This means their access to drugs, although not non-existent, significantly more limited than in the community.
146-1	23918-23922	This	_
146-2	23923-23928	means	_
146-3	23929-23934	their	_
146-4	23935-23941	access	_
146-5	23942-23944	to	_
146-6	23945-23950	drugs	_
146-7	23950-23951	,	_
146-8	23952-23960	although	_
146-9	23961-23964	not	_
146-10	23965-23977	non-existent	_
146-11	23977-23978	,	_
146-12	23979-23992	significantly	_
146-13	23993-23997	more	_
146-14	23998-24005	limited	_
146-15	24006-24010	than	_
146-16	24011-24013	in	_
146-17	24014-24017	the	_
146-18	24018-24027	community	_
146-19	24027-24028	.	_

#Text=We do not anticipate that the results would be substantively different if our participants were using in the community, given the literature finding that voluntarily abstinent stimulant users still have indications of structural and functional brain abnormalities.
147-1	24029-24031	We	_
147-2	24032-24034	do	_
147-3	24035-24038	not	_
147-4	24039-24049	anticipate	_
147-5	24050-24054	that	_
147-6	24055-24058	the	_
147-7	24059-24066	results	_
147-8	24067-24072	would	_
147-9	24073-24075	be	_
147-10	24076-24089	substantively	_
147-11	24090-24099	different	_
147-12	24100-24102	if	_
147-13	24103-24106	our	_
147-14	24107-24119	participants	_
147-15	24120-24124	were	_
147-16	24125-24130	using	_
147-17	24131-24133	in	_
147-18	24134-24137	the	_
147-19	24138-24147	community	_
147-20	24147-24148	,	_
147-21	24149-24154	given	_
147-22	24155-24158	the	_
147-23	24159-24169	literature	_
147-24	24170-24177	finding	_
147-25	24178-24182	that	_
147-26	24183-24194	voluntarily	_
147-27	24195-24204	abstinent	_
147-28	24205-24214	stimulant	_
147-29	24215-24220	users	_
147-30	24221-24226	still	_
147-31	24227-24231	have	_
147-32	24232-24243	indications	_
147-33	24244-24246	of	_
147-34	24247-24257	structural	_
147-35	24258-24261	and	_
147-36	24262-24272	functional	_
147-37	24273-24278	brain	_
147-38	24279-24292	abnormalities	_
147-39	24292-24293	.	_

#Text=Moreover, by investigating stimulant users who were largely abstinent, our results were not confounded by the acute effects of heavy substance use.
148-1	24294-24302	Moreover	_
148-2	24302-24303	,	_
148-3	24304-24306	by	_
148-4	24307-24320	investigating	_
148-5	24321-24330	stimulant	_
148-6	24331-24336	users	_
148-7	24337-24340	who	_
148-8	24341-24345	were	_
148-9	24346-24353	largely	_
148-10	24354-24363	abstinent	_
148-11	24363-24364	,	_
148-12	24365-24368	our	_
148-13	24369-24376	results	_
148-14	24377-24381	were	_
148-15	24382-24385	not	_
148-16	24386-24396	confounded	_
148-17	24397-24399	by	_
148-18	24400-24403	the	_
148-19	24404-24409	acute	_
148-20	24410-24417	effects	_
148-21	24418-24420	of	_
148-22	24421-24426	heavy	_
148-23	24427-24436	substance	_
148-24	24437-24440	use	_
148-25	24440-24441	.	_

#Text=However, these results may not generalize to individuals actively or inactively using substances at a dependence level; a replication study in active stimulant users is needed to verify the generalizability of our findings to the stimulant using community as a whole.
149-1	24442-24449	However	_
149-2	24449-24450	,	_
149-3	24451-24456	these	_
149-4	24457-24464	results	_
149-5	24465-24468	may	_
149-6	24469-24472	not	_
149-7	24473-24483	generalize	_
149-8	24484-24486	to	_
149-9	24487-24498	individuals	_
149-10	24499-24507	actively	_
149-11	24508-24510	or	_
149-12	24511-24521	inactively	_
149-13	24522-24527	using	_
149-14	24528-24538	substances	_
149-15	24539-24541	at	_
149-16	24542-24543	a	_
149-17	24544-24554	dependence	_
149-18	24555-24560	level	_
149-19	24560-24561	;	_
149-20	24562-24563	a	_
149-21	24564-24575	replication	_
149-22	24576-24581	study	_
149-23	24582-24584	in	_
149-24	24585-24591	active	_
149-25	24592-24601	stimulant	_
149-26	24602-24607	users	_
149-27	24608-24610	is	_
149-28	24611-24617	needed	_
149-29	24618-24620	to	_
149-30	24621-24627	verify	_
149-31	24628-24631	the	_
149-32	24632-24648	generalizability	_
149-33	24649-24651	of	_
149-34	24652-24655	our	_
149-35	24656-24664	findings	_
149-36	24665-24667	to	_
149-37	24668-24671	the	_
149-38	24672-24681	stimulant	_
149-39	24682-24687	using	_
149-40	24688-24697	community	_
149-41	24698-24700	as	_
149-42	24701-24702	a	_
149-43	24703-24708	whole	_
149-44	24708-24709	.	_

#Text=It is also important to note that the results of this study cannot be used to make strong causal claims regarding the influence of stimulant use on moral cognition.
150-1	24710-24712	It	_
150-2	24713-24715	is	_
150-3	24716-24720	also	_
150-4	24721-24730	important	_
150-5	24731-24733	to	_
150-6	24734-24738	note	_
150-7	24739-24743	that	_
150-8	24744-24747	the	_
150-9	24748-24755	results	_
150-10	24756-24758	of	_
150-11	24759-24763	this	_
150-12	24764-24769	study	_
150-13	24770-24776	cannot	_
150-14	24777-24779	be	_
150-15	24780-24784	used	_
150-16	24785-24787	to	_
150-17	24788-24792	make	_
150-18	24793-24799	strong	_
150-19	24800-24806	causal	_
150-20	24807-24813	claims	_
150-21	24814-24823	regarding	_
150-22	24824-24827	the	_
150-23	24828-24837	influence	_
150-24	24838-24840	of	_
150-25	24841-24850	stimulant	_
150-26	24851-24854	use	_
150-27	24855-24857	on	_
150-28	24858-24863	moral	_
150-29	24864-24873	cognition	_
150-30	24873-24874	.	_

#Text=It is possible that individuals prone to regular stimulant use exhibited the observed abnormalities in moral processing before they began using stimulants.
151-1	24875-24877	It	_
151-2	24878-24880	is	_
151-3	24881-24889	possible	_
151-4	24890-24894	that	_
151-5	24895-24906	individuals	_
151-6	24907-24912	prone	_
151-7	24913-24915	to	_
151-8	24916-24923	regular	_
151-9	24924-24933	stimulant	_
151-10	24934-24937	use	_
151-11	24938-24947	exhibited	_
151-12	24948-24951	the	_
151-13	24952-24960	observed	_
151-14	24961-24974	abnormalities	_
151-15	24975-24977	in	_
151-16	24978-24983	moral	_
151-17	24984-24994	processing	_
151-18	24995-25001	before	_
151-19	25002-25006	they	_
151-20	25007-25012	began	_
151-21	25013-25018	using	_
151-22	25019-25029	stimulants	_
151-23	25029-25030	.	_

#Text=We did, however, see a change in vmPFC and ACC engagement as a function of increasing duration of stimulant use, a correlation that may indicate the impact of methamphetamine and cocaine use on the brain.
152-1	25031-25033	We	_
152-2	25034-25037	did	_
152-3	25037-25038	,	_
152-4	25039-25046	however	_
152-5	25046-25047	,	_
152-6	25048-25051	see	_
152-7	25052-25053	a	_
152-8	25054-25060	change	_
152-9	25061-25063	in	_
152-10	25064-25069	vmPFC	_
152-11	25070-25073	and	_
152-12	25074-25077	ACC	_
152-13	25078-25088	engagement	_
152-14	25089-25091	as	_
152-15	25092-25093	a	_
152-16	25094-25102	function	_
152-17	25103-25105	of	_
152-18	25106-25116	increasing	_
152-19	25117-25125	duration	_
152-20	25126-25128	of	_
152-21	25129-25138	stimulant	_
152-22	25139-25142	use	_
152-23	25142-25143	,	_
152-24	25144-25145	a	_
152-25	25146-25157	correlation	_
152-26	25158-25162	that	_
152-27	25163-25166	may	_
152-28	25167-25175	indicate	_
152-29	25176-25179	the	_
152-30	25180-25186	impact	_
152-31	25187-25189	of	_
152-32	25190-25205	methamphetamine	_
152-33	25206-25209	and	_
152-34	25210-25217	cocaine	_
152-35	25218-25221	use	_
152-36	25222-25224	on	_
152-37	25225-25228	the	_
152-38	25229-25234	brain	_
152-39	25234-25235	.	_

#Text=There were some limitations of this study.
153-1	25236-25241	There	_
153-2	25242-25246	were	_
153-3	25247-25251	some	_
153-4	25252-25263	limitations	_
153-5	25264-25266	of	_
153-6	25267-25271	this	_
153-7	25272-25277	study	_
153-8	25277-25278	.	_

#Text=Many of our participants (both stimulant users and non-stimulant users) had comorbid substance abuse.
154-1	25279-25283	Many	_
154-2	25284-25286	of	_
154-3	25287-25290	our	_
154-4	25291-25303	participants	_
154-5	25304-25305	(	_
154-6	25305-25309	both	_
154-7	25310-25319	stimulant	_
154-8	25320-25325	users	_
154-9	25326-25329	and	_
154-10	25330-25343	non-stimulant	_
154-11	25344-25349	users	_
154-12	25349-25350	)	_
154-13	25351-25354	had	_
154-14	25355-25363	comorbid	_
154-15	25364-25373	substance	_
154-16	25374-25379	abuse	_
154-17	25379-25380	.	_

#Text=Our stimulant and non-stimulant groups did differ on levels of non-stimulant substance use; although our results were substantively the same after covarying total years of non-stimulant substance abuse, there may be differences in poly-drug users above and beyond the duration of such use.
155-1	25381-25384	Our	_
155-2	25385-25394	stimulant	_
155-3	25395-25398	and	_
155-4	25399-25412	non-stimulant	_
155-5	25413-25419	groups	_
155-6	25420-25423	did	_
155-7	25424-25430	differ	_
155-8	25431-25433	on	_
155-9	25434-25440	levels	_
155-10	25441-25443	of	_
155-11	25444-25457	non-stimulant	_
155-12	25458-25467	substance	_
155-13	25468-25471	use	_
155-14	25471-25472	;	_
155-15	25473-25481	although	_
155-16	25482-25485	our	_
155-17	25486-25493	results	_
155-18	25494-25498	were	_
155-19	25499-25512	substantively	_
155-20	25513-25516	the	_
155-21	25517-25521	same	_
155-22	25522-25527	after	_
155-23	25528-25537	covarying	_
155-24	25538-25543	total	_
155-25	25544-25549	years	_
155-26	25550-25552	of	_
155-27	25553-25566	non-stimulant	_
155-28	25567-25576	substance	_
155-29	25577-25582	abuse	_
155-30	25582-25583	,	_
155-31	25584-25589	there	_
155-32	25590-25593	may	_
155-33	25594-25596	be	_
155-34	25597-25608	differences	_
155-35	25609-25611	in	_
155-36	25612-25621	poly-drug	_
155-37	25622-25627	users	_
155-38	25628-25633	above	_
155-39	25634-25637	and	_
155-40	25638-25644	beyond	_
155-41	25645-25648	the	_
155-42	25649-25657	duration	_
155-43	25658-25660	of	_
155-44	25661-25665	such	_
155-45	25666-25669	use	_
155-46	25669-25670	.	_

#Text=It is worth noting that comorbid substance use is common in stimulant users.
156-1	25671-25673	It	_
156-2	25674-25676	is	_
156-3	25677-25682	worth	_
156-4	25683-25689	noting	_
156-5	25690-25694	that	_
156-6	25695-25703	comorbid	_
156-7	25704-25713	substance	_
156-8	25714-25717	use	_
156-9	25718-25720	is	_
156-10	25721-25727	common	_
156-11	25728-25730	in	_
156-12	25731-25740	stimulant	_
156-13	25741-25746	users	_
156-14	25746-25747	.	_

#Text=Thus, despite potential complicating effects of poly-drug use, our sample of stimulant users is highly representative of the stimulant using population.
157-1	25748-25752	Thus	_
157-2	25752-25753	,	_
157-3	25754-25761	despite	_
157-4	25762-25771	potential	_
157-5	25772-25784	complicating	_
157-6	25785-25792	effects	_
157-7	25793-25795	of	_
157-8	25796-25805	poly-drug	_
157-9	25806-25809	use	_
157-10	25809-25810	,	_
157-11	25811-25814	our	_
157-12	25815-25821	sample	_
157-13	25822-25824	of	_
157-14	25825-25834	stimulant	_
157-15	25835-25840	users	_
157-16	25841-25843	is	_
157-17	25844-25850	highly	_
157-18	25851-25865	representative	_
157-19	25866-25868	of	_
157-20	25869-25872	the	_
157-21	25873-25882	stimulant	_
157-22	25883-25888	using	_
157-23	25889-25899	population	_
157-24	25899-25900	.	_

#Text=Another potential limitation was that our measure of duration did not account for the amount of the drugs used.
158-1	25901-25908	Another	_
158-2	25909-25918	potential	_
158-3	25919-25929	limitation	_
158-4	25930-25933	was	_
158-5	25934-25938	that	_
158-6	25939-25942	our	_
158-7	25943-25950	measure	_
158-8	25951-25953	of	_
158-9	25954-25962	duration	_
158-10	25963-25966	did	_
158-11	25967-25970	not	_
158-12	25971-25978	account	_
158-13	25979-25982	for	_
158-14	25983-25986	the	_
158-15	25987-25993	amount	_
158-16	25994-25996	of	_
158-17	25997-26000	the	_
158-18	26001-26006	drugs	_
158-19	26007-26011	used	_
158-20	26011-26012	.	_

#Text=Although previous research indicates that the duration measure of stimulant use can have meaningful correlates in the brain (i.e.,, 2013) this may not have adequately quantified severity of use.
159-1	26013-26021	Although	_
159-2	26022-26030	previous	_
159-3	26031-26039	research	_
159-4	26040-26049	indicates	_
159-5	26050-26054	that	_
159-6	26055-26058	the	_
159-7	26059-26067	duration	_
159-8	26068-26075	measure	_
159-9	26076-26078	of	_
159-10	26079-26088	stimulant	_
159-11	26089-26092	use	_
159-12	26093-26096	can	_
159-13	26097-26101	have	_
159-14	26102-26112	meaningful	_
159-15	26113-26123	correlates	_
159-16	26124-26126	in	_
159-17	26127-26130	the	_
159-18	26131-26136	brain	_
159-19	26137-26138	(	_
159-20	26138-26141	i.e	_
159-21	26141-26142	.	_
159-22	26142-26143	,	_
159-23	26143-26144	,	_
159-24	26145-26149	2013	_
159-25	26149-26150	)	_
159-26	26151-26155	this	_
159-27	26156-26159	may	_
159-28	26160-26163	not	_
159-29	26164-26168	have	_
159-30	26169-26179	adequately	_
159-31	26180-26190	quantified	_
159-32	26191-26199	severity	_
159-33	26200-26202	of	_
159-34	26203-26206	use	_
159-35	26206-26207	.	_

#Text=In conclusion, regular stimulant users demonstrated abnormal neural activity during moral processing in fronto-limbic regions.
160-1	26208-26210	In	_
160-2	26211-26221	conclusion	_
160-3	26221-26222	,	_
160-4	26223-26230	regular	_
160-5	26231-26240	stimulant	_
160-6	26241-26246	users	_
160-7	26247-26259	demonstrated	_
160-8	26260-26268	abnormal	_
160-9	26269-26275	neural	_
160-10	26276-26284	activity	_
160-11	26285-26291	during	_
160-12	26292-26297	moral	_
160-13	26298-26308	processing	_
160-14	26309-26311	in	_
160-15	26312-26325	fronto-limbic	_
160-16	26326-26333	regions	_
160-17	26333-26334	.	_

#Text=Specifically, lifetime regular stimulant users had hypoactivation in the amygdala, while duration of stimulant use was related to decreased ACC engagement.
161-1	26335-26347	Specifically	_
161-2	26347-26348	,	_
161-3	26349-26357	lifetime	_
161-4	26358-26365	regular	_
161-5	26366-26375	stimulant	_
161-6	26376-26381	users	_
161-7	26382-26385	had	_
161-8	26386-26400	hypoactivation	_
161-9	26401-26403	in	_
161-10	26404-26407	the	_
161-11	26408-26416	amygdala	_
161-12	26416-26417	,	_
161-13	26418-26423	while	_
161-14	26424-26432	duration	_
161-15	26433-26435	of	_
161-16	26436-26445	stimulant	_
161-17	26446-26449	use	_
161-18	26450-26453	was	_
161-19	26454-26461	related	_
161-20	26462-26464	to	_
161-21	26465-26474	decreased	_
161-22	26475-26478	ACC	_
161-23	26479-26489	engagement	_
161-24	26489-26490	.	_

#Text=These results correspond to the fronto-limbic moral processing system, suggesting that stimulant users may have impairment in regions in this system.
162-1	26491-26496	These	_
162-2	26497-26504	results	_
162-3	26505-26515	correspond	_
162-4	26516-26518	to	_
162-5	26519-26522	the	_
162-6	26523-26536	fronto-limbic	_
162-7	26537-26542	moral	_
162-8	26543-26553	processing	_
162-9	26554-26560	system	_
162-10	26560-26561	,	_
162-11	26562-26572	suggesting	_
162-12	26573-26577	that	_
162-13	26578-26587	stimulant	_
162-14	26588-26593	users	_
162-15	26594-26597	may	_
162-16	26598-26602	have	_
162-17	26603-26613	impairment	_
162-18	26614-26616	in	_
162-19	26617-26624	regions	_
162-20	26625-26627	in	_
162-21	26628-26632	this	_
162-22	26633-26639	system	_
162-23	26639-26640	.	_

#Text=This is the first study to suggest impairments in the neural systems of moral processing in both cocaine and methamphetamine users.
163-1	26641-26645	This	_
163-2	26646-26648	is	_
163-3	26649-26652	the	_
163-4	26653-26658	first	_
163-5	26659-26664	study	_
163-6	26665-26667	to	_
163-7	26668-26675	suggest	_
163-8	26676-26687	impairments	_
163-9	26688-26690	in	_
163-10	26691-26694	the	_
163-11	26695-26701	neural	_
163-12	26702-26709	systems	_
163-13	26710-26712	of	_
163-14	26713-26718	moral	_
163-15	26719-26729	processing	_
163-16	26730-26732	in	_
163-17	26733-26737	both	_
163-18	26738-26745	cocaine	_
163-19	26746-26749	and	_
163-20	26750-26765	methamphetamine	_
163-21	26766-26771	users	_
163-22	26771-26772	.	_

#Text=Although further research into the connectivity of systems in stimulant use is needed, this provides promising initial understanding of fronto-limbic deficits in stimulant users.
164-1	26773-26781	Although	_
164-2	26782-26789	further	_
164-3	26790-26798	research	_
164-4	26799-26803	into	_
164-5	26804-26807	the	_
164-6	26808-26820	connectivity	_
164-7	26821-26823	of	_
164-8	26824-26831	systems	_
164-9	26832-26834	in	_
164-10	26835-26844	stimulant	_
164-11	26845-26848	use	_
164-12	26849-26851	is	_
164-13	26852-26858	needed	_
164-14	26858-26859	,	_
164-15	26860-26864	this	_
164-16	26865-26873	provides	_
164-17	26874-26883	promising	_
164-18	26884-26891	initial	_
164-19	26892-26905	understanding	_
164-20	26906-26908	of	_
164-21	26909-26922	fronto-limbic	_
164-22	26923-26931	deficits	_
164-23	26932-26934	in	_
164-24	26935-26944	stimulant	_
164-25	26945-26950	users	_
164-26	26950-26951	.	_

#Text=The authors do not have any financial conflicts of interest.
165-1	26952-26955	The	_
165-2	26956-26963	authors	_
165-3	26964-26966	do	_
165-4	26967-26970	not	_
165-5	26971-26975	have	_
165-6	26976-26979	any	_
165-7	26980-26989	financial	_
165-8	26990-26999	conflicts	_
165-9	27000-27002	of	_
165-10	27003-27011	interest	_
165-11	27011-27012	.	_

#Text=Neuroprediction of future rearrest
#Text=Gene x Disease Interaction on Orbitofrontal Gray Matter in Cocaine Addiction
#Text=Location, location: using functional magnetic resonance imaging to pinpoint brain differences relevant to stimulant use
#Text=Amygdala–frontal connectivity during emotion regulation
#Text=Serial pathways from primate prefrontal cortex to autonomic areas may influence emotional expression
#Text=Age-related brain volume reductions in amphetamine and cocaine addicts and normal controls: implications for addiction research
#Text=The somatic marker hypothesis: A neural theory of economic decision
#Text=Decision-making deficits, linked to a dysfunctional ventromedial prefrontal cortex, revealed in alcohol and stimulant abusers
#Text=
#Text=The amygdala and ventromedial prefrontal cortex in morality and psychopathy
#Text=Orbitofrontal cortex dysfunction in abstinent cocaine abusers performing a decision-making task
#Text=Safety and efficacy of γ-vinyl GABA (GVG) for the treatment of methamphetamine and/or cocaine addiction
#Text=Parsing the neural correlates of moral cognition: ALE meta-analysis on morality, theory of mind, and empathy
#Text=Abnormal frontostriatal activity in recently abstinent cocaine users during implicit moral processing
#Text=Selective deficit in personal moral judgment following damage to ventromedial prefrontal cortex
#Text=Reduced fMRI activity predicts relapse in patients recovering from stimulant dependence
#Text=Substrates of neuropsychological functioning in stimulant dependence: a review of functional neuroimaging research
#Text=Separable neural components in the processing of black and white faces
#Text=Levels and correlates of polydrug use among heroin users and regular amphetamine users
#Text=Medial prefrontal gray matter volume reductions in users of amphetamine-type stimulants revealed by combined tract-based spatial statistics and voxel-based morphometry
#Text=Echoencephalographic findings in neonates assciiated with maternal cocaine and methamphetamine use: Incidence and clinical correlates
#Text=Abnormal structure of frontostriatal brain systems is associated with aspects of impulsivity and compulsivity in cocaine dependence
#Text=Abnormal Brain Structure Implicated in Stimulant Drug Addiction
#Text=Addiction and empathy: a preliminary analysis
#Text=
#Text=Other Minds in the Brain - a Functional Imaging Study of Theory of Mind in Story Comprehension
#Text=Difficulties in emotion regulation and impulse control during cocaine abstinence
#Text=Selective Cocaine-Related Difficulties in Emotional Intelligence: Relationship to Stress and Impulse Control
#Text=Decreased gray matter concentration in the insular, orbitofrontal, cingulate, and temporal cortices of cocaine patients
#Text=What is the best similarity measure for motion correction in fMRI time series?
166-1	27013-27028	Neuroprediction	_
166-2	27029-27031	of	_
166-3	27032-27038	future	_
166-4	27039-27047	rearrest	_
166-5	27048-27052	Gene	_
166-6	27053-27054	x	_
166-7	27055-27062	Disease	_
166-8	27063-27074	Interaction	_
166-9	27075-27077	on	_
166-10	27078-27091	Orbitofrontal	_
166-11	27092-27096	Gray	_
166-12	27097-27103	Matter	_
166-13	27104-27106	in	_
166-14	27107-27114	Cocaine	_
166-15	27115-27124	Addiction	_
166-16	27125-27133	Location	_
166-17	27133-27134	,	_
166-18	27135-27143	location	_
166-19	27143-27144	:	_
166-20	27145-27150	using	_
166-21	27151-27161	functional	_
166-22	27162-27170	magnetic	_
166-23	27171-27180	resonance	_
166-24	27181-27188	imaging	_
166-25	27189-27191	to	_
166-26	27192-27200	pinpoint	_
166-27	27201-27206	brain	_
166-28	27207-27218	differences	_
166-29	27219-27227	relevant	_
166-30	27228-27230	to	_
166-31	27231-27240	stimulant	_
166-32	27241-27244	use	_
166-33	27245-27261	Amygdala–frontal	_
166-34	27262-27274	connectivity	_
166-35	27275-27281	during	_
166-36	27282-27289	emotion	_
166-37	27290-27300	regulation	_
166-38	27301-27307	Serial	_
166-39	27308-27316	pathways	_
166-40	27317-27321	from	_
166-41	27322-27329	primate	_
166-42	27330-27340	prefrontal	_
166-43	27341-27347	cortex	_
166-44	27348-27350	to	_
166-45	27351-27360	autonomic	_
166-46	27361-27366	areas	_
166-47	27367-27370	may	_
166-48	27371-27380	influence	_
166-49	27381-27390	emotional	_
166-50	27391-27401	expression	_
166-51	27402-27413	Age-related	_
166-52	27414-27419	brain	_
166-53	27420-27426	volume	_
166-54	27427-27437	reductions	_
166-55	27438-27440	in	_
166-56	27441-27452	amphetamine	_
166-57	27453-27456	and	_
166-58	27457-27464	cocaine	_
166-59	27465-27472	addicts	_
166-60	27473-27476	and	_
166-61	27477-27483	normal	_
166-62	27484-27492	controls	_
166-63	27492-27493	:	_
166-64	27494-27506	implications	_
166-65	27507-27510	for	_
166-66	27511-27520	addiction	_
166-67	27521-27529	research	_
166-68	27530-27533	The	_
166-69	27534-27541	somatic	_
166-70	27542-27548	marker	_
166-71	27549-27559	hypothesis	_
166-72	27559-27560	:	_
166-73	27561-27562	A	_
166-74	27563-27569	neural	_
166-75	27570-27576	theory	_
166-76	27577-27579	of	_
166-77	27580-27588	economic	_
166-78	27589-27597	decision	_
166-79	27598-27613	Decision-making	_
166-80	27614-27622	deficits	_
166-81	27622-27623	,	_
166-82	27624-27630	linked	_
166-83	27631-27633	to	_
166-84	27634-27635	a	_
166-85	27636-27649	dysfunctional	_
166-86	27650-27662	ventromedial	_
166-87	27663-27673	prefrontal	_
166-88	27674-27680	cortex	_
166-89	27680-27681	,	_
166-90	27682-27690	revealed	_
166-91	27691-27693	in	_
166-92	27694-27701	alcohol	_
166-93	27702-27705	and	_
166-94	27706-27715	stimulant	_
166-95	27716-27723	abusers	_
166-96	27725-27728	The	_
166-97	27729-27737	amygdala	_
166-98	27738-27741	and	_
166-99	27742-27754	ventromedial	_
166-100	27755-27765	prefrontal	_
166-101	27766-27772	cortex	_
166-102	27773-27775	in	_
166-103	27776-27784	morality	_
166-104	27785-27788	and	_
166-105	27789-27800	psychopathy	_
166-106	27801-27814	Orbitofrontal	_
166-107	27815-27821	cortex	_
166-108	27822-27833	dysfunction	_
166-109	27834-27836	in	_
166-110	27837-27846	abstinent	_
166-111	27847-27854	cocaine	_
166-112	27855-27862	abusers	_
166-113	27863-27873	performing	_
166-114	27874-27875	a	_
166-115	27876-27891	decision-making	_
166-116	27892-27896	task	_
166-117	27897-27903	Safety	_
166-118	27904-27907	and	_
166-119	27908-27916	efficacy	_
166-120	27917-27919	of	_
166-121	27920-27927	γ-vinyl	_
166-122	27928-27932	GABA	_
166-123	27933-27934	(	_
166-124	27934-27937	GVG	_
166-125	27937-27938	)	_
166-126	27939-27942	for	_
166-127	27943-27946	the	_
166-128	27947-27956	treatment	_
166-129	27957-27959	of	_
166-130	27960-27975	methamphetamine	_
166-131	27976-27979	and	_
166-132	27979-27980	/	_
166-133	27980-27982	or	_
166-134	27983-27990	cocaine	_
166-135	27991-28000	addiction	_
166-136	28001-28008	Parsing	_
166-137	28009-28012	the	_
166-138	28013-28019	neural	_
166-139	28020-28030	correlates	_
166-140	28031-28033	of	_
166-141	28034-28039	moral	_
166-142	28040-28049	cognition	_
166-143	28049-28050	:	_
166-144	28051-28054	ALE	_
166-145	28055-28068	meta-analysis	_
166-146	28069-28071	on	_
166-147	28072-28080	morality	_
166-148	28080-28081	,	_
166-149	28082-28088	theory	_
166-150	28089-28091	of	_
166-151	28092-28096	mind	_
166-152	28096-28097	,	_
166-153	28098-28101	and	_
166-154	28102-28109	empathy	_
166-155	28110-28118	Abnormal	_
166-156	28119-28133	frontostriatal	_
166-157	28134-28142	activity	_
166-158	28143-28145	in	_
166-159	28146-28154	recently	_
166-160	28155-28164	abstinent	_
166-161	28165-28172	cocaine	_
166-162	28173-28178	users	_
166-163	28179-28185	during	_
166-164	28186-28194	implicit	_
166-165	28195-28200	moral	_
166-166	28201-28211	processing	_
166-167	28212-28221	Selective	_
166-168	28222-28229	deficit	_
166-169	28230-28232	in	_
166-170	28233-28241	personal	_
166-171	28242-28247	moral	_
166-172	28248-28256	judgment	_
166-173	28257-28266	following	_
166-174	28267-28273	damage	_
166-175	28274-28276	to	_
166-176	28277-28289	ventromedial	_
166-177	28290-28300	prefrontal	_
166-178	28301-28307	cortex	_
166-179	28308-28315	Reduced	_
166-180	28316-28320	fMRI	_
166-181	28321-28329	activity	_
166-182	28330-28338	predicts	_
166-183	28339-28346	relapse	_
166-184	28347-28349	in	_
166-185	28350-28358	patients	_
166-186	28359-28369	recovering	_
166-187	28370-28374	from	_
166-188	28375-28384	stimulant	_
166-189	28385-28395	dependence	_
166-190	28396-28406	Substrates	_
166-191	28407-28409	of	_
166-192	28410-28428	neuropsychological	_
166-193	28429-28440	functioning	_
166-194	28441-28443	in	_
166-195	28444-28453	stimulant	_
166-196	28454-28464	dependence	_
166-197	28464-28465	:	_
166-198	28466-28467	a	_
166-199	28468-28474	review	_
166-200	28475-28477	of	_
166-201	28478-28488	functional	_
166-202	28489-28501	neuroimaging	_
166-203	28502-28510	research	_
166-204	28511-28520	Separable	_
166-205	28521-28527	neural	_
166-206	28528-28538	components	_
166-207	28539-28541	in	_
166-208	28542-28545	the	_
166-209	28546-28556	processing	_
166-210	28557-28559	of	_
166-211	28560-28565	black	_
166-212	28566-28569	and	_
166-213	28570-28575	white	_
166-214	28576-28581	faces	_
166-215	28582-28588	Levels	_
166-216	28589-28592	and	_
166-217	28593-28603	correlates	_
166-218	28604-28606	of	_
166-219	28607-28615	polydrug	_
166-220	28616-28619	use	_
166-221	28620-28625	among	_
166-222	28626-28632	heroin	_
166-223	28633-28638	users	_
166-224	28639-28642	and	_
166-225	28643-28650	regular	_
166-226	28651-28662	amphetamine	_
166-227	28663-28668	users	_
166-228	28669-28675	Medial	_
166-229	28676-28686	prefrontal	_
166-230	28687-28691	gray	_
166-231	28692-28698	matter	_
166-232	28699-28705	volume	_
166-233	28706-28716	reductions	_
166-234	28717-28719	in	_
166-235	28720-28725	users	_
166-236	28726-28728	of	_
166-237	28729-28745	amphetamine-type	_
166-238	28746-28756	stimulants	_
166-239	28757-28765	revealed	_
166-240	28766-28768	by	_
166-241	28769-28777	combined	_
166-242	28778-28789	tract-based	_
166-243	28790-28797	spatial	_
166-244	28798-28808	statistics	_
166-245	28809-28812	and	_
166-246	28813-28824	voxel-based	_
166-247	28825-28836	morphometry	_
166-248	28837-28857	Echoencephalographic	_
166-249	28858-28866	findings	_
166-250	28867-28869	in	_
166-251	28870-28878	neonates	_
166-252	28879-28889	assciiated	_
166-253	28890-28894	with	_
166-254	28895-28903	maternal	_
166-255	28904-28911	cocaine	_
166-256	28912-28915	and	_
166-257	28916-28931	methamphetamine	_
166-258	28932-28935	use	_
166-259	28935-28936	:	_
166-260	28937-28946	Incidence	_
166-261	28947-28950	and	_
166-262	28951-28959	clinical	_
166-263	28960-28970	correlates	_
166-264	28971-28979	Abnormal	_
166-265	28980-28989	structure	_
166-266	28990-28992	of	_
166-267	28993-29007	frontostriatal	_
166-268	29008-29013	brain	_
166-269	29014-29021	systems	_
166-270	29022-29024	is	_
166-271	29025-29035	associated	_
166-272	29036-29040	with	_
166-273	29041-29048	aspects	_
166-274	29049-29051	of	_
166-275	29052-29063	impulsivity	_
166-276	29064-29067	and	_
166-277	29068-29080	compulsivity	_
166-278	29081-29083	in	_
166-279	29084-29091	cocaine	_
166-280	29092-29102	dependence	_
166-281	29103-29111	Abnormal	_
166-282	29112-29117	Brain	_
166-283	29118-29127	Structure	_
166-284	29128-29138	Implicated	_
166-285	29139-29141	in	_
166-286	29142-29151	Stimulant	_
166-287	29152-29156	Drug	_
166-288	29157-29166	Addiction	_
166-289	29167-29176	Addiction	_
166-290	29177-29180	and	_
166-291	29181-29188	empathy	_
166-292	29188-29189	:	_
166-293	29190-29191	a	_
166-294	29192-29203	preliminary	_
166-295	29204-29212	analysis	_
166-296	29214-29219	Other	_
166-297	29220-29225	Minds	_
166-298	29226-29228	in	_
166-299	29229-29232	the	_
166-300	29233-29238	Brain	_
166-301	29239-29240	-	_
166-302	29241-29242	a	_
166-303	29243-29253	Functional	_
166-304	29254-29261	Imaging	_
166-305	29262-29267	Study	_
166-306	29268-29270	of	_
166-307	29271-29277	Theory	_
166-308	29278-29280	of	_
166-309	29281-29285	Mind	_
166-310	29286-29288	in	_
166-311	29289-29294	Story	_
166-312	29295-29308	Comprehension	_
166-313	29309-29321	Difficulties	_
166-314	29322-29324	in	_
166-315	29325-29332	emotion	_
166-316	29333-29343	regulation	_
166-317	29344-29347	and	_
166-318	29348-29355	impulse	_
166-319	29356-29363	control	_
166-320	29364-29370	during	_
166-321	29371-29378	cocaine	_
166-322	29379-29389	abstinence	_
166-323	29390-29399	Selective	_
166-324	29400-29415	Cocaine-Related	_
166-325	29416-29428	Difficulties	_
166-326	29429-29431	in	_
166-327	29432-29441	Emotional	_
166-328	29442-29454	Intelligence	_
166-329	29454-29455	:	_
166-330	29456-29468	Relationship	_
166-331	29469-29471	to	_
166-332	29472-29478	Stress	_
166-333	29479-29482	and	_
166-334	29483-29490	Impulse	_
166-335	29491-29498	Control	_
166-336	29499-29508	Decreased	_
166-337	29509-29513	gray	_
166-338	29514-29520	matter	_
166-339	29521-29534	concentration	_
166-340	29535-29537	in	_
166-341	29538-29541	the	_
166-342	29542-29549	insular	_
166-343	29549-29550	,	_
166-344	29551-29564	orbitofrontal	_
166-345	29564-29565	,	_
166-346	29566-29575	cingulate	_
166-347	29575-29576	,	_
166-348	29577-29580	and	_
166-349	29581-29589	temporal	_
166-350	29590-29598	cortices	_
166-351	29599-29601	of	_
166-352	29602-29609	cocaine	_
166-353	29610-29618	patients	_
166-354	29619-29623	What	_
166-355	29624-29626	is	_
166-356	29627-29630	the	_
166-357	29631-29635	best	_
166-358	29636-29646	similarity	_
166-359	29647-29654	measure	_
166-360	29655-29658	for	_
166-361	29659-29665	motion	_
166-362	29666-29676	correction	_
166-363	29677-29679	in	_
166-364	29680-29684	fMRI	_
166-365	29685-29689	time	_
166-366	29690-29696	series	_
166-367	29696-29697	?	_

#Text=Cue-induced cocaine craving: neuroanatomical specificity for drug users and drug stimuli
#Text=The neural bases of cognitive conflict and control in moral judgment
#Text=
#Text=The Fagerström test for nicotine dependence: a revision of the Fagerstrom Tolerance Questionnaire
#Text=Psychopathy and substance use
#Text=Social-cognitive difficulties in former users of methamphetamine
#Text=Cortical activation during delay discounting in abstinent methamphetamine dependent individuals
#Text=Contrasting trajectories of heroin, cocaine, and methamphetamine use
#Text=Prevalence, correlates, and comorbidity of nonmedical prescription drug use and drug use disorders in the United States: Results of the National Epidemiologic Survey on Alcohol and Related Conditions
#Text=Anatomical connectivity of the subgenual cingulate region targeted with deep brain stimulation for treatment-resistant depression
#Text=Dissociating medial frontal and posterior cingulate activity during self-reflection
#Text=Failure to regulate: counterproductive recruitment of top-down prefrontal-subcortical circuitry in major depression
#Text=Impaired fear recognition in regular recreational cocaine users
#Text=Brain potentials implicate temporal lobe abnormalities in criminal psychopaths
#Text=The structural and functional connectivity of the amygdala: from normal emotion to pathological anxiety
#Text=Prefrontal grey-matter changes in short-term and long-term abstinent methamphetamine abusers
#Text=Impairments of facial emotion recognition and theory of mind in methamphetamine abusers
#Text=Alterations in cortical activity of male methamphetamine abusers performing an empathy task: fMRI study
#Text=Damage to the prefrontal cortex increases utilitarian moral judgements
#Text=Risky decision making, prefrontal cortex, and mesocorticolimbic functional connectivity in methamphetamine dependence
#Text=Midbrain functional connectivity and ventral striatal dopamine D2-type receptors: link to impulsivity in methamphetamine users
#Text=The role of the striatopallidal and extended amygdala systems in drug addiction
#Text=Chronic methamphetamine abuse and corticostriatal deficits revealed by neuroimaging
#Text=Are there volumetric brain differences associated with the use of cocaine and amphetamine-type stimulants?
167-1	29698-29709	Cue-induced	_
167-2	29710-29717	cocaine	_
167-3	29718-29725	craving	_
167-4	29725-29726	:	_
167-5	29727-29742	neuroanatomical	_
167-6	29743-29754	specificity	_
167-7	29755-29758	for	_
167-8	29759-29763	drug	_
167-9	29764-29769	users	_
167-10	29770-29773	and	_
167-11	29774-29778	drug	_
167-12	29779-29786	stimuli	_
167-13	29787-29790	The	_
167-14	29791-29797	neural	_
167-15	29798-29803	bases	_
167-16	29804-29806	of	_
167-17	29807-29816	cognitive	_
167-18	29817-29825	conflict	_
167-19	29826-29829	and	_
167-20	29830-29837	control	_
167-21	29838-29840	in	_
167-22	29841-29846	moral	_
167-23	29847-29855	judgment	_
167-24	29857-29860	The	_
167-25	29861-29871	Fagerström	_
167-26	29872-29876	test	_
167-27	29877-29880	for	_
167-28	29881-29889	nicotine	_
167-29	29890-29900	dependence	_
167-30	29900-29901	:	_
167-31	29902-29903	a	_
167-32	29904-29912	revision	_
167-33	29913-29915	of	_
167-34	29916-29919	the	_
167-35	29920-29930	Fagerstrom	_
167-36	29931-29940	Tolerance	_
167-37	29941-29954	Questionnaire	_
167-38	29955-29966	Psychopathy	_
167-39	29967-29970	and	_
167-40	29971-29980	substance	_
167-41	29981-29984	use	_
167-42	29985-30001	Social-cognitive	_
167-43	30002-30014	difficulties	_
167-44	30015-30017	in	_
167-45	30018-30024	former	_
167-46	30025-30030	users	_
167-47	30031-30033	of	_
167-48	30034-30049	methamphetamine	_
167-49	30050-30058	Cortical	_
167-50	30059-30069	activation	_
167-51	30070-30076	during	_
167-52	30077-30082	delay	_
167-53	30083-30094	discounting	_
167-54	30095-30097	in	_
167-55	30098-30107	abstinent	_
167-56	30108-30123	methamphetamine	_
167-57	30124-30133	dependent	_
167-58	30134-30145	individuals	_
167-59	30146-30157	Contrasting	_
167-60	30158-30170	trajectories	_
167-61	30171-30173	of	_
167-62	30174-30180	heroin	_
167-63	30180-30181	,	_
167-64	30182-30189	cocaine	_
167-65	30189-30190	,	_
167-66	30191-30194	and	_
167-67	30195-30210	methamphetamine	_
167-68	30211-30214	use	_
167-69	30215-30225	Prevalence	_
167-70	30225-30226	,	_
167-71	30227-30237	correlates	_
167-72	30237-30238	,	_
167-73	30239-30242	and	_
167-74	30243-30254	comorbidity	_
167-75	30255-30257	of	_
167-76	30258-30268	nonmedical	_
167-77	30269-30281	prescription	_
167-78	30282-30286	drug	_
167-79	30287-30290	use	_
167-80	30291-30294	and	_
167-81	30295-30299	drug	_
167-82	30300-30303	use	_
167-83	30304-30313	disorders	_
167-84	30314-30316	in	_
167-85	30317-30320	the	_
167-86	30321-30327	United	_
167-87	30328-30334	States	_
167-88	30334-30335	:	_
167-89	30336-30343	Results	_
167-90	30344-30346	of	_
167-91	30347-30350	the	_
167-92	30351-30359	National	_
167-93	30360-30373	Epidemiologic	_
167-94	30374-30380	Survey	_
167-95	30381-30383	on	_
167-96	30384-30391	Alcohol	_
167-97	30392-30395	and	_
167-98	30396-30403	Related	_
167-99	30404-30414	Conditions	_
167-100	30415-30425	Anatomical	_
167-101	30426-30438	connectivity	_
167-102	30439-30441	of	_
167-103	30442-30445	the	_
167-104	30446-30455	subgenual	_
167-105	30456-30465	cingulate	_
167-106	30466-30472	region	_
167-107	30473-30481	targeted	_
167-108	30482-30486	with	_
167-109	30487-30491	deep	_
167-110	30492-30497	brain	_
167-111	30498-30509	stimulation	_
167-112	30510-30513	for	_
167-113	30514-30533	treatment-resistant	_
167-114	30534-30544	depression	_
167-115	30545-30557	Dissociating	_
167-116	30558-30564	medial	_
167-117	30565-30572	frontal	_
167-118	30573-30576	and	_
167-119	30577-30586	posterior	_
167-120	30587-30596	cingulate	_
167-121	30597-30605	activity	_
167-122	30606-30612	during	_
167-123	30613-30628	self-reflection	_
167-124	30629-30636	Failure	_
167-125	30637-30639	to	_
167-126	30640-30648	regulate	_
167-127	30648-30649	:	_
167-128	30650-30667	counterproductive	_
167-129	30668-30679	recruitment	_
167-130	30680-30682	of	_
167-131	30683-30691	top-down	_
167-132	30692-30714	prefrontal-subcortical	_
167-133	30715-30724	circuitry	_
167-134	30725-30727	in	_
167-135	30728-30733	major	_
167-136	30734-30744	depression	_
167-137	30745-30753	Impaired	_
167-138	30754-30758	fear	_
167-139	30759-30770	recognition	_
167-140	30771-30773	in	_
167-141	30774-30781	regular	_
167-142	30782-30794	recreational	_
167-143	30795-30802	cocaine	_
167-144	30803-30808	users	_
167-145	30809-30814	Brain	_
167-146	30815-30825	potentials	_
167-147	30826-30835	implicate	_
167-148	30836-30844	temporal	_
167-149	30845-30849	lobe	_
167-150	30850-30863	abnormalities	_
167-151	30864-30866	in	_
167-152	30867-30875	criminal	_
167-153	30876-30887	psychopaths	_
167-154	30888-30891	The	_
167-155	30892-30902	structural	_
167-156	30903-30906	and	_
167-157	30907-30917	functional	_
167-158	30918-30930	connectivity	_
167-159	30931-30933	of	_
167-160	30934-30937	the	_
167-161	30938-30946	amygdala	_
167-162	30946-30947	:	_
167-163	30948-30952	from	_
167-164	30953-30959	normal	_
167-165	30960-30967	emotion	_
167-166	30968-30970	to	_
167-167	30971-30983	pathological	_
167-168	30984-30991	anxiety	_
167-169	30992-31002	Prefrontal	_
167-170	31003-31014	grey-matter	_
167-171	31015-31022	changes	_
167-172	31023-31025	in	_
167-173	31026-31036	short-term	_
167-174	31037-31040	and	_
167-175	31041-31050	long-term	_
167-176	31051-31060	abstinent	_
167-177	31061-31076	methamphetamine	_
167-178	31077-31084	abusers	_
167-179	31085-31096	Impairments	_
167-180	31097-31099	of	_
167-181	31100-31106	facial	_
167-182	31107-31114	emotion	_
167-183	31115-31126	recognition	_
167-184	31127-31130	and	_
167-185	31131-31137	theory	_
167-186	31138-31140	of	_
167-187	31141-31145	mind	_
167-188	31146-31148	in	_
167-189	31149-31164	methamphetamine	_
167-190	31165-31172	abusers	_
167-191	31173-31184	Alterations	_
167-192	31185-31187	in	_
167-193	31188-31196	cortical	_
167-194	31197-31205	activity	_
167-195	31206-31208	of	_
167-196	31209-31213	male	_
167-197	31214-31229	methamphetamine	_
167-198	31230-31237	abusers	_
167-199	31238-31248	performing	_
167-200	31249-31251	an	_
167-201	31252-31259	empathy	_
167-202	31260-31264	task	_
167-203	31264-31265	:	_
167-204	31266-31270	fMRI	_
167-205	31271-31276	study	_
167-206	31277-31283	Damage	_
167-207	31284-31286	to	_
167-208	31287-31290	the	_
167-209	31291-31301	prefrontal	_
167-210	31302-31308	cortex	_
167-211	31309-31318	increases	_
167-212	31319-31330	utilitarian	_
167-213	31331-31336	moral	_
167-214	31337-31347	judgements	_
167-215	31348-31353	Risky	_
167-216	31354-31362	decision	_
167-217	31363-31369	making	_
167-218	31369-31370	,	_
167-219	31371-31381	prefrontal	_
167-220	31382-31388	cortex	_
167-221	31388-31389	,	_
167-222	31390-31393	and	_
167-223	31394-31411	mesocorticolimbic	_
167-224	31412-31422	functional	_
167-225	31423-31435	connectivity	_
167-226	31436-31438	in	_
167-227	31439-31454	methamphetamine	_
167-228	31455-31465	dependence	_
167-229	31466-31474	Midbrain	_
167-230	31475-31485	functional	_
167-231	31486-31498	connectivity	_
167-232	31499-31502	and	_
167-233	31503-31510	ventral	_
167-234	31511-31519	striatal	_
167-235	31520-31528	dopamine	_
167-236	31529-31531	D2	_
167-237	31531-31532	-	_
167-238	31532-31536	type	_
167-239	31537-31546	receptors	_
167-240	31546-31547	:	_
167-241	31548-31552	link	_
167-242	31553-31555	to	_
167-243	31556-31567	impulsivity	_
167-244	31568-31570	in	_
167-245	31571-31586	methamphetamine	_
167-246	31587-31592	users	_
167-247	31593-31596	The	_
167-248	31597-31601	role	_
167-249	31602-31604	of	_
167-250	31605-31608	the	_
167-251	31609-31624	striatopallidal	_
167-252	31625-31628	and	_
167-253	31629-31637	extended	_
167-254	31638-31646	amygdala	_
167-255	31647-31654	systems	_
167-256	31655-31657	in	_
167-257	31658-31662	drug	_
167-258	31663-31672	addiction	_
167-259	31673-31680	Chronic	_
167-260	31681-31696	methamphetamine	_
167-261	31697-31702	abuse	_
167-262	31703-31706	and	_
167-263	31707-31722	corticostriatal	_
167-264	31723-31731	deficits	_
167-265	31732-31740	revealed	_
167-266	31741-31743	by	_
167-267	31744-31756	neuroimaging	_
167-268	31757-31760	Are	_
167-269	31761-31766	there	_
167-270	31767-31777	volumetric	_
167-271	31778-31783	brain	_
167-272	31784-31795	differences	_
167-273	31796-31806	associated	_
167-274	31807-31811	with	_
167-275	31812-31815	the	_
167-276	31816-31819	use	_
167-277	31820-31822	of	_
167-278	31823-31830	cocaine	_
167-279	31831-31834	and	_
167-280	31835-31851	amphetamine-type	_
167-281	31852-31862	stimulants	_
167-282	31862-31863	?	_

#Text=Decreased absolute amygdala volume in cocaine addicts
#Text=Precentral gyrus discrepancy in electronic versions of the Talairach atlas
#Text=An automated method for neuroanatomic and cytoarchitectonic atlas-based interrogation of fMRI data sets
#Text=Frontal cortical tissue composition in abstinent cocaine abusers: a magnetic resonance imaging study
#Text=Methods and software for fMRI analysis of clinical subjects
#Text=The fifth edition of the Addiction Severity Index
#Text=Misunderstanding analysis of covariance
#Text=The neural basis of human moral cognition
#Text=Frontoparietal cortical activity of methamphetamine-dependent and comparison subjects performing a delay discounting task
#Text=Gray-matter volume in methamphetamine dependence: cigarette smoking and changes with abstinence from methamphetamine
#Text=Trait impulsivity and prefrontal gray matter reductions in cocaine dependent individuals
#Text=A psychophysiological investigation of moral judgment after ventromedial prefrontal damage
#Text=Deficient fear recognition in regular cocaine users is not attributable to elevated impulsivity or conduct disorder prior to cocaine use
#Text=Ventromedial prefrontal cortex is critical for the regulation of amygdala activity in humans
#Text=Methamphetamine users show greater than normal age-related cortical gray matter loss
#Text=
#Text=Cocaine users differ from normals on cognitive tasks which show poorer performance during drug abstinence
#Text=Behavioral and functional neuroimaging evidence for prefrontal dysfunction in methamphetamine-dependent subjects
#Text=Neural correlates of affect processing and aggression in methamphetamine dependence
#Text=Differences in cortical activity between methamphetamine-dependent and healthy individuals performing a facial affect matching task
#Text=Prevalence of DSM-IV substance abuse and dependence disorders among prison inmates
#Text=Impaired emotional empathy and related social network deficits in cocaine users
#Text=
#Text=Sex differences in decreased limbic and cortical grey matter volume in cocaine dependence: a voxel-based morphometric study
#Text=Methamphetamine and cocaine users: differences in characteristics and treatment retention
#Text=Functional connectivity of the human amygdala using resting state fMRI
#Text=Development and preliminary validation of a Satz-Mogel short form of the WAIS-III in a sample of persons with substance abuse disorders
#Text=
#Text=
#Text=Neural basis of moral verdict and moral deliberation
#Text=The integration of negative affect, pain and cognitive control in the cingulate cortex
#Text=Cerebellar gray matter volume correlates with duration of cocaine use in cocaine-dependent subjects
#Text=Harming kin to save strangers: further evidence for abnormally utilitarian moral judgments after ventromedial prefrontal damage
#Text=Structural abnormalities in the brains of human subjects who use methamphetamine
#Text=Amygdala and ventromedial prefrontal cortex are inversely coupled during regulation of negative affect and predict the diurnal pattern of cortisol secretion among older adults
#Text=Executive control deficits in substance-dependent individuals: a comparison of alcohol, cocaine, and methamphetamine and of men and women
#Text=Functional alteration in frontolimbic systems relevant to moral judgment in cocaine-dependent subjects
#Text=Functional heterogeneity in cingulate cortex: the anterior executive and posterior evaluative regions
#Text=Beyond social deviance: Substance use disorders and the dimensions of psychopathy
#Text=
#Text=Mode of functional connectivity in amygdala pathways dissociates level of awareness for signals of fear
#Text=Regions of interests for the analyses looking at stimulant use analyses are represented using actual masks plotted as blobs on a canonical T1 template.
168-1	31864-31873	Decreased	_
168-2	31874-31882	absolute	_
168-3	31883-31891	amygdala	_
168-4	31892-31898	volume	_
168-5	31899-31901	in	_
168-6	31902-31909	cocaine	_
168-7	31910-31917	addicts	_
168-8	31918-31928	Precentral	_
168-9	31929-31934	gyrus	_
168-10	31935-31946	discrepancy	_
168-11	31947-31949	in	_
168-12	31950-31960	electronic	_
168-13	31961-31969	versions	_
168-14	31970-31972	of	_
168-15	31973-31976	the	_
168-16	31977-31986	Talairach	_
168-17	31987-31992	atlas	_
168-18	31993-31995	An	_
168-19	31996-32005	automated	_
168-20	32006-32012	method	_
168-21	32013-32016	for	_
168-22	32017-32030	neuroanatomic	_
168-23	32031-32034	and	_
168-24	32035-32052	cytoarchitectonic	_
168-25	32053-32064	atlas-based	_
168-26	32065-32078	interrogation	_
168-27	32079-32081	of	_
168-28	32082-32086	fMRI	_
168-29	32087-32091	data	_
168-30	32092-32096	sets	_
168-31	32097-32104	Frontal	_
168-32	32105-32113	cortical	_
168-33	32114-32120	tissue	_
168-34	32121-32132	composition	_
168-35	32133-32135	in	_
168-36	32136-32145	abstinent	_
168-37	32146-32153	cocaine	_
168-38	32154-32161	abusers	_
168-39	32161-32162	:	_
168-40	32163-32164	a	_
168-41	32165-32173	magnetic	_
168-42	32174-32183	resonance	_
168-43	32184-32191	imaging	_
168-44	32192-32197	study	_
168-45	32198-32205	Methods	_
168-46	32206-32209	and	_
168-47	32210-32218	software	_
168-48	32219-32222	for	_
168-49	32223-32227	fMRI	_
168-50	32228-32236	analysis	_
168-51	32237-32239	of	_
168-52	32240-32248	clinical	_
168-53	32249-32257	subjects	_
168-54	32258-32261	The	_
168-55	32262-32267	fifth	_
168-56	32268-32275	edition	_
168-57	32276-32278	of	_
168-58	32279-32282	the	_
168-59	32283-32292	Addiction	_
168-60	32293-32301	Severity	_
168-61	32302-32307	Index	_
168-62	32308-32324	Misunderstanding	_
168-63	32325-32333	analysis	_
168-64	32334-32336	of	_
168-65	32337-32347	covariance	_
168-66	32348-32351	The	_
168-67	32352-32358	neural	_
168-68	32359-32364	basis	_
168-69	32365-32367	of	_
168-70	32368-32373	human	_
168-71	32374-32379	moral	_
168-72	32380-32389	cognition	_
168-73	32390-32404	Frontoparietal	_
168-74	32405-32413	cortical	_
168-75	32414-32422	activity	_
168-76	32423-32425	of	_
168-77	32426-32451	methamphetamine-dependent	_
168-78	32452-32455	and	_
168-79	32456-32466	comparison	_
168-80	32467-32475	subjects	_
168-81	32476-32486	performing	_
168-82	32487-32488	a	_
168-83	32489-32494	delay	_
168-84	32495-32506	discounting	_
168-85	32507-32511	task	_
168-86	32512-32523	Gray-matter	_
168-87	32524-32530	volume	_
168-88	32531-32533	in	_
168-89	32534-32549	methamphetamine	_
168-90	32550-32560	dependence	_
168-91	32560-32561	:	_
168-92	32562-32571	cigarette	_
168-93	32572-32579	smoking	_
168-94	32580-32583	and	_
168-95	32584-32591	changes	_
168-96	32592-32596	with	_
168-97	32597-32607	abstinence	_
168-98	32608-32612	from	_
168-99	32613-32628	methamphetamine	_
168-100	32629-32634	Trait	_
168-101	32635-32646	impulsivity	_
168-102	32647-32650	and	_
168-103	32651-32661	prefrontal	_
168-104	32662-32666	gray	_
168-105	32667-32673	matter	_
168-106	32674-32684	reductions	_
168-107	32685-32687	in	_
168-108	32688-32695	cocaine	_
168-109	32696-32705	dependent	_
168-110	32706-32717	individuals	_
168-111	32718-32719	A	_
168-112	32720-32739	psychophysiological	_
168-113	32740-32753	investigation	_
168-114	32754-32756	of	_
168-115	32757-32762	moral	_
168-116	32763-32771	judgment	_
168-117	32772-32777	after	_
168-118	32778-32790	ventromedial	_
168-119	32791-32801	prefrontal	_
168-120	32802-32808	damage	_
168-121	32809-32818	Deficient	_
168-122	32819-32823	fear	_
168-123	32824-32835	recognition	_
168-124	32836-32838	in	_
168-125	32839-32846	regular	_
168-126	32847-32854	cocaine	_
168-127	32855-32860	users	_
168-128	32861-32863	is	_
168-129	32864-32867	not	_
168-130	32868-32880	attributable	_
168-131	32881-32883	to	_
168-132	32884-32892	elevated	_
168-133	32893-32904	impulsivity	_
168-134	32905-32907	or	_
168-135	32908-32915	conduct	_
168-136	32916-32924	disorder	_
168-137	32925-32930	prior	_
168-138	32931-32933	to	_
168-139	32934-32941	cocaine	_
168-140	32942-32945	use	_
168-141	32946-32958	Ventromedial	_
168-142	32959-32969	prefrontal	_
168-143	32970-32976	cortex	_
168-144	32977-32979	is	_
168-145	32980-32988	critical	_
168-146	32989-32992	for	_
168-147	32993-32996	the	_
168-148	32997-33007	regulation	_
168-149	33008-33010	of	_
168-150	33011-33019	amygdala	_
168-151	33020-33028	activity	_
168-152	33029-33031	in	_
168-153	33032-33038	humans	_
168-154	33039-33054	Methamphetamine	_
168-155	33055-33060	users	_
168-156	33061-33065	show	_
168-157	33066-33073	greater	_
168-158	33074-33078	than	_
168-159	33079-33085	normal	_
168-160	33086-33097	age-related	_
168-161	33098-33106	cortical	_
168-162	33107-33111	gray	_
168-163	33112-33118	matter	_
168-164	33119-33123	loss	_
168-165	33125-33132	Cocaine	_
168-166	33133-33138	users	_
168-167	33139-33145	differ	_
168-168	33146-33150	from	_
168-169	33151-33158	normals	_
168-170	33159-33161	on	_
168-171	33162-33171	cognitive	_
168-172	33172-33177	tasks	_
168-173	33178-33183	which	_
168-174	33184-33188	show	_
168-175	33189-33195	poorer	_
168-176	33196-33207	performance	_
168-177	33208-33214	during	_
168-178	33215-33219	drug	_
168-179	33220-33230	abstinence	_
168-180	33231-33241	Behavioral	_
168-181	33242-33245	and	_
168-182	33246-33256	functional	_
168-183	33257-33269	neuroimaging	_
168-184	33270-33278	evidence	_
168-185	33279-33282	for	_
168-186	33283-33293	prefrontal	_
168-187	33294-33305	dysfunction	_
168-188	33306-33308	in	_
168-189	33309-33334	methamphetamine-dependent	_
168-190	33335-33343	subjects	_
168-191	33344-33350	Neural	_
168-192	33351-33361	correlates	_
168-193	33362-33364	of	_
168-194	33365-33371	affect	_
168-195	33372-33382	processing	_
168-196	33383-33386	and	_
168-197	33387-33397	aggression	_
168-198	33398-33400	in	_
168-199	33401-33416	methamphetamine	_
168-200	33417-33427	dependence	_
168-201	33428-33439	Differences	_
168-202	33440-33442	in	_
168-203	33443-33451	cortical	_
168-204	33452-33460	activity	_
168-205	33461-33468	between	_
168-206	33469-33494	methamphetamine-dependent	_
168-207	33495-33498	and	_
168-208	33499-33506	healthy	_
168-209	33507-33518	individuals	_
168-210	33519-33529	performing	_
168-211	33530-33531	a	_
168-212	33532-33538	facial	_
168-213	33539-33545	affect	_
168-214	33546-33554	matching	_
168-215	33555-33559	task	_
168-216	33560-33570	Prevalence	_
168-217	33571-33573	of	_
168-218	33574-33580	DSM-IV	_
168-219	33581-33590	substance	_
168-220	33591-33596	abuse	_
168-221	33597-33600	and	_
168-222	33601-33611	dependence	_
168-223	33612-33621	disorders	_
168-224	33622-33627	among	_
168-225	33628-33634	prison	_
168-226	33635-33642	inmates	_
168-227	33643-33651	Impaired	_
168-228	33652-33661	emotional	_
168-229	33662-33669	empathy	_
168-230	33670-33673	and	_
168-231	33674-33681	related	_
168-232	33682-33688	social	_
168-233	33689-33696	network	_
168-234	33697-33705	deficits	_
168-235	33706-33708	in	_
168-236	33709-33716	cocaine	_
168-237	33717-33722	users	_
168-238	33724-33727	Sex	_
168-239	33728-33739	differences	_
168-240	33740-33742	in	_
168-241	33743-33752	decreased	_
168-242	33753-33759	limbic	_
168-243	33760-33763	and	_
168-244	33764-33772	cortical	_
168-245	33773-33777	grey	_
168-246	33778-33784	matter	_
168-247	33785-33791	volume	_
168-248	33792-33794	in	_
168-249	33795-33802	cocaine	_
168-250	33803-33813	dependence	_
168-251	33813-33814	:	_
168-252	33815-33816	a	_
168-253	33817-33828	voxel-based	_
168-254	33829-33841	morphometric	_
168-255	33842-33847	study	_
168-256	33848-33863	Methamphetamine	_
168-257	33864-33867	and	_
168-258	33868-33875	cocaine	_
168-259	33876-33881	users	_
168-260	33881-33882	:	_
168-261	33883-33894	differences	_
168-262	33895-33897	in	_
168-263	33898-33913	characteristics	_
168-264	33914-33917	and	_
168-265	33918-33927	treatment	_
168-266	33928-33937	retention	_
168-267	33938-33948	Functional	_
168-268	33949-33961	connectivity	_
168-269	33962-33964	of	_
168-270	33965-33968	the	_
168-271	33969-33974	human	_
168-272	33975-33983	amygdala	_
168-273	33984-33989	using	_
168-274	33990-33997	resting	_
168-275	33998-34003	state	_
168-276	34004-34008	fMRI	_
168-277	34009-34020	Development	_
168-278	34021-34024	and	_
168-279	34025-34036	preliminary	_
168-280	34037-34047	validation	_
168-281	34048-34050	of	_
168-282	34051-34052	a	_
168-283	34053-34063	Satz-Mogel	_
168-284	34064-34069	short	_
168-285	34070-34074	form	_
168-286	34075-34077	of	_
168-287	34078-34081	the	_
168-288	34082-34090	WAIS-III	_
168-289	34091-34093	in	_
168-290	34094-34095	a	_
168-291	34096-34102	sample	_
168-292	34103-34105	of	_
168-293	34106-34113	persons	_
168-294	34114-34118	with	_
168-295	34119-34128	substance	_
168-296	34129-34134	abuse	_
168-297	34135-34144	disorders	_
168-298	34147-34153	Neural	_
168-299	34154-34159	basis	_
168-300	34160-34162	of	_
168-301	34163-34168	moral	_
168-302	34169-34176	verdict	_
168-303	34177-34180	and	_
168-304	34181-34186	moral	_
168-305	34187-34199	deliberation	_
168-306	34200-34203	The	_
168-307	34204-34215	integration	_
168-308	34216-34218	of	_
168-309	34219-34227	negative	_
168-310	34228-34234	affect	_
168-311	34234-34235	,	_
168-312	34236-34240	pain	_
168-313	34241-34244	and	_
168-314	34245-34254	cognitive	_
168-315	34255-34262	control	_
168-316	34263-34265	in	_
168-317	34266-34269	the	_
168-318	34270-34279	cingulate	_
168-319	34280-34286	cortex	_
168-320	34287-34297	Cerebellar	_
168-321	34298-34302	gray	_
168-322	34303-34309	matter	_
168-323	34310-34316	volume	_
168-324	34317-34327	correlates	_
168-325	34328-34332	with	_
168-326	34333-34341	duration	_
168-327	34342-34344	of	_
168-328	34345-34352	cocaine	_
168-329	34353-34356	use	_
168-330	34357-34359	in	_
168-331	34360-34377	cocaine-dependent	_
168-332	34378-34386	subjects	_
168-333	34387-34394	Harming	_
168-334	34395-34398	kin	_
168-335	34399-34401	to	_
168-336	34402-34406	save	_
168-337	34407-34416	strangers	_
168-338	34416-34417	:	_
168-339	34418-34425	further	_
168-340	34426-34434	evidence	_
168-341	34435-34438	for	_
168-342	34439-34449	abnormally	_
168-343	34450-34461	utilitarian	_
168-344	34462-34467	moral	_
168-345	34468-34477	judgments	_
168-346	34478-34483	after	_
168-347	34484-34496	ventromedial	_
168-348	34497-34507	prefrontal	_
168-349	34508-34514	damage	_
168-350	34515-34525	Structural	_
168-351	34526-34539	abnormalities	_
168-352	34540-34542	in	_
168-353	34543-34546	the	_
168-354	34547-34553	brains	_
168-355	34554-34556	of	_
168-356	34557-34562	human	_
168-357	34563-34571	subjects	_
168-358	34572-34575	who	_
168-359	34576-34579	use	_
168-360	34580-34595	methamphetamine	_
168-361	34596-34604	Amygdala	_
168-362	34605-34608	and	_
168-363	34609-34621	ventromedial	_
168-364	34622-34632	prefrontal	_
168-365	34633-34639	cortex	_
168-366	34640-34643	are	_
168-367	34644-34653	inversely	_
168-368	34654-34661	coupled	_
168-369	34662-34668	during	_
168-370	34669-34679	regulation	_
168-371	34680-34682	of	_
168-372	34683-34691	negative	_
168-373	34692-34698	affect	_
168-374	34699-34702	and	_
168-375	34703-34710	predict	_
168-376	34711-34714	the	_
168-377	34715-34722	diurnal	_
168-378	34723-34730	pattern	_
168-379	34731-34733	of	_
168-380	34734-34742	cortisol	_
168-381	34743-34752	secretion	_
168-382	34753-34758	among	_
168-383	34759-34764	older	_
168-384	34765-34771	adults	_
168-385	34772-34781	Executive	_
168-386	34782-34789	control	_
168-387	34790-34798	deficits	_
168-388	34799-34801	in	_
168-389	34802-34821	substance-dependent	_
168-390	34822-34833	individuals	_
168-391	34833-34834	:	_
168-392	34835-34836	a	_
168-393	34837-34847	comparison	_
168-394	34848-34850	of	_
168-395	34851-34858	alcohol	_
168-396	34858-34859	,	_
168-397	34860-34867	cocaine	_
168-398	34867-34868	,	_
168-399	34869-34872	and	_
168-400	34873-34888	methamphetamine	_
168-401	34889-34892	and	_
168-402	34893-34895	of	_
168-403	34896-34899	men	_
168-404	34900-34903	and	_
168-405	34904-34909	women	_
168-406	34910-34920	Functional	_
168-407	34921-34931	alteration	_
168-408	34932-34934	in	_
168-409	34935-34947	frontolimbic	_
168-410	34948-34955	systems	_
168-411	34956-34964	relevant	_
168-412	34965-34967	to	_
168-413	34968-34973	moral	_
168-414	34974-34982	judgment	_
168-415	34983-34985	in	_
168-416	34986-35003	cocaine-dependent	_
168-417	35004-35012	subjects	_
168-418	35013-35023	Functional	_
168-419	35024-35037	heterogeneity	_
168-420	35038-35040	in	_
168-421	35041-35050	cingulate	_
168-422	35051-35057	cortex	_
168-423	35057-35058	:	_
168-424	35059-35062	the	_
168-425	35063-35071	anterior	_
168-426	35072-35081	executive	_
168-427	35082-35085	and	_
168-428	35086-35095	posterior	_
168-429	35096-35106	evaluative	_
168-430	35107-35114	regions	_
168-431	35115-35121	Beyond	_
168-432	35122-35128	social	_
168-433	35129-35137	deviance	_
168-434	35137-35138	:	_
168-435	35139-35148	Substance	_
168-436	35149-35152	use	_
168-437	35153-35162	disorders	_
168-438	35163-35166	and	_
168-439	35167-35170	the	_
168-440	35171-35181	dimensions	_
168-441	35182-35184	of	_
168-442	35185-35196	psychopathy	_
168-443	35198-35202	Mode	_
168-444	35203-35205	of	_
168-445	35206-35216	functional	_
168-446	35217-35229	connectivity	_
168-447	35230-35232	in	_
168-448	35233-35241	amygdala	_
168-449	35242-35250	pathways	_
168-450	35251-35262	dissociates	_
168-451	35263-35268	level	_
168-452	35269-35271	of	_
168-453	35272-35281	awareness	_
168-454	35282-35285	for	_
168-455	35286-35293	signals	_
168-456	35294-35296	of	_
168-457	35297-35301	fear	_
168-458	35302-35309	Regions	_
168-459	35310-35312	of	_
168-460	35313-35322	interests	_
168-461	35323-35326	for	_
168-462	35327-35330	the	_
168-463	35331-35339	analyses	_
168-464	35340-35347	looking	_
168-465	35348-35350	at	_
168-466	35351-35360	stimulant	_
168-467	35361-35364	use	_
168-468	35365-35373	analyses	_
168-469	35374-35377	are	_
168-470	35378-35389	represented	_
168-471	35390-35395	using	_
168-472	35396-35402	actual	_
168-473	35403-35408	masks	_
168-474	35409-35416	plotted	_
168-475	35417-35419	as	_
168-476	35420-35425	blobs	_
168-477	35426-35428	on	_
168-478	35429-35430	a	_
168-479	35431-35440	canonical	_
168-480	35441-35443	T1	_
168-481	35444-35452	template	_
168-482	35452-35453	.	_

#Text=Characteristics of Lifetime Stimulant and Non-Stimulant Users Correlations Between Covariates in Lifetime Regular Stimulant Users
#Text=Covariate\tNon-Regular Stimulant Users\tLifetime Regular Stimulant Users\t \t\t \t\tMean\tSD\tMean\tSD\t \tAge\t36.11\t10.79\t33.85\t9.97\t \tIQ\t97.25\t11.24\t98.52\t12.57\t \tYears Regular Stim Use*\t0.00\t0.00\t8.75\t9.62\t \tYears Regular Non-Stim Use*\t11.88\t11.59\t23.91\t14.47\t \tPCL-R Total Score\t20.80\t7.75\t22.01\t6.95\t \tFagerstrom Symptoms\t3.51\t2.94\t3.25\t3.06\t \tAge of First Cocaine Use\t-\t-\t19.01\t5.839\t \tAge of First Meth Use\t-\t-\t20.80\t6.804\t \t
#Text=Note: Asterisks in covariate column indicates significant between-group difference according to an independent samples t-test at a level of p < .001
#Text=Table of Group Averages and Regression Statistics for Behavioral Task Results
#Text=\tNon-Regular Stimulant Users\tLifetime Regular Stimulant Users\tRegression with Years of Stimulant Use\t \t\tMean\tSD\tMean\tSD\tR2\t \tControversial Item Response Time\t2608\t553\t2472\t514\t.000\t \tNoncontroversial Item Response Time\t2136\t531\t2037\t458\t.002\t \tNumber “Wrong” Button Presses\t70.73\t16.64\t70.56\t18.04\t.004\t \tNumber “Not Wrong”Button Presses\t72.29\t16.40\t70.90\t18.03\t.001\t \t
#Text=Table of ROI Analysis Results for Group Comparison Controversial > Noncontroversial
#Text=\tLifetime Stimulant Users > Non- Stimulant Users\tLifetime Cocaine Users Non-Cocaine Users >\tLifetime Methamphetamine Users > Non-Methamphetamine Users\t \tROI\tx\ty\tz\tk\tT\tx\t\tY\tz\tK\tT\tx\ty\tz\tk\tT\t \tRight Amygdala\t30\t−3\t−27\t51\t−3.13*\t30\t−3\t−27\t\t49\t−2.80†\t21\t3\t−21\t63\t−2.88*\t \tAnterior Cingulate Cortex\tN.S.
169-1	35454-35469	Characteristics	_
169-2	35470-35472	of	_
169-3	35473-35481	Lifetime	_
169-4	35482-35491	Stimulant	_
169-5	35492-35495	and	_
169-6	35496-35509	Non-Stimulant	_
169-7	35510-35515	Users	_
169-8	35516-35528	Correlations	_
169-9	35529-35536	Between	_
169-10	35537-35547	Covariates	_
169-11	35548-35550	in	_
169-12	35551-35559	Lifetime	_
169-13	35560-35567	Regular	_
169-14	35568-35577	Stimulant	_
169-15	35578-35583	Users	_
169-16	35584-35593	Covariate	_
169-17	35594-35605	Non-Regular	_
169-18	35606-35615	Stimulant	_
169-19	35616-35621	Users	_
169-20	35622-35630	Lifetime	_
169-21	35631-35638	Regular	_
169-22	35639-35648	Stimulant	_
169-23	35649-35654	Users	_
169-24	35661-35665	Mean	_
169-25	35666-35668	SD	_
169-26	35669-35673	Mean	_
169-27	35674-35676	SD	_
169-28	35679-35682	Age	_
169-29	35683-35688	36.11	_
169-30	35689-35694	10.79	_
169-31	35695-35700	33.85	_
169-32	35701-35705	9.97	_
169-33	35708-35710	IQ	_
169-34	35711-35716	97.25	_
169-35	35717-35722	11.24	_
169-36	35723-35728	98.52	_
169-37	35729-35734	12.57	_
169-38	35737-35742	Years	_
169-39	35743-35750	Regular	_
169-40	35751-35755	Stim	_
169-41	35756-35759	Use	_
169-42	35759-35760	*	_
169-43	35761-35765	0.00	_
169-44	35766-35770	0.00	_
169-45	35771-35775	8.75	_
169-46	35776-35780	9.62	_
169-47	35783-35788	Years	_
169-48	35789-35796	Regular	_
169-49	35797-35805	Non-Stim	_
169-50	35806-35809	Use	_
169-51	35809-35810	*	_
169-52	35811-35816	11.88	_
169-53	35817-35822	11.59	_
169-54	35823-35828	23.91	_
169-55	35829-35834	14.47	_
169-56	35837-35842	PCL-R	_
169-57	35843-35848	Total	_
169-58	35849-35854	Score	_
169-59	35855-35860	20.80	_
169-60	35861-35865	7.75	_
169-61	35866-35871	22.01	_
169-62	35872-35876	6.95	_
169-63	35879-35889	Fagerstrom	_
169-64	35890-35898	Symptoms	_
169-65	35899-35903	3.51	_
169-66	35904-35908	2.94	_
169-67	35909-35913	3.25	_
169-68	35914-35918	3.06	_
169-69	35921-35924	Age	_
169-70	35925-35927	of	_
169-71	35928-35933	First	_
169-72	35934-35941	Cocaine	_
169-73	35942-35945	Use	_
169-74	35946-35947	-	_
169-75	35948-35949	-	_
169-76	35950-35955	19.01	_
169-77	35956-35961	5.839	_
169-78	35964-35967	Age	_
169-79	35968-35970	of	_
169-80	35971-35976	First	_
169-81	35977-35981	Meth	_
169-82	35982-35985	Use	_
169-83	35986-35987	-	_
169-84	35988-35989	-	_
169-85	35990-35995	20.80	_
169-86	35996-36001	6.804	_
169-87	36005-36009	Note	_
169-88	36009-36010	:	_
169-89	36011-36020	Asterisks	_
169-90	36021-36023	in	_
169-91	36024-36033	covariate	_
169-92	36034-36040	column	_
169-93	36041-36050	indicates	_
169-94	36051-36062	significant	_
169-95	36063-36076	between-group	_
169-96	36077-36087	difference	_
169-97	36088-36097	according	_
169-98	36098-36100	to	_
169-99	36101-36103	an	_
169-100	36104-36115	independent	_
169-101	36116-36123	samples	_
169-102	36124-36130	t-test	_
169-103	36131-36133	at	_
169-104	36134-36135	a	_
169-105	36136-36141	level	_
169-106	36142-36144	of	_
169-107	36145-36146	p	_
169-108	36147-36148	<	_
169-109	36149-36153	.001	_
169-110	36154-36159	Table	_
169-111	36160-36162	of	_
169-112	36163-36168	Group	_
169-113	36169-36177	Averages	_
169-114	36178-36181	and	_
169-115	36182-36192	Regression	_
169-116	36193-36203	Statistics	_
169-117	36204-36207	for	_
169-118	36208-36218	Behavioral	_
169-119	36219-36223	Task	_
169-120	36224-36231	Results	_
169-121	36233-36244	Non-Regular	_
169-122	36245-36254	Stimulant	_
169-123	36255-36260	Users	_
169-124	36261-36269	Lifetime	_
169-125	36270-36277	Regular	_
169-126	36278-36287	Stimulant	_
169-127	36288-36293	Users	_
169-128	36294-36304	Regression	_
169-129	36305-36309	with	_
169-130	36310-36315	Years	_
169-131	36316-36318	of	_
169-132	36319-36328	Stimulant	_
169-133	36329-36332	Use	_
169-134	36336-36340	Mean	_
169-135	36341-36343	SD	_
169-136	36344-36348	Mean	_
169-137	36349-36351	SD	_
169-138	36352-36354	R2	_
169-139	36357-36370	Controversial	_
169-140	36371-36375	Item	_
169-141	36376-36384	Response	_
169-142	36385-36389	Time	_
169-143	36390-36394	2608	_
169-144	36395-36398	553	_
169-145	36399-36403	2472	_
169-146	36404-36407	514	_
169-147	36408-36412	.000	_
169-148	36415-36431	Noncontroversial	_
169-149	36432-36436	Item	_
169-150	36437-36445	Response	_
169-151	36446-36450	Time	_
169-152	36451-36455	2136	_
169-153	36456-36459	531	_
169-154	36460-36464	2037	_
169-155	36465-36468	458	_
169-156	36469-36473	.002	_
169-157	36476-36482	Number	_
169-158	36483-36484	“	_
169-159	36484-36489	Wrong	_
169-160	36489-36490	”	_
169-161	36491-36497	Button	_
169-162	36498-36505	Presses	_
169-163	36506-36511	70.73	_
169-164	36512-36517	16.64	_
169-165	36518-36523	70.56	_
169-166	36524-36529	18.04	_
169-167	36530-36534	.004	_
169-168	36537-36543	Number	_
169-169	36544-36545	“	_
169-170	36545-36548	Not	_
169-171	36549-36554	Wrong	_
169-172	36554-36555	”	_
169-173	36555-36561	Button	_
169-174	36562-36569	Presses	_
169-175	36570-36575	72.29	_
169-176	36576-36581	16.40	_
169-177	36582-36587	70.90	_
169-178	36588-36593	18.03	_
169-179	36594-36598	.001	_
169-180	36602-36607	Table	_
169-181	36608-36610	of	_
169-182	36611-36614	ROI	_
169-183	36615-36623	Analysis	_
169-184	36624-36631	Results	_
169-185	36632-36635	for	_
169-186	36636-36641	Group	_
169-187	36642-36652	Comparison	_
169-188	36653-36666	Controversial	_
169-189	36667-36668	>	_
169-190	36669-36685	Noncontroversial	_
169-191	36687-36695	Lifetime	_
169-192	36696-36705	Stimulant	_
169-193	36706-36711	Users	_
169-194	36712-36713	>	_
169-195	36714-36717	Non	_
169-196	36717-36718	-	_
169-197	36719-36728	Stimulant	_
169-198	36729-36734	Users	_
169-199	36735-36743	Lifetime	_
169-200	36744-36751	Cocaine	_
169-201	36752-36757	Users	_
169-202	36758-36769	Non-Cocaine	_
169-203	36770-36775	Users	_
169-204	36776-36777	>	_
169-205	36778-36786	Lifetime	_
169-206	36787-36802	Methamphetamine	_
169-207	36803-36808	Users	_
169-208	36809-36810	>	_
169-209	36811-36830	Non-Methamphetamine	_
169-210	36831-36836	Users	_
169-211	36839-36842	ROI	_
169-212	36843-36844	x	_
169-213	36845-36846	y	_
169-214	36847-36848	z	_
169-215	36849-36850	k	_
169-216	36851-36852	T	_
169-217	36853-36854	x	_
169-218	36856-36857	Y	_
169-219	36858-36859	z	_
169-220	36860-36861	K	_
169-221	36862-36863	T	_
169-222	36864-36865	x	_
169-223	36866-36867	y	_
169-224	36868-36869	z	_
169-225	36870-36871	k	_
169-226	36872-36873	T	_
169-227	36876-36881	Right	_
169-228	36882-36890	Amygdala	_
169-229	36891-36893	30	_
169-230	36894-36895	−	_
169-231	36895-36896	3	_
169-232	36897-36898	−	_
169-233	36898-36900	27	_
169-234	36901-36903	51	_
169-235	36904-36905	−	_
169-236	36905-36909	3.13	_
169-237	36909-36910	*	_
169-238	36911-36913	30	_
169-239	36914-36915	−	_
169-240	36915-36916	3	_
169-241	36917-36918	−	_
169-242	36918-36920	27	_
169-243	36922-36924	49	_
169-244	36925-36926	−	_
169-245	36926-36930	2.80	_
169-246	36930-36931	†	_
169-247	36932-36934	21	_
169-248	36935-36936	3	_
169-249	36937-36938	−	_
169-250	36938-36940	21	_
169-251	36941-36943	63	_
169-252	36944-36945	−	_
169-253	36945-36949	2.88	_
169-254	36949-36950	*	_
169-255	36953-36961	Anterior	_
169-256	36962-36971	Cingulate	_
169-257	36972-36978	Cortex	_
169-258	36979-36982	N.S	_
169-259	36982-36983	.	_

#Text=N.S.
170-1	36984-36987	N.S	_
170-2	36987-36988	.	_

#Text=N.S.
171-1	36989-36992	N.S	_
171-2	36992-36993	.	_

#Text=Posterior Cingulate Cortex\tN.S.
172-1	36996-37005	Posterior	_
172-2	37006-37015	Cingulate	_
172-3	37016-37022	Cortex	_
172-4	37023-37026	N.S	_
172-5	37026-37027	.	_

#Text=N.S.
173-1	37028-37031	N.S	_
173-2	37031-37032	.	_

#Text=N.S.
174-1	37033-37036	N.S	_
174-2	37036-37037	.	_

#Text=Ventromedial Prefrontal Cortex\tN.S.
175-1	37040-37052	Ventromedial	_
175-2	37053-37063	Prefrontal	_
175-3	37064-37070	Cortex	_
175-4	37071-37074	N.S	_
175-5	37074-37075	.	_

#Text=N.S.
176-1	37076-37079	N.S	_
176-2	37079-37080	.	_

#Text=N.S.
177-1	37081-37084	N.S	_
177-2	37084-37085	.	_

#Text=Notes:.
178-1	37089-37094	Notes	_
178-2	37094-37095	:	_
178-3	37095-37096	.	_

#Text=Results reported covarying for years of non-stimulant and alcohol use.
179-1	37097-37104	Results	_
179-2	37105-37113	reported	_
179-3	37114-37123	covarying	_
179-4	37124-37127	for	_
179-5	37128-37133	years	_
179-6	37134-37136	of	_
179-7	37137-37150	non-stimulant	_
179-8	37151-37154	and	_
179-9	37155-37162	alcohol	_
179-10	37163-37166	use	_
179-11	37166-37167	.	_

#Text=Significance indicated for all tests as follows:
#Text=p <.10,
#Text=p < .05,
#Text=Family-Wise Error (FWE) corrected.
180-1	37168-37180	Significance	_
180-2	37181-37190	indicated	_
180-3	37191-37194	for	_
180-4	37195-37198	all	_
180-5	37199-37204	tests	_
180-6	37205-37207	as	_
180-7	37208-37215	follows	_
180-8	37215-37216	:	_
180-9	37217-37218	p	_
180-10	37219-37220	<	_
180-11	37220-37223	.10	_
180-12	37223-37224	,	_
180-13	37225-37226	p	_
180-14	37227-37228	<	_
180-15	37229-37232	.05	_
180-16	37232-37233	,	_
180-17	37234-37245	Family-Wise	_
180-18	37246-37251	Error	_
180-19	37252-37253	(	_
180-20	37253-37256	FWE	_
180-21	37256-37257	)	_
180-22	37258-37267	corrected	_
180-23	37267-37268	.	_

#Text=N.S. indicates that no clusters were found to survive small volume correction at a trend level or higher.
181-1	37269-37272	N.S	_
181-2	37272-37273	.	_
181-3	37274-37283	indicates	_
181-4	37284-37288	that	_
181-5	37289-37291	no	_
181-6	37292-37300	clusters	_
181-7	37301-37305	were	_
181-8	37306-37311	found	_
181-9	37312-37314	to	_
181-10	37315-37322	survive	_
181-11	37323-37328	small	_
181-12	37329-37335	volume	_
181-13	37336-37346	correction	_
181-14	37347-37349	at	_
181-15	37350-37351	a	_
181-16	37352-37357	trend	_
181-17	37358-37363	level	_
181-18	37364-37366	or	_
181-19	37367-37373	higher	_
181-20	37373-37374	.	_

#Text=Table of ROI Analysis Results for Duration in Controversial > Noncontroversial
#Text=\tLifetime Stimulant Users\t\tLifetime Cocaine Users\tLifetime Methamphetamine Users\t \tROI\tx\ty\tz\tk\tT\tx\tY\tz\tK\tT\tx\ty\tz\tk\tT\t \tRight Amygdala\tN.S.
182-1	37375-37380	Table	_
182-2	37381-37383	of	_
182-3	37384-37387	ROI	_
182-4	37388-37396	Analysis	_
182-5	37397-37404	Results	_
182-6	37405-37408	for	_
182-7	37409-37417	Duration	_
182-8	37418-37420	in	_
182-9	37421-37434	Controversial	_
182-10	37435-37436	>	_
182-11	37437-37453	Noncontroversial	_
182-12	37455-37463	Lifetime	_
182-13	37464-37473	Stimulant	_
182-14	37474-37479	Users	_
182-15	37481-37489	Lifetime	_
182-16	37490-37497	Cocaine	_
182-17	37498-37503	Users	_
182-18	37504-37512	Lifetime	_
182-19	37513-37528	Methamphetamine	_
182-20	37529-37534	Users	_
182-21	37537-37540	ROI	_
182-22	37541-37542	x	_
182-23	37543-37544	y	_
182-24	37545-37546	z	_
182-25	37547-37548	k	_
182-26	37549-37550	T	_
182-27	37551-37552	x	_
182-28	37553-37554	Y	_
182-29	37555-37556	z	_
182-30	37557-37558	K	_
182-31	37559-37560	T	_
182-32	37561-37562	x	_
182-33	37563-37564	y	_
182-34	37565-37566	z	_
182-35	37567-37568	k	_
182-36	37569-37570	T	_
182-37	37573-37578	Right	_
182-38	37579-37587	Amygdala	_
182-39	37588-37591	N.S	_
182-40	37591-37592	.	_

#Text=N.S.
183-1	37593-37596	N.S	_
183-2	37596-37597	.	_

#Text=N.S.
184-1	37598-37601	N.S	_
184-2	37601-37602	.	_

#Text=Anterior Cingulate Cortex\t−15\t21\t27\t29\t−3.68*\t−15\t18\t27\t24\t−3.53\tN.S.
185-1	37605-37613	Anterior	_
185-2	37614-37623	Cingulate	_
185-3	37624-37630	Cortex	_
185-4	37631-37632	−	_
185-5	37632-37634	15	_
185-6	37635-37637	21	_
185-7	37638-37640	27	_
185-8	37641-37643	29	_
185-9	37644-37645	−	_
185-10	37645-37649	3.68	_
185-11	37649-37650	*	_
185-12	37651-37652	−	_
185-13	37652-37654	15	_
185-14	37655-37657	18	_
185-15	37658-37660	27	_
185-16	37661-37663	24	_
185-17	37664-37665	−	_
185-18	37665-37669	3.53	_
185-19	37670-37673	N.S	_
185-20	37673-37674	.	_

#Text=Posterior Cingulate Cortex\tN.S.
186-1	37677-37686	Posterior	_
186-2	37687-37696	Cingulate	_
186-3	37697-37703	Cortex	_
186-4	37704-37707	N.S	_
186-5	37707-37708	.	_

#Text=N.S.
187-1	37709-37712	N.S	_
187-2	37712-37713	.	_

#Text=N.S.
188-1	37714-37717	N.S	_
188-2	37717-37718	.	_

#Text=Ventromedial Prefrontal Cortex\t12\t48\t6\t51\t3.48†\tN.S.\t6\t63\t15\t72\t3.69*\t \t
#Text=Notes:.
189-1	37721-37733	Ventromedial	_
189-2	37734-37744	Prefrontal	_
189-3	37745-37751	Cortex	_
189-4	37752-37754	12	_
189-5	37755-37757	48	_
189-6	37758-37759	6	_
189-7	37760-37762	51	_
189-8	37763-37767	3.48	_
189-9	37767-37768	†	_
189-10	37769-37772	N.S	_
189-11	37772-37773	.	_
189-12	37774-37775	6	_
189-13	37776-37778	63	_
189-14	37779-37781	15	_
189-15	37782-37784	72	_
189-16	37785-37789	3.69	_
189-17	37789-37790	*	_
189-18	37794-37799	Notes	_
189-19	37799-37800	:	_
189-20	37800-37801	.	_

#Text=Results reported covarying for years of non-stimulant and alcohol use.
190-1	37802-37809	Results	_
190-2	37810-37818	reported	_
190-3	37819-37828	covarying	_
190-4	37829-37832	for	_
190-5	37833-37838	years	_
190-6	37839-37841	of	_
190-7	37842-37855	non-stimulant	_
190-8	37856-37859	and	_
190-9	37860-37867	alcohol	_
190-10	37868-37871	use	_
190-11	37871-37872	.	_

#Text=Significance indicated for all tests as follows:
#Text=p <.10,
#Text=p < .05,
#Text=Family-Wise Error (FWE) corrected.
191-1	37873-37885	Significance	_
191-2	37886-37895	indicated	_
191-3	37896-37899	for	_
191-4	37900-37903	all	_
191-5	37904-37909	tests	_
191-6	37910-37912	as	_
191-7	37913-37920	follows	_
191-8	37920-37921	:	_
191-9	37922-37923	p	_
191-10	37924-37925	<	_
191-11	37925-37928	.10	_
191-12	37928-37929	,	_
191-13	37930-37931	p	_
191-14	37932-37933	<	_
191-15	37934-37937	.05	_
191-16	37937-37938	,	_
191-17	37939-37950	Family-Wise	_
191-18	37951-37956	Error	_
191-19	37957-37958	(	_
191-20	37958-37961	FWE	_
191-21	37961-37962	)	_
191-22	37963-37972	corrected	_
191-23	37972-37973	.	_

#Text=N.S. indicates that no clusters were found to survive small volume correction at a trend level or higher.
192-1	37974-37977	N.S	_
192-2	37977-37978	.	_
192-3	37979-37988	indicates	_
192-4	37989-37993	that	_
192-5	37994-37996	no	_
192-6	37997-38005	clusters	_
192-7	38006-38010	were	_
192-8	38011-38016	found	_
192-9	38017-38019	to	_
192-10	38020-38027	survive	_
192-11	38028-38033	small	_
192-12	38034-38040	volume	_
192-13	38041-38051	correction	_
192-14	38052-38054	at	_
192-15	38055-38056	a	_
192-16	38057-38062	trend	_
192-17	38063-38068	level	_
192-18	38069-38071	or	_
192-19	38072-38078	higher	_
192-20	38078-38079	.	_
